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Summary 
Maternal milk is produced to nourish the newborn child and provide all nutrients required for ideal 
growth and development. Apart from delivering energy via the macronutrients lactose, fat and 
protein, milk contains multiple bioactive components that play a role in the immune development 
and response of the infant. These immunoregulatory factors are involved in diverse health benefits 
associated with breast-feeding. Among these beneficial human milk components are 
polyunsaturated fatty acids and human milk oligosaccharides. Especially the omega-3 and omega-6 
long-chain polyunsaturated fatty acids fulfill important functions in brain and eye development and 
provide precursors for the eicosanoid lipid mediators controlling the immune system. Human milk 
oligosaccharides influence the immune system by acting as soluble receptors and binding to host 
proteins. Additionally, they shape the microbiota of the infant’s gut by acting as prebiotics. This 
indirectly influences the action of the mucosal immune system. How long-chain fatty acids and milk 
oligosaccharides influence the intestinal microbiota and the immune response is the focus of this 
work. 
Fatty acid composition of human milk and its change over the first month of lactation was 
determined by gas chromatography-mass spectrometry. While the relative content of most of the 
measured fatty acids is stable over the observed time period, it decreases for the omega-3 
docosahexaenoic acid and steadily increases for its precursor α-linolenic acid. The higher 
docosahexaenoic acid levels right after birth might be crucial for the early brain development of the 
newborn and enhance the biosynthesis of anti-inflammatory lipid mediators. High levels of selected 
bioactive lipid mediators in human milk were newly discovered by liquid chromatography-tandem 
mass spectrometry. These data indicate that human milk delivers physiologically significant amounts 
of pro-inflammatory leukotriene B4 and anti-inflammatory and pro-resolving lipoxin A4, resolvin D1 
and resolvin E1 and their hydroxy fatty acid precursors. Lipid mediator levels are stable with the 
exception of the direct precursor of resolvin D1, whose concentration declines over the first month 
postpartum. The high concentrations of anti-inflammatory and pro-resolving lipid mediators might 
lower the inflammatory state of the breast-fed infant. 
The lactational change of selected human milk oligosaccharides over the first month postpartum was 
investigated by anion exchange chromatography with pulsed amperometric detection. For most milk 
oligosaccharides, the relative amount decreases over this time period. The most abundant milk 
oligosaccharide fucosyllactose shows stable levels over time, but high inter-individual differences. To 
study associations between neonatal fecal microbiota and the milk oligosaccharide levels of their 
mother’s breast-milk, the fecal microbiota composition of corresponding breast-fed infants was 
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examined by denaturing gradient gel electrophoresis. Especially fucosyllactose might have a prebiotic 
effect, because high levels in human milk occurred together with the presence of a Bifidobacteria 
species in the infant feces. Fucosyllactose was further tested for its effects on microbial colonization 
and intestinal inflammation in a mouse supplementation study. Administration of fucosyllactose 
increased the intestinal content of Barnesiella in newborn mice. The ability of Barnesiella to utilize 
fucosyllactose as energy source was demonstrated in vitro. Additionally, fucosyllactose 
supplementation lowered the inflammatory response to dextran sulfate sodium-induced colitis in 
mice. 
These results underline the uniqueness and bioactive potential of maternal milk. The tailor-made 
adjustment of docosahexaenoic acid concentration, the supply of anti-inflammatory lipid mediators 
and the potential of fucosyllactose to shape the microbiota and to lower the intestinal inflammatory 
response are beneficial features of human milk. They add to the health-promoting effects of human 
milk and cannot be mimicked by infant formula. 
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Zusammenfassung 
Muttermilch wird erzeugt, um das neugeborene Kind zu versorgen und alle Nährstoffe 
bereitzustellen, die für ein optimales Wachstum und eine ideale Entwicklung benötigt werden. 
Neben ihrer Funktion als Energielieferant durch die Makronährstoffe Laktose, Fett und Protein, 
enthält Milch vielerlei bioaktive Komponenten, die eine Rolle bei der Entwicklung des Immunsystems 
und der Immunantwort des Säuglings spielen. Diese immunregulatorischen Faktoren sind Ursache 
verschiedener gesundheitlicher Vorteile, die mit Muttermilch in Verbindung gebracht werden. Zu 
diesen positiv wirkenden Muttermilchkomponenten gehören mehrfach ungesättigte Fettsäuren und 
Milcholigosaccharide. Besonders die langkettigen mehrfach ungesättigten omega-3- und omega-6-
Fettsäuren erfüllen wichtige Funktionen in der Gehirn- und Augenentwicklung und liefern Vorstufen 
für die Biosynthese von Eicosanoid-Lipidmediatoren, die das Immunsystem kontrollieren. Humane 
Milcholigosaccharide beeinflussen das Immunsystem, indem sie sowohl als lösliche Rezeptoren 
fungieren als auch an körpereigene Proteine binden. Darüberhinaus formen sie die Mikrobiota des 
kindlichen Darms durch ihre Wirkung als Präbiotika. Dieses beeinflusst wiederum indirekt die 
Funktionsweise des mukosalen Immunsystems. In welcher Weise langkettige Fettsäuren und humane 
Milcholigosaccharide die intestinale Mikrobiota und die Immunantwort beeinflussen liegt im Fokus 
dieser Arbeit. 
Die Fettsäurenkomposition der Muttermilch und ihre Veränderung innerhalb des ersten Monats der 
Laktation wurden mittels Gaschromatographie-Massenspektrometrie bestimmt. Während die 
meisten gemessenen Fettsäuren stabile Konzentrationen über den Beobachtungszeitraum 
aufweisen, sinkt der relative Gehalt der omega-3 Docosahexaensäure und steigt stetig für deren 
Vorstufe α-Linolensäure. Die höheren Gehalte an Docosahexaensäure direkt nach der Geburt 
könnten für die frühe neonatale Entwicklung des Gehirns entscheidend sein und die Biosynthese von 
anti-inflammatorischen Lipidmediatoren verstärken. Hohe Konzentrationen ausgewählter bioaktiver 
Lipidmediatoren in der Muttermilch wurden neu entdeckt mittels Flüssigchromatographie-
Tandemmassenspektrometrie. Die Daten zeigen, dass Muttermilch physiologisch bedeutende 
Mengen des pro-inflammatorischen Leukotrienes B4 und der anti-inflammatorischen und 
entzündungsauflösenden Lipidmediatoren Lipoxin A4, Resolvin D1 und Resolvin E1 und deren 
Hydroxyfettsäuren-Vorstufen liefert. Die Level der Lipidmediatoren sind stabil mit der Ausnahme der 
direkten Vorstufe des Resolvin D1, dessen Konzentration während des ersten Monats nach der 
Geburt sinkt. Die hohen Konzentrationen anti-inflammatorischer und entzündungsauflösender 
Lipidmediatoren könnten den Entzündungsstatus des gestillten Säuglings herabsetzen. 
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Die Veränderungen ausgewählter Milcholigosaccharide während der Laktation wurden über den 
ersten Monat nach der Geburt mittels Anionenaustauscherchromatographie mit pulsierender 
amperometrischer Detektion untersucht. Der relative Gehalt der meisten Milcholigosaccharide sinkt 
über diesen Zeitraum. Der am reichlichsten vorhandene Milcholigosaccharid Fucosyllaktose weist 
zeitlich stabile Level auf, dafür jedoch grosse interindividuelle Unterschiede. Um den Zusammenhang 
zwischen fekaler Mikrobiota eines Neugeborenen und der Milcholigosaccharidkonzentrationen 
seiner Mutter zu untersuchen, wurde die Zusammensetzung der fekalen Mikrobiota der zugehörigen 
gestillten Säuglinge mittels denaturierender Gradientengelelektrophorese bestimmt. Besonders 
Fucosyllaktose könnte einen präbiotischen Effekt haben, da hohe Level in der Muttermilch 
gleichzeitig mit dem Vorkommen einer Bifidobakterienspezies im Feces des Kindes auftraten. 
Fucosyllaktose wurde daraufhin auf ihre Effekte auf die mikrobielle Darmkolonisation und intestinale 
Entzündung in einer Maussupplementationsstudie untersucht. Die Gabe von Fucosyllaktose erhöhte 
den intestinalen Anteil von Barnesiella bei neugeborenen Mäusen. Die Fähigkeit, Fucosyllaktose als 
Energiequelle zu nutzen, wurde für Barnesiella in vitro bestätigt. Die Supplementation von 
Fucosyllaktose führte bei den Mäusen zusätzlich zu einer verminderten Entzündungsantwort auf 
Natrium-Dextransulfat induzierte Colitis. 
Diese Ergebnisse unterstreichen die Einzigartigkeit und das bioaktive Potential der Muttermilch. Die 
bedarfsgerechte Anpassung der Docosahexaensäurekonzentration, die Versorgung mit anti-
inflammatorischen Lipidmediatoren und das Potential von Fucosyllaktose, die Mikrobiota zu formen 
und die intestinale Immunantwort zu vermindern, sind positiv wirkende Eigenschaften der 
Muttermilch. Diese tragen zu den gesundheitsfördernden Effekten der Muttermilch bei und können 
nicht von Säuglingsmilchnahrung nachgeahmt werden. 
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Abbreviations 
12-HETE, 12-hydroxyeicosatetraenoic acid; 15-HETE, 15-hydroxyeicosatetraenoic acid; 17-HDHA, 17-
hydroxydocosahexaenoic acid; 18-HEPE, 18-hydroxyeicosapentaenoic acid; 2FL, 2-fucosyllactose; 3FL, 
3-fucosyllactose; 3SL, α2,3-sialyllactose; 6SL, α2,6-sialyllactose; AA, arachidonic acid; ACN, 
acetonitrile; DC, dendritic cell; DGGE, denaturing gradient gel electrophoresis; DHA, 
docosahexaenoic acid; DSS, dextran sulfate sodium; EPA, eicosapentaenoic acid; Gal, galactose; 
GalNAc, N-acetylgalactosamine; GC-MS, gas chromatography mass spectrometry; Glc, glucose; 
GlcNAc, N-acetylglucosamine; GU, glucose units; HIV, human immunodeficiency virus; HPAEC-PAD, 
high-performance anion exchange chromatography-pulsed amperometric detection; HPLC-MS/MS, 
high-performance liquid chromatography tandem mass spectrometry; IL, interleukin; KO, knockout; 
LCPUFA, long-chain polyunsaturated fatty acid; LTA4, leukotriene A4; LTB4, leukotriene B4; LXA4, 
lipoxin A4; MALDI-TOF-MS/MS, matrix assisted laser desorption ionization-time of flight-tandem 
mass spectrometry; NEC, necrotizing enterocolitis; NeuAc, N-acetylneuraminic acid; PGD2, 
prostaglandin D2; PGE2, prostaglandin E2; PGF2α, prostaglandin F2α, PGI2, prostacyclin; PUFA, 
polyunsaturated fatty acid; RvD1, resolvin D1; RvE1, resolvin E1; Sia, sialic acid; SPE, solid phase 
extraction; TFA, trifluoroacetic acid; TXA2, thromboxane A2 
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Introduction 
Human milk is the natural creation of a food that contains everything a newborn child needs. 
Therefore, breast-feeding is regarded as gold standard for the infant‘s nutrition. It is associated with 
various beneficial effects on the newborn’s health. In breast-fed children, the incidence of allergic 
and inflammatory conditions is decreased. The question that is intensely investigated but still not 
fully answered is which components of human milk influence the breast-fed child, so that it develops 
advantages in growth, health status and immunity over formula-fed children. 
1 Breast milk versus formula – what are the differences? 
1.1  Effects on health 
Breast-fed children have evidently certain health advantages in comparison to formula-fed children 
(1). In several studies, beneficial effects of breastfeeding were shown on different levels. For many 
autoimmune diseases for example, the risk of developing the disease is reduced by breastfeeding. 
Type 1 diabetes occurs after autoimmune destruction of the pancreatic beta cells and its prevalence 
has steadily increased (2). The risk of developing this type of diabetes is lower in breast-fed children 
than in children fed infant formula (3). Furthermore, the development of coeliac disease, an 
autoimmune disorder triggered by gluten protein and resulting in inflammation and destruction of 
the intestinal lining, is negatively correlated with the duration of breastfeeding (4). 
Also, breast-feeding influences the onset ot atopic diseases like atopic dermatitis and atopic asthma. 
Exclusive breast-feeding for three months lowered the susceptibility to atopic dermatitis (5, 6) and 
childhood asthma (7-9), especially in families with a history of atopy. The risk of food allergies is as 
well reduced with longer breastfeeding. Children who were breast-fed for less than one month or not 
at all had a significantly higher incidence of food allergy at the age of 1 to 3 years than children 
breast-fed for more than one month (10). 
Moreover, breastfeeding plays a protective role in several medical disorders that occur generally in 
adulthood and in combination are known as the metabolic syndrome which is associated with 
increased risk for cardiovascular disease (11, 12). These disorders include obesity, hyperglycemia, 
dyslipidemia and hypertension. In several studies, a lower risk of obesity in adulthood has been 
confirmed for breast-fed children (13-15). Also type 2 diabetes, often accompanying obesity and 
characterized by insulin resistance, occurs less often in breast-fed children compared to formula-fed 
ones (16). One symptom of dyslipidemia is a low content of high density lipoprotein cholesterol 
Introduction 
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together with a higher content of low density lipoprotein cholesterol in the blood (17). Breastfeeding 
entails a reduced risk of dyslipidemia, since total cholesterol as well as low density lipoprotein 
cholesterol seem to be lower (18), while high density lipoprotein cholesterol was shown to be higher 
in adults that had been breastfed (12). In addition, the fourth component of the metabolic syndrome, 
hypertension, seems to be less likely in later life of the breastfed child according to several studies 
(19). The blood pressure, systolic more than diastolic, was shown to be significantly lower when 
breastfed after birth (19). But this effect is rather modest and seems to be negligible when 
considering future health outcomes (20). 
A matter of controversial debate is the effect of infant feeding mode on the intelligence of the child. 
While a positive effect of breastfeeding on the intelligence quotient is found in some studies (21-23), 
it is not confirmed by others in which it was shown that the link between breastfeeding and cognitive 
abilities is rather due to confounding factors like maternal intelligence quotient (24). 
The direct impact of breast milk is probably observed in the digestive tract of the newborn, the site 
of direct contact and interaction with the mucosal epithelium as well as with the intestinal 
microbiota. These firsthand effects of breast milk are less controversial than the observed long-term 
influences. For example, the beneficial consequences of breastfeeding in the development of the 
mucosal immune system are evident. When comparing different feeding modes, a major difference 
appears in the occurrence of gastrointestinal infections resulting in diarrhea. Morbidity and mortality 
due to diarrhea is reduced in breast-fed infants (25). In diarrhea caused by infections with 
Campylobacter jejuni, attack rates in the first six months of age were shown to be 2.3-fold higher in 
infants that were not fed breast milk (26). In a study from Bangladesh, reduced mortality resulting 
from diarrhea was confirmed for breast-fed infants (27). Here, the risk of death from diarrhea was 
almost 4-fold higher in partially or non-breast-fed infants. Considering that the study was conducted 
with infants born in slum areas, the lower risk associated with exclusive breast-feeding might partly 
be attributed to the lower exposure to contaminated food and drinking water. Apart from preventing 
infections, breast milk also reduces the risk of inflammatory bowel diseases like Crohn’s disease (28). 
Also necrotizing enterocolitis (NEC), necrosis of bowel tissue that is primarily observed in preterm 
neonates, occurred less often in preterm infants who were fed human milk (29, 30). Feeding human 
milk is associated with a six-fold lower risk for NEC in low birth weight infants (31). 
Feeding breast milk seems to entail many advantages for the growth and development of the 
neonate and the key to these functional benefits is a plethora of health-promoting compounds that 
are contained in human breast milk. 
Introduction 
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1.2 Composition of human milk and infant formula 
Although the composition of infant formula is made to imitate breast milk, it still differs considerably 
from maternal milk. In Switzerland, the mandatory concentrations of the macronutrients 
carbohydrates, fat and protein of infant formula are concordant with the one of mature term breast 
milk (Table 1). But looking at the molecular structures inside these categories carbohydrates, fat and 
protein reveals the actual differences between human milk and formula. 
Table 1: Macronutrient (g/dl) and energy (kcal/dl) composition of human milk (adapted from (32)) 
 
Protein 
Mean (±2 SD) 
Fat 
Mean (±2 SD) 
Lactose 
Mean (±2 SD) 
Energy 
Mean (±2 SD) 
Ref. 
Term infants, 24-h collection, mature milk (3 months postpartum) 
 
1.2 (0.9, 1.5) 3.6 (2.2, 5.0) 7.4 (7.2, 7.7) 70 (57, 83) (33) 
Donor human milk samples  
United States milk bank donors 1.2 (0.7, 1.7) 3.2 (1.2, 5.2) 7.8 (6.0, 9.6) 65 (43, 87) (34) 
Danish milk bank donors 0.9 (0.6, 1.4)a 3.6 (1.8, 8.9)a 7.2 (6.4, 7.6)a 67 (50,115)a (35) 
Preterm (23 to 33 weeks’ gestational age), 24-h collection, first 8 weeks of life 
 Born <29 weeks 2.2 (1.3, 3.3) 4.4 (2.6, 6.2) 7.6 (6.4, 8.8) 78 (61, 94) (36) 
 Born 32–33 weeks 1.9 (1.3, 2.5) 4.8 (2.8, 6.8) 7.5 (6.5, 8.5) 77 (64, 89) (36) 
Preterm donor milk  
 
1.4 (0.8, 1.9) 4.2 (2.4, 5.9) 6.7 (5.5, 7.9) 70 (53, 87) (37) 
Swiss regulations for infant formula composition 
 
1.1-2.1b 2.6-4.2b >2.9c 60-70b (38) 
a Median (lower 2.5 percentile, upper 97.5 percentile). 
b Minimum and maximum value. 
c Total amount of carbohydrates 5.4-9.8 g/dl. 
SD, standard deviation; Ref., Reference. 
 
1.2.1 Proteins 
The protein fraction of mature human milk consists of 60% whey protein and 40% casein (39). The 
whey protein of human milk comprises many bioactive proteins like immunoglobulins, lactoferrin 
and lysozyme that have antimicrobial activity. The high percentage of acid soluble whey protein and 
the low percentage of acid insoluble casein eases the digestion for the newborn (40). The protein in 
cow’s milk has only 20% whey protein and 80% casein (41), which makes it more difficult to digest. In 
addition, the total protein content of cow’s milk is 3.3% (42), hence, almost three times higher than 
in human milk. Therefore, former infant formulas based on cow’s milk had a very dissimilar protein 
profile to human milk. But nowadays, the protein content and also the corresponding share of whey 
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and casein is controlled in formula production and is generally adjusted to the values of human milk 
(43).  
1.2.2 Carbohydrates 
The carbohydrate fraction in breast milk as well as in infant formula is mainly constituted of lactose. 
But in formula, there often is a considerable amount of starch added, to thicken the formula to 
reduce regurgitation, for example. But most importantly, formula miss a significant part of 
carbohydrates that are unique for human breast milk, namely the human milk oligosaccharides. 
These oligosaccharides are present in a vast structural variety and in concentrations of up to 23 g/l 
breast milk (44). The amount and also the number of different structures is lower in cow’s milk (45, 
46) and in milk from other mammals (46, 47). Therefore, many milk oligosaccharides unique for 
human milk are not available for supplementation of infant formula so far (48). Nowadays, a few 
types of formula are fortified with oligosaccharides that are structurally different to human milk 
oligosaccharides, though. But these galacto- and fructooligosaccharides seem to affect the 
microbiota in such a way that it is more similar to the microbiota of breast-fed infants (49, 50).  
1.2.3 Fat 
Fat is not only the main energy source of breast milk, it also fulfills many functions in the 
development and growth of the infant. Especially, the polyunsaturated fatty acids (PUFAs) are 
important for the nervous tissue, visual system development and eicosanoid synthesis (51). The fatty 
acid composition of formula used to deviate a lot from the one of human milk. The biggest difference 
used to be the content of long-chain PUFAs (LCPUFAs). Human milk contains up to 5% of the total fat 
content as omega-3 and omega-6 LCPUFAs (52). While LCPUFAs were not added to infant formula in 
earlier times, they usually are nowadays in amounts of circa 4% of the total fat content (53-55), 
although the addition is not mandatory according to the Swiss law (38). Especially, docosahexaenoic 
acid (DHA) and arachidonic acid (AA) got a lot of attention after it was proven to be present in breast 
milk in quite considerable amounts (56). In 2001, the US Food and Drug Administration approved the 
claim and considered DHA and AA as generally recognized as safe (57). From 2002, DHA and AA were 
added to some infant formula (58). 
1.2.4 Immunomodulatory factors in human breast milk 
In general, nutrition can influence the development of the immune system of young infants in several 
ways (59). On the one hand, it is a source of antigens that train the immune system to develop 
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tolerance. On the other hand, it delivers substances that modulate processes of the immune system 
either directly or indirectly. The indirect way comprises an effect on the intestinal microbiota that as 
well can modulate the immune response (60). For instance, alterations of the core microbiome of the 
body can lead to diseases like Crohn’s disease, NEC, allergy and susceptibility to infections (61). 
Human breast milk delivers plenty of substances that are potent immune-regulators to support the 
innate and also the not yet fully developed adaptive immunity of the newborn, in a direct way or 
indirectly via the gut microbiota (62). Components of the adaptive immune system that are 
transferred from the mother to the newborn are immunoglobulins. In human milk, more than 90% of 
the immunoglobulins are present as secretory immunoglobulin A (63). Secretory immunoglobulin A 
inhibits the adherence of enteric pathogens and thereby lowers infections (62). The innate immune 
system of human milk comprises many proteins with antimicrobial activity, including κ-casein, α-
lactalbumin, lactoferrin, haptocorrin and lysozyme (63). κ-Casein is a highly glycosylated protein in 
human milk that binds to Helicobacter pylori and reduces its adhesion to the mucosal cell (64). After 
partial proteolysis in the gastrointestinal tract, the polypeptide fragments of α-lactalbumin present 
antimicrobial activity against several pathogens (65). Apart from diverse antibacterial and antiviral 
effects, Lactoferrin influences bacterial colonization by rendering iron unavailable for iron-requiring 
pathogens, and haptocorrin is able to inhibit the growth of enterotoxigenic Escherichia coli (62). The 
enzyme lysozyme in human milk protects against bacteria by breaking down peptidoglycans of the 
bacterial cell wall (66). This leads to cell lysis and destroys Gram-positive as well as Gram-negative 
bacteria (67). 
While the human milk proteins described above protect the newborn by acting on pathogenic 
bacteria or viruses, other proteins support the newborn’s immunocompetence, the ability to develop 
an immune response. This immune response can be mediated by the action of protein hormones 
such as cytokines. Human milk contains a number of cytokines including interleukin (IL)-1, IL-1β, IL-6, 
IL-8, IL-10, tumor necrosis factor-α, transforming growth factor-β and interferon-γ (68). They are 
present in their free form, but are also secreted by maternal immune cells that are contained in 
human milk (63). Also the corresponding soluble receptors have been detected in human milk (69). 
These cytokines have pro- or anti-inflammatory effects (32). The neonatal production of some 
cytokines is reduced (68). Thus, a supply through breast milk might ascertain a proper regulation of 
inflammatory and immune responses despite the developmental delay of the neonatal immune 
system. 
The composition of these immune-regulating molecules is one of the major differences when 
comparing the nutrients of breast milk to the one of infant formula. There have been many 
immunomodulatory factors identified in human milk to date and the number is still expanding. Milk 
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oligosaccharides have been identified as one of them (62). The high levels of PUFAs in human milk 
might also play a role in the positive effect of human milk on the immune system. The influence of 
these two human milk components, oligosaccharides and fatty acids, especially polyunsaturated 
ones, on the structure of the intestinal microbiota and on the immune system are the focus of this 
work. 
2 Lipids 
2.1 Human milk fat 
Human milk contains approximately 30-50 g fat per liter. However, the fat concentration of human 
milk is highly variable. It varies greatly between individuals and from early to late lactation (30, 70). 
Some studies also describe changes in the fat content over the day (71, 72). Feedings in the night and 
morning were found to deliver milk with a lower fat content than in the afternoons and evenings 
(71). During one feed, the initial part of the milk, so-called foremilk, contains two to three times less 
fat than hindmilk, the second part of the milk (70). The reason is the constant fat production in the 
mammary gland providing the same absolute amount of fat with simultaneously decreasing milk 
volume during breast emptying (73). 
Human milk fat is present as fat droplets (74). These fat droplets consist of a core surrounded by a 
lipoprotein membrane. The core mainly comprises mono-, di- and triglycerides and free fatty acids. 
The fat globule membrane is built up of phospholipids, cholesterol and cholesteryl ester. It also 
contains a variety of glycolipids, gangliosides, glycoproteins and mucins. Looking at the total 
distribution of lipids in human milk, almost all (circa 97%) are triglycerides (75). Mono- and 
diglycerides account for circa 0.2% and 0.5%, respectively. Approximately 0.6% of the milk lipids are 
free fatty acids. The remaining percentages cover the membrane lipids with roughly equal 
concentrations of phospholipids and cholesterol. Cholesteryl esters account for 20% of cholesterol. 
Human milk fat is the main energy source for the breast-fed newborn. Fifty to sixty percent of the 
calories in human milk derive from fat (74). Since 97% of the milk fat are triglycerides of which 90% 
are fatty acids, 88% of human milk fat are esterified fatty acids (74). Besides delivering energy, the 
different fatty acids fulfill several functions. 
The most abundant fatty acids in human milk fat are oleic acid (C18:1) and palmitic acid (C16:0), 
followed by linoleic acid (C18:2) (75, 76). These three fatty acids account for 70-80% of the total fatty 
acid content. The remaining 20-30% are mainly represented by stearic acid (C18:0), palmitoleic acid 
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less efficient than in adults (85). In that case, the nutritional supply should be guaranteed since AA, 
DHA and EPA are important for growth and development. 
DHA and AA are needed for normal development of brain, retina and the nervous system (86, 87). 
DHA and AA are the major polyunsaturated fatty acids of neural tissues, and DHA is the most 
abundant fatty acid in the retina (88, 89). Due to lower DHA content in infant formula than in breast 
milk, formula-fed infants have a lower cerebral content of DHA, but not of AA, than breast-fed 
infants (90, 91). The omega-3 fatty acids EPA and DHA play protective roles in cardiovascular health. 
A higher EPA and DHA content in red blood cell membranes is associated with a decreased onset of 
coronary heart diseases (92). The DHA content of red blood cells is also lower in formula-fed infants 
than in breast-fed infants (84). Additionally, LCPUFAs are precursors of pro- and anti-inflammatory 
lipid mediators. These lipid mediators are hormone-like substances that play an important role in the 
process of inflammation. Breastfeeding reduces the occurrence of inflammation in the newborn, for 
example in the respiratory and gastrointestinal tract. This protective effect of breast milk could be 
mediated by delivering lipid mediator precursors, in form of LCPUFAs.  
The anti-inflammatory potential of LCPUFAs was shown in the treatment of several inflammatory and 
autoimmune diseases (93), like inflammatory bowel diseases (94). Administration of EPA led to an 
improvement of ulcerative colitis (95, 96). In Crohn’s disease, omega-3 LCPUFAs could reduce the 
rate of relapse (97). LCPUFA also reduces the risk of developing NEC. The supplementation of infant 
formula with LCPUFA resulted in a lower incidence of NEC in rats (98). Moreover, the lower incidence 
of childhood allergy and eczema in breast-fed infants compared to formula-fed ones may be 
attributed to the beneficial effects of the LCPUFAs in breast milk (99). 
DHA and other LCPUFAs are accumulated primarily in the last ten weeks of pregnancy and the first 
year of life (100). In pregnancy, the transplacental transfer is in favor of DHA over other fatty acids 
during the last trimester (101). Intrauterine accretion in this time was shown to be 43 mg/kg/day of 
DHA and 212 mg/kg/day of AA (102). Preterm infants that lack this period of LCPUFA accumulation 
have higher dietary requirements after birth, because their synthesis at one month of age with 13 
mg/kg/day DHA and 27 mg/kg/day AA do not meet the requirements defined by the fetal accretion 
rates (103). In view of this mismatch, AA and DHA is discussed to be conditionally essential, with one 
of these conditions being prematurity (104). Interestingly, the DHA content of preterm milk is higher 
than in term milk (105) which matches the elevated need of preterm infants for DHA.  
Several factors influence the fatty acid composition of breast milk. Next to lactational and gestational 
age, diseases and individual factors have an influence (106). But the greatest effect comes from the 
maternal diet, which also accounts for seasonal and geographical differences. In a study in China, the 
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breast milk fatty acid composition of women from urban, rural, pastoral and marine regions were 
compared (107). The biggest difference was the concentration of DHA. While in urban, rural and 
pastoral areas, women had a DHA content between 0.1 and 0.9 wt%, it was 2.78 wt% in breast milk 
from marine regions. The comparison of the diet revealed a significantly higher intake of seafood and 
also soybean oil in the marine region. The DHA content in breast milk can also be increased by 
supplementation (108). The daily intake of DHA increased the DHA concentration in human milk in a 
dose-dependent manner. The content of omega-3 fatty acids could be increased by fish oil 
supplementation during lactation (109). Women who got fish oil containing a mix of DHA and EPA 
had three times higher concentrations of omega-3 fatty acids in their breast milk. The dependency of 
the milk fatty acid composition on the maternal diet was already demonstrated earlier when a high 
consumption of corn oil with a linoleic acid content of 52% led to an increased linoleic acid 
concentration in breast milk of up to 43% (110). The fact that increased maternal PUFA intake raises 
PUFA concentration in breast milk can be applied advantageously to guarantee the optimal supply to 
the newborn. For example, women with low DHA intake are recommended DHA supplementation for 
the time of breastfeeding (111, 112).  
2.2 Lipid mediators 
Human milk contains multiple bioactive components. Next to oligosaccharides, immunoglobulins, 
growth factors, immune cells and cytokines, also lipids are relevant for the immune system 
development. LCPUFAs have been shown to be immunoregulatory (113). The molecular basis of their 
beneficial actions might be the LCPUFA derivatives, the so-called lipid mediators. They are produced 
by the combined action of lipoxygenases, cyclooxygenases, hydrolases and cytochrome P450 (Figure 
2.2 and Figure 2.3). In many inflammatory disorders of the gastrointestinal tract, neutrophil 
migration into the mucosa parallels epithelial injury. Lipid mediators significantly influence these 
leukocyte-epithelium interactions. They have hormone-like functions and are crucial for the process 
of inflammation. Their effects can be pro- or anti-inflammatory, i.e. they regulate the onset or the 
resolution of inflammation. Their presence in human milk is unknown so far. 
2.2.1 The onset of inflammation – Pro-inflammatory lipid mediators 
Acute inflammation is the response to tissue injury, infection with microorganisms or surgical trauma 
(114). Also restoration of blood flow after its complete or partial arrest as in ischemia-reperfusion 
injury can trigger inflammation. The process starts with the release of chemical mediators that act as 
chemoattractants and initiate the recruitment of neutrophils to the site of inflammation. As the first 
line of defence, the neutrophils infiltrate the inflamed tissue and are able to phagocytise cellular 
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debris and invading microorganisms. The chemoattractant mediators are either exogenous, for 
example antimicrobial peptides, or endogenous, for example eicosanoids. The endogenous chemical 
mediators that promote acute inflammation are released by neutrophils migrating into the tissue. 
They include, next to cytokines and chemokines, also lipid mediators like prostaglandins, 
thromboxanes and leukotrienes (115). 
The 2-series prostanoids, including prostaglandins, 
prostacylins and thromboxanes, and the 4-series 
leukotrienes are derived from AA via cyclooxygenases and 
lipoxygenases, respectively (Figure 2.2). The same 
enzymes convert EPA to 3-series prostanoids and 5-series 
leukotrienes (116). However, these eicosanoids show a 
lower bioactivity and are less pro-inflammatory (117, 
118). 
Both isoforms of cyclooxygenase, COX-1 and COX-2, 
produce prostaglandin H2 which serves as common 
precursor for the synthesis of thromboxane A2 (TXA2) and 
the four principal bioactive prostaglandins prostaglandin 
E2 (PGE2), prostaglandin D2 (PGD2), prostacyclin (PGI2), 
prostaglandin F2α (PGF2α) (119). One of the most abundant 
prostaglandins is PGE2. This mediator plays a dual role 
exerting pro- and anti-inflammatory responses. It 
regulates cytokine expression of dendritic cells and 
stimulates their migration to draining lymph nodes, and 
thus, enhances the activation of T cells (120, 121). In contrast, its influence on innate immune cells 
can be anti-inflammatory, for example the initiation of the anti-inflammatory lipid mediator 
biosynthesis in neutrophils (122). 
PGD2 plays a pro-inflammatory role in allergic inflammation, especially acute allergic responses as 
seen in asthma, and seems to contribute to the development of atherosclerosis (119).  Contrarily, it 
inhibits dendritic cell migration and the proliferation of T cells (123), thereby reducing the severity of 
the inflammatory response. PGF2α is a biomarker of oxidative stress and inflammation. Elevated 
levels of this mediator have been associated to many pathophysiological conditions (124). The 
mediators PGI2 and TXA2 have some opposing functions. PGI2 inhibits platelet aggregation and causes 
vasodilatation (125), whereas TXA2 promotes platelet adhesion and aggregation and acts as 
 
Figure 2.2: Arachidonic acid as precursor 
for pro-inflammatory prostaglandins, 
thromboxanes and leukotrienes (cited 
from (116)). COX, cyclooxygenase; PG, 
prostaglandin; PGI, prostacyclin; TX, 
thromboxane; 5-LO, 5-lipoxygenase; 5-
H(p)ETE, 5-Hydro(pero)xyeicosatetraenoic 
acid; LT, leukotrienes 
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vasoconstrictor (126). In addition, PGI2 is described as anti-inflammatory and immunosuppressive, 
while TXA2 rather shows pro-inflammatory activities. 
Leukotrienes are generated by 5-lipoxygenase action on AA yielding leukotrienes A4 (LTA4) (Figure 
2.2). The conjugation of LTA4 with glutathione yields the cysteinyl leukotrienes LTC4, LTD4 and LTE4. 
Together, they build the slow reacting substance of anaphylaxis that causes immediate 
hypersensitivity and bronchoconstriction (127). Apart from this function, they seem to play a role in 
chronic inflammatory cell responses (128). Leukotriene B4 (LTB4) is generated from LTA4 by LTA4 
hydrolase (115) and plays a crucial role in acute inflammation. It is a potent chemoattractant that 
activates firm adhesion of leukocytes and initiates their migration (129). Additionally, it induces the 
production of reactive oxygen species in neutrophils and inhibits neutrophilic apoptosis (130, 131). 
The inflammatory response is a well-orchestrated process of many cascades initiated by these 
specific pro-inflammatory lipid mediators that have distinct and partially overlapping effects. Some of 
the described pro-inflammatory lipid mediators are also able to restrain acute inflammation. Apart 
from them, some anti-inflammatory and pro-resolving lipid mediators are specialized on the task of 
bringing inflammation to an end (114). 
2.2.2 The resolution of inflammation – Anti-inflammatory lipid mediators 
Not only the initiation of inflammation, but also its resolution is an active process (132). The 
inflammatory response is the first line of defense and protects the host, but it needs to be self-
limiting to prevent consequences of exaggerated inflammation. Uncontrolled, excessive neutrophil 
infiltration increases inadvertent spilling of neutrophil granule content (133). This granule content 
contains degenerative enzymes and reactive oxygen species that can cause tissue damage. Another 
undesired outcome is the development of chronic inflammation. Thus, the regeneration of 
homeostasis, i.e. the resolution of inflammation, needs to be regulated. 
During the process of acute inflammation, the pro-inflammatory PGE2 and PGD2 also show pro-
resolution activities. They change the expression of enzymes in neutrophils to generate anti-
inflammatory lipid mediators. They stimulate the lipid mediator class switch from pro- to anti-
inflammatory with the result that concentrations of anti-inflammatory and pro-resolving lipid 
mediators rise (114, 134). Those include lipoxins, resolvins, protectins/neuroprotectins and maresins. 
They oppose many actions of and also inhibit pro-inflammatory mediators with the aim to stop or 
prevent inflammation (114). Their biosynthesis is done either via the lipoxygenase metabolism 
(Figure 2.3), resulting in the S-series lipid mediators, or by an aspirin-triggered cyclooxygenase or 
cytochrome P450 metabolism (135, 136). From the aspirin-triggered pathway, a second series of lipid 
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mediators evolves: the R-lipoxins, R-resolvins, R-protectins and R-neuroprotectins. These aspirin-
triggered lipid mediators have anti-inflammatory potential which is equivalent to the S-series 
mediators (136). 
 
Figure 2.3: Biosynthesis of anti-inflammatory and pro-resolving lipid mediators (cited from (116)). LO, 
lipoxygenase; H(p)ETE, hydro(pero)xyeicosatetraenoic acid; LTA4, leukotriene A4; LX, lipoxin; H(p)DHA, 
hydro(pero)xydocosahexaenoic acid; PD1, protectin D1; RvD, resolvin D-series; RvE, resolvin E-series; MaR1, 
maresin 1; CYP450, cytochrome P450; HEPE, hydroxyeicosapetaenoic acid 
 
The generation of lipoxins has been observed in mucosal tissues of the oral cavity, the respiratory 
and the gastrointestinal tract (137). The direct precursor 15-hydroxyeicosatetraenoic acid (15-HETE) 
is provided by epithelial cells whose 15-lipoxygenase acts on AA of the cell membrane (138). 15-HETE 
is further converted to lipoxins by 5-lipoxygenase and hydrolases in leukocytes. An alternative route 
includes the conversion of AA to LTA4 in leukocytes. LTA4 can be further metabolized to lipoxin by 
mucosal 15-lipoxygenase or by 12-lipoxygenase in platelets (Figure 2.3). Lipoxins act as regulators of 
inflammation by inhibiting the chemotaxis of neutrophils (114, 139). They reduce neutrophil and 
eosinophil adhesion and migration and oppose some leukocyte responses to pro-inflammatory 
leukotrienes. Additionally, they increase the activation of monocytes and macrophages, which take 
up apoptotic neutrophils. Thus, they initiate the resolution of inflammation.  
The anti-inflammatory and pro-resolving actions of lipoxins and aspirin-triggered lipoxins have been 
demonstrated on multiple levels (reviewed in ref. (114)). In gastrointestinal physiology, lipoxin A4 
analogs were able to attenuate inflammation in chemically induced colitis in mice and even inhibit 
the expression of intestinal pro-inflammatory genes (140-142). Several characteristics of 
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inflammation during colitis could be reduced by oral treatment with lipoxin A4 analogs including 
weight loss, colon injury, neutrophil infiltration and mRNA levels of several pro-inflammatory 
mediators like tumor necrosis factor-α and interferon-γ. A disturbed biosynthesis of lipoxin A4 might 
be the reason for persistent intestinal inflammation. Colonic mucosa of patients with ulcerative 
colitis, a chronic inflammatory bowel disease, had significantly lower levels of lipoxin A4 than mucosa 
from healthy controls (143). Only patients in medically-induced remission had an up-regulation of 
lipoxin A4 levels underlining the importance of lipoxin A4 in resolution of intestinal inflammation 
(144). Also in the stomach, lipoxin A4 seems to be protective against mucosal inflammation. If the 
aspirin-triggered lipoxin synthesis via cyclooxygenase is blocked, the gastric-damaging actions of 
aspirin fully unfold (145-147). In this case, aspirin leads to increased leukocyte adhesion and, thus, 
promotes lesions in the stomach epithelium. Therefore, the usually observed inhibition of leukocyte 
adhesion by aspirin is mediated by aspirin-triggered lipoxins. Injections of lipoxin A4 also reduced the 
severity of aspirin-induced gastric damage in rats (148). 
A similar inhibitory effect on leukocyte adhesion is observed with resolvins. These anti-inflammatory 
and pro-resolving mediators are derived from the omega-3 fatty acids DHA (D-series) and EPA (E-
series) (Figure 2.3). For resolvins of the E-series, EPA is converted by cytochrome P450 to 18-
hydroxyeicosapentaenoic acid (18-HEPE) in endothelial cells and further transformed to resolvin E1 
and resolvin E2 by 5-lipoxygenase in neutrophils (149). Both resolvins of the E-series block the 
transendothelial migration of neutrophils (149, 150). Resolvin E1 also enhances the clearance of 
apoptotic neutrophils from sites of inflammation by stimulating the phagocytic activity of 
macrophages (151).  It influences the link to adaptive immunity by lowering the migration of 
dendritic cells into T cell areas of the spleen and by reducing the IL-12 production of dendritic cells 
(152) which lowers the generation of T helper type 1 cells (153). Resolvins have diverse sites of 
action. Treatment with resolvin E1 could resolve allergic airway inflammation in mice (154). The 
protection against developing colitis upon chemical challenge in mice proved the beneficial impact of 
resolvin E1 on intestinal inflammation (155-157). 
Resolvins of the D-series are generated via the 15- and 5-lipoxygenase metabolism (Figure 2.3) 
exemplified via leukocyte-endothelial cell interactions. They are of particular interest in neural 
tissues, since the concentration of the precursor DHA is high in brain and synapses (158). Resolvin D1 
and also its precursor 17-hydroxydocosahexaenoic acid (17-HDHA) inhibit the production of the 
inflammatory mediator IL-1β in microglial cells which plays a role in inflammation and host defense 
in neural tissues (159). But resolvins of the D-series are potent regulators of inflammation in many 
other locations as well. In general, resolvin D1 and D2 are potent regulators of neutrophil traffic 
(159-161). In the kidney, this renders resolvin D1 protective against renal ischemic injury (162). In the 
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intestine, resolvin D1 and D2 and their precursor 17-HDHA protect against the development of 
chemically induced colitis (163). Recent studies demonstrate the role of resolvins in pain regulation. 
In rats with adjuvant-induced arthritis, treatment with resolvin D1 and its precursor 17-HDHA 
reduced inflammatory pain (164, 165). Resolvin D3 has been characterized recently and its anti-
inflammatory and pro-resolving activities in neutrophil regulation and macrophage stimulation has 
been confirmed (166). Until today, little is known about the effects of resolvin D4 to D6. 
Together with resolvins, another pro-resolving lipid mediator called protectin has been described 
(159). Protectin is, like resolvins of the D-series, produced from DHA by neutrophils, especially in 
neural tissues, where it is called neuroprotectin (167). It has the same inhibitory effect on microglial 
cells as resolvin D1 and stimulates the phagocytosis of apoptotic neutrophils in macrophages as 
resolvin E1 (151, 168). Its anti-inflammatory effects include the protection against ischemic injury in 
the kidney (162) and in the brain (169). In humans, the association of asthma with low levels of 
protectin D1 has been described (170). Furthermore, the administration of protectin D1 significantly 
reduced symptoms of allergic airway inflammation in mice (170). Protectin D1 also links innate and 
adaptive immune system by directly inhibiting the cytokine production of T cells and promoting T cell 
apoptosis (171). 
Anti-inflammatory and pro-resolving lipid mediators have manifold beneficial effects and protect 
against uncontrolled inflammation. They actively regulate the extent of the immune response in 
diverse tissues. These mediators could be the link between breast-feeding and the observed lower 
incidence of intestinal (172) and respiratory (9) inflammation in breast-fed infants. Human milk 
provides relatively high amounts of the precursors DHA, EPA and AA. But so far, it is unknown, 
whether maternal milk also supplies anti-inflammatory and pro-resolving lipid mediators. 
2.2.3 Quantitative analysis of lipid mediators in breast milk 
The only lipid mediators that have been quantified in human breast milk are prostaglandins, most 
often PGE2. The mean concentrations of PGE2 measured by radioimmunoassay vary between 149 and 
902 pg/ml (173-176) which is over 100-fold higher than the concentration measured in plasma of 1.3 
pg/ml (174). Concentrations of other lipid mediators, especially the anti-inflammatory ones, have not 
been reported yet. Although the methodology to measure lipid mediators in biological samples 
selectively and specifically by liquid chromatography-tandem mass spectrometry has been developed 
(177), it has not been applied to human milk yet. 
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3 Human milk oligosaccharides 
The complex sugars found in human breast milk are mysterious. Next to lactose, there are more than 
200 identified structures (178, 179) that are produced in the mammary gland by the concerted action 
of glycosyltransferase enzymes. These oligosaccharides do not have any nutritious value for the 
newborn, since the neonate does not possess the set of enzymes to degrade them (180). Milk 
oligosaccharides obviously can be absorbed, since ca. 1-2% of some ingested milk oligosaccharides 
have been detected in the infants’ urine (181) . Absorbed milk oligosaccharides have been found to 
be used for the biosynthesis of gangliosides and glycoproteins (182). But for the 90% of the milk 
oligosaccharides that pass the small intestine unabsorbed and undigested (183), the colon lumen 
seems to be the site of action. The amount of oligosaccharides supplied by human milk reaches 
concentrations of approximately 23 g/l in colostrum and circa 13 g/l in mature milk (44, 184). 
Assuming an average intake for mature milk of around 700 ml per day (185), a considerable amount 
of several grams of oligosaccharides are passing the newborn’s gut every day. They certainly must 
fulfill other functions than being an energy source, because the efficiency-oriented evolution would 
have ensured the extinction of any unnecessary usage of biosynthetic machinery. 
The diversity of milk oligosaccharides is high, but the structures have certain similarities (Figure 3.1). 
Every milk oligosaccharide has a lactose core. This lactose core is alternatively elongated with 
galactose (Gal) and N-acetylglucosamine (GlcNAc) as lactosamine (Galβ1-4GlcNAc) or lacto-N-biose 
(Galβ1-3GlcNAc) units. The resulting oligosaccharides are linear or branched (180).  Termini are 
usually decorated with fucose and/or N-acetylneuraminic acid (NeuAc), also called sialic acid (Sia). 
The presence of Sia renders oligosaccharides acidic. Milk oligosaccharides without Sia are defined as 
neutral. Fructo- and galactooligosaccharides are used for prebiotic supplementation of infant 
formula. They consist of a glucose (Glc) elongated with fructose or Gal, respectively (Figure 3.1). 
These artificial linear structures are very distinct to human milk oligosaccharides. 
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Figure 3.1: Basic structure of human milk oligosaccharides, fructo- and 
galactooligosaccharides (cited from (186)). Structures are depicted as symbols 
representing fucose (red triangle), sialic acid (N-acetylneuraminic acid, Neu5Ac, 
purple rhombus), N-acetylglucosamine (blue square), galactose (yellow circle), 
glucose (blue circle) and fructose (blue hexagon). 
 
The glycosyltransferase enzymes responsible for the milk oligosaccharide synthesis are expressed in 
the mammary gland, but the exact pathway of milk oligosaccharide biosynthesis is still unknown, 
apart from the initial building of lactose and the final fucosylation and sialylation (187). Lactose is 
built by β1-4-galactosyltransferase complexed with lactalbumin that attaches Gal to Glc in the Golgi 
of the mammary gland epithelial cell. The required enzymes for the elongation with GlcNAc and Gal 
seem to be the same that are in charge for the glycosylation of proteins and lipids of the epithelial 
cell, namely β1,3-N-acetylglucosaminyltransferase (iGnT), β1,6-N-acetylglucosaminyltransferase 
(IGnT), β1,4-galactosyltransferase (β4GalT) and β1,3-galactosyltransferase (β3GalT) (188). The final 
decoration with fucose is done by multiple fucosyltransferases in α1-2-, α1-3- or α1-4-linkage. Sia is 
attached by at least three sialyltransferases in α2-3- or α2-6-linkage (187). 
Depending on the linkage between Gal and GlcNAc, milk oligosaccharides are defined as type I 
(Galβ1-3GlcNAc; lacto-N-biose) and type II (Galβ1-4GlcNAc; lactosamine) structures (180). In humans, 
2-fucosyllactose (2FL) and type I oligosaccharides containing lacto-N-biose units predominate (184). 
In comparison, cow’s milk contains only type II milk oligosaccharides. Oligosaccharides are in general 
less abundant in cow’s milk (189). The detected total amount of bovine milk oligosaccharides is 
reported to be only traces (Table 2) (45). Others found around 1 g/l in bovine colostrum rapidly 
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declining over two days (46, 190). Apart from type II dominance, the complexity of bovine milk 
oligosaccharides is lower and the grade of fucosylation and sialylation is different compared to 
human milk oligosaccharides (189). While approximately 70% of the human milk oligosaccharides are 
fucosylated, bovine milk oligosaccharides hardly contain fucose (46, 189). In cow’s milk, 70% of milk 
oligosaccharides are sialylated (189), whereas in human milk approximately 20% contain Sia (189). 
Infant formula is based on cow’s milk. Because of the low concentration of milk oligosaccharides in 
cow’s milk, the amount of oligosaccharides in non-supplemented infant formula is negligible (Table 
2) (191).  
Table 2: Amount of selected oligosaccharides in human breast milk and cow’s milk (adapted from (45)) 
Component 
Amount in 
human milk 
(g/l) (45) 
Amount in cow's 
milk (g/l) (45) 
Amount in bovine 
colostrum (g/l) 
(190) 
Infant formula 
(g/l) (191) 
Lactose 55–70 40–50   
Oligosaccharides     
 Lacto-N-tetraose 0.5–1.5 Traces   
 Lacto-N-fucopentaose I 1.2–1.7 —   
 Lacto-N-fucopentaose II 0.3–1.0 —   
 Lacto-N-fucopentaose III 0.01–0.2 —   
 Lacto-N-difucohexaose I 0.1–0.2 —   
 NeuAc(α2-6)lactose 0.3–0.5  0.05-0.15 0.003-0.005 
   0.03–0.06   
 NeuAc(α2-3)lactose 0.1–0.3  0.2-1.0 0.01-0.02 
 NeuAc-lacto-N-tetraose a 0.03–0.2 Traces   
 NeuAc-lacto-N-tetraose c 0.1–0.6 Traces   
 NeuAc2-lacto-N-tetraose 0.2–0.6 Traces   
 NeuAc2-lactose    <0.001 
 NeuAc(α2-6)lactosamine —  0.05-0.2  
Oligosaccharides (total) 5.0–8.0 Traces   
NeuAc, N-acetylneuraminic acid 
 
Milk oligosaccharides are transferred with the breast milk into the digestive tract of the newborn 
where they reach the colon in their intact form. In the small intestine, they are not degraded, since 
the newborn does not express the required glycosidases (180). For instance, lactase cannot digest 
sialyl- or fucosyllactose. The neuraminidase required for cleaving off Sia and α-fucosidase for 
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removing fucose are not part of the brush border enzymes in humans (47). Instead of being used as 
an energy source, milk oligosaccharides are digested by commensal bacteria, act as soluble receptors 
for pathogens or influence immune processes by acting as ligands to signaling molecules. Many of 
these diverse functions are structure-specific that explains the variety of milk oligosaccharides. 
3.1 Functions of human milk oligosaccharides 
3.1.1 Prebiotic activity 
The influence of breast milk on the mucosal immune response is to a large extent due to its impact 
on the gut microbiota. The gut microbiota is an important factor of being healthy. A disturbed 
composition is linked to several diseases and a disordered early colonization might increase the risk 
of developing them (192). The gut microbiota is established immediately after birth. Already after a 
few days, the amount of bacteria in the gut reaches 1010 colony forming units per gram feces (193, 
194), already almost as much as in the adult gut which harbors approximately 1011 to 1012 bacteria 
per gram feces (195). But the composition of the microbiota in the adult differs greatly from the one 
in the neonate’s gut, since the microbial composition continuously evolves during development 
(196). The early colonization of the intestine depends on several environmental factors. These factors 
comprise mode of delivery (197), the composition of the maternal microbiota (198), the mode of 
feeding (199), use of antibiotics, gestational age and geographical influences (192, 196, 200). The 
impact of the type of feeding could be to some extent due to the presence of bacteria in the milk 
that are able to colonize the newborn’s intestine (201, 202).  
As nutrition has a major impact on the bacterial composition, breastfeeding and formula-feeding 
result in different colonization patterns. Certainly, the content of milk oligosaccharides in human milk 
represents a major factor for the difference in gut colonization observed in differently fed neonates. 
Milk oligosaccharides are indigestible by humans. They pass the enzymatic action of the stomach and 
small intestine structurally unaffected and reach the colon of the infant (203, 204) where they are 
fermented by beneficial gut microbiota like bifidobacteria (205), and thus are able to shape the 
microbiota of the newborn’s intestine (206). It has been shown that the predominant bacteria in 
breast-fed infants are bifidobacteria while the microbiological variability in formula-fed infants is 
more diverse (205, 207, 208). But higher levels of bifidobacteria due to breastfeeding have not been 
confirmed in some more recent studies (193). However, the microbiota of formula-fed infants are 
characterized by higher levels of less desired clostridia and Escherichia coli (193, 194, 207).  
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To utilize human milk oligosaccharides, bacteria need four types of enzymes (209). α-Fucosidase and 
α-sialidase are required to cleave terminal fucose and/or Sia. After this first step, the remaining 
structures are available for detaching GlcNAc by hexosaminidase as a monosaccharide or by lacto-N-
biosidase as a disaccharide together with Gal. Gal can be detached from GlcNAc by β-galactosidase. 
Especially, fucosidase and sialidase activity is essential for the usage of milk oligosaccharides, since 
the majority of those structures are terminated by fucose (70%) or Sia (20-50%), and Gal and GlcNAc 
are only accessible after the removal of these terminal monosaccharides (209).  
By providing specific structures that can be utilized by certain bacteria due to their enzymatic 
equipment, milk oligosaccharides enhance the growth of desirable bacteria like bifidobacteria and 
inhibit or poorly support the establishment of pathogenic bacteria like clostridia, eubacteria, 
enterococci or enterobacteria (199, 210). Breastfeeding leads to intestinal colonization by mainly 
bifidobacteria (207, 211). The proportion of bifidobacteria in the total fecal bacterial community was 
shown to be 60-90% in breast-fed and approximately 50% in formula-fed infants (205, 207). 
Bifidobacteria are described as health-promoting for the newborn and able to outcompete 
undesirable bacteria by creating an acidic environment which inhibits the growth of many pathogens 
(210, 212, 213). Bifidobacterium longum subsp. infantis (termed Bifidobacterium infantis) and 
Bifidobacterium bifidum employ the set of enzymes enabling using milk oligosaccharides as energy 
source (214, 215). In contrast, the low oligosaccharide consumer Bifidobacterium longum does not 
have the required fucosidase and sialidase enzymes (216, 217). Not all bifidobacteria can grow on 
human milk oligosaccharides. Strains of Bifidobacterium adolescentis and Bifidobacterium animales 
lack this ability (206, 218), which probably is the reason why they are not detected in the breast-fed 
infant gut (219). 
The capability to use milk oligosaccharides is also not limited to bifidobacteria. Bacteroides species 
are as well able to grow on milk oligosaccharides (216, 220, 221). Especially, Bacteroides fragilis and 
Bacteroides vulgatus show strong growth on human milk oligosaccharides while species like 
Clostridium difficile, Enterococcus faecalis, Escherichia coli and Veillonella parvula are not able to 
utilize them and therefore, do not show any growth advantage (216). Bifidobacteria and bacteroides 
seem to have preferences when it comes to oligosaccharide consumption. Some species, e.g. 
Bifidobacterium infantis, preferentially use fucosylated oligosaccharides, while others, e.g. 
Bacteroides fragilis, favor non-fucosylated ones (216, 222). These preferences of the different 
bacterial strains are always dependent on the cleavage specificities of the oligosaccharide degrading 
glycosidases that are differently expressed by the individual strains (216). The bacterial strains 
employing enzymes required for degrading the lacto-N-biose unit in type 1 oligosaccharides have an 
advantage in colonizing the gut of the breast-fed child. The typical microbiome of the breast-fed child 
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probably co-developed with the predominance of type 1 oligosaccharides in human milk, since the 
predominant species in the breast-fed infant gut, for example Bifidobacterium bifidum, 
Bifidobacterium breve and Bifidobacterium infantis, prefer type 1 milk oligosaccharides (217, 223, 
224). 
Galactooligosaccharides that are often added to infant formula can also be utilized by bifidobacteria 
(225). A mixture of galacto- and fructooligosaccharides added to a bovine milk based infant formula 
changed the microbiota towards higher concentration of bifidobacteria and lower numbers of 
pathogens (50, 211, 226). The absolute amount and the composition of bifidobacteria in infants fed 
with prebiotic-supplemented formula was comparable to the one in breast-fed infants, while infants 
fed non-supplemented formula showed a lower absolute amount and a lower diversity of 
Bifidobacterium species (211). 
The different consumption of oligosaccharides by intestinal microbiota confers a high selectivity of 
milk oligosaccharides in promoting bacterial growth. Human milk oligosaccharides support specific 
groups of beneficial bacteria, which then replace less favorable ones. Therefore, they enable the 
protection of the newborn against pathogens (227). Additionally, milk oligosaccharides influence the 
newborn’s health by promoting bacteria that positively affect the maturation of the newborn’s 
immune system (228) by modulating, for example, cytokine and antibody production (229). 
3.1.2 Milk oligosaccharides as soluble receptors 
Bacteria have specific glycan-binding proteins, so called lectins (230). These lectins enable host and 
tissue specific adhesion to the epithelial surface of the host. The adhesion involves binding to the 
oligosaccharides of the epithelial cell and allows the colonization of the human intestine. In case of 
pathogenic bacteria, adhesion is required in order to invade the host (231). Milk oligosaccharides 
display glyco-patterns that resemble specific binding sites for pathogens, thereby acting as soluble 
receptors (187). Consequently, pathogenic bacteria and also viruses can bind to milk oligosaccharides 
instead of the epithelial surface. The inhibited adhesion of pathogens leads to a reduction of 
inflammation in the intestine (183). 
Anti-adhesive properties of milk oligosaccharides were shown for numerous pathogenic bacteria and 
viruses including Streptococcus pneumonia (232), Listeria monocytogenes (233), Vibrio cholerae, 
Salmonella fyris, enteropathogenic Escherichia coli (234) and Campylobacter jejuni (235) (Table 3).  
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Table 3: Glycan structures identified as soluble receptors for pathogens (adapted from (45, 236)) 
Receptor Pathogen Reference 
Oligosaccharides Streptococcus pneumoniae (232, 237) 
 
Enteropathogenic Escherichia coli (EPEC)  (238) 
 
Listeria monocytogenes (233) 
 
Human immunodeficiency virus (HIV) (239) 
Fucosylated oligosaccharides Campylobacter jejuni (235) 
 
Vibrio cholerae (234) 
 
Escherichia coli (stable enterotoxin) (240) 
Fuc1-2Gal epitopes Candida albicans (241) 
Sialyllactose Cholera toxin (242) 
 
Escherichia coli (S-fimbriae) (243, 244) 
 
Pseudomonas aeruginosa (245) 
 
Aspergillus fumigatus conidia (246) 
 
Influenza virus (45, 247, 248) 
 
Polyomavirus (249) 
 
Helicobacter pylori (250, 251) 
Sialylated oligosaccharides Enterotoxigenic Escherichia coli (ETEC) 
Uropathogenic Escherichia coli (UPEC) 
(252) 
Sialylated glycoproteins Escherichia coli (S-fimbriae) (253) 
Sialylated glycoproteins (α2-3-linked) and 
sialylated poly-N-acetyllactosamine 
Mycoplasma pneumoniae (254) 
Sialylated (α2-3)poly-N-
acetylactosaminoglycans 
Streptococcus suis (255) 
Mannosylated glycopeptide Enterohemorrhagic Escherichia coli (EHEC)  (256) 
Macromolecule-associated glycans Noroviruses, Pseudomonas aeruginosa (257, 258) 
Gal(ß1-4)GlcNAc or Gal(ß1-3)GlcNAc Pseudomonas aeruginosa (259) 
Lactadherin Rotavirus (260) 
 
Milk oligosaccharides have also been shown to be protective against human immunodeficiency virus 
(HIV) by blocking the entry of HIV into dendritic cells (187, 239). Specific milk oligosaccharide 
structures inhibit the adhesion of selected bacteria due to the different binding patterns of the 
bacterial lectins. For instance, the S-fimbriae of Escherichia coli bind preferentially to sialylated 
structures, whereas adhesion of Campylobacter jejuni is inhibited by α1,2-fucosylated 
oligosaccharides (Table 3). Also the induction of diarrhea by the stable enterotoxin of Escherichia coli 
is inhibited by fucosylated oligosaccharides (240) at concentrations found in human milk (183). In this 
case, the responsible milk oligosaccharide does not bind to the pathogen, but competitively to the 
host cell-surface receptor which blocks the adhesion of the stable enterotoxin (261). 
A recent study suggests another mechanism how milk oligosaccharides reduce the binding of 
pathogens (262). Exogenous milk oligosaccharides might alter the cell surface glycobiome, so that 
certain pathogens cannot bind anymore. The exposure to α2,3-sialyllactose (3SL) led to a decrease of 
Sia in the cell surface oligosaccharides and a subsequent reduction in the adhesion of 
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enteropathogenic Escherichia coli by 90% in vitro (262). The changes in the glycocalyx of the cell were 
due to a lower expression of genes encoding specific α2-3-sialyltransferases. This indicates that 
exposure to milk oligosaccharides might be able to affect gene expression. 
Whichever mechanism is responsible for blocking bacterial adhesion, either binding directly to the 
pathogen or disabling pathogenic binding to the cell by genetically changing the glyco-pattern of the 
cell surface, its activation by administering oligosaccharides opens possibilities for future disease 
treatments (263). The manipulation of the bacterial adhesion process by carbohydrates was shown in 
several animal studies (reviewed in ref. (263)). For instance, the administration of lacto-N-
neotetraose decreased pneumonia caused by Streptococcus pneumoniae in rabbits and infant rats 
(125). Glycopeptides reduced the attachment of Escherichia coli K99 to calf intestinal epithelial cells 
100-fold (264). Oligosaccharides inhibit bacterial adhesion competitively. Thus, they are able to 
detach already bound bacteria. The oligosaccharide 3SL is able to prevent de novo adhesion, and 
moreover, removes bound Helicobacter pylori from epithelial monolayers (137).  
On the basis of these in vitro and in vivo studies, carbohydrates bearing specific pathogen blocking 
structures are discussed as future treatment possibilities in bacterial diseases. As a result of recent 
advances in oligosaccharide production (265, 266), some structures are available in larger quantities. 
This might enable the testing of safety and efficacy by clinical trials. Studies in humans so far included 
the nasal administration of sialyllacto-N-neotetraose to prevent acute otitis media (267) and the oral 
treatment with 3SL to suppress infection with Helicobacter pylori (268). Both trials did not reveal a 
therapeutic effect suggesting a more complex interaction between bacterial lectins and epithelial 
cells or incorrect application and/or dosage. A proper inhibition might require not only one 
oligosaccharide structure, but also a mixture. 
3.1.3 Regulation of immune processes by binding to proteins 
Milk oligosaccharides are not only soluble receptors, but also ligands for the body’s own 
carbohydrate-binding proteins like selectins and integrins (269). These proteins mediate cell-cell 
interactions of the immune system. Selectins are transmembrane proteins in the endothelial cell 
membrane and bind to carbohydrate moieties, for example to glycoproteins expressed on 
leukocytes. Thereby, they facilitate leukocyte adhesion and extravasation to sites of inflammation 
(48). Integrins are also cell adhesion molecules like selectins. In the form of transmembrane 
receptors, they are important in the signal transduction from cell to extracellular matrix and vice 
versa (270). They also mediate the binding of cells to diverse viruses (271).  
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The immune response of the human body includes the recruitment of leukocytes to sites of 
inflammation. But if leukocytes infiltrate epithelial cells excessively, the underlying tissues can get 
severely damaged (272). Leukocytes also build complexes with platelets resulting in leukocytes with 
an activated adhesion molecule profile and elevated production of reactive oxygen species (273).  
The processes of leukocyte infiltration and complex building are mediated by selectins and integrins 
(274). Low levels of milk oligosaccharides reach the systemic circulation and are able to bind to these 
carbohydrate-binding proteins since they mimic several glyco-chains found at leukocytes or 
pathogens (275).  
The oligosaccharide structure that binds to 
selectins is sialyl-Lewis x, a tetrasaccharide 
consisting of lactosamine with a Sia attached to 
Gal and α1,3-linked fucose at the GlcNAc (277) 
(Figure 3.2). The fucosylation as well as the 
sialylation is required in order to bind to 
selectins and successfully interfere with cell-cell-
interactions (48). Human milk contains several 
oligosaccharides that bear this selectin binding 
determinant (278). As selectin-ligand analogs, 
milk oligosaccharides regulate various immune processes (278). They inhibit leukocyte adhesion and 
activation as well as leukocyte-platelet complex formation, the latter of which leads to a decrease in 
leukocyte integrin expression (274, 279). The overall reduction of leukocyte adhesion by milk 
oligosaccharides causes a lower immune response of the child. 
For some oligosaccharides, other direct effects on immune cells, also of the adaptive immune 
system, was reported. Acidic oligosaccharides isolated from human milk significantly increased the 
cytokine production and activation of cord blood T cells in vitro (280). Lacto-N-fucopentaose III, a 
milk oligosaccharide containing the trisaccharide Lewis x, was able to raise the proliferation of B cells 
and the production of anti-inflammatory IL-10 with the consequence of T helper cell type 1 down-
regulation in mice (281). Also lacto-N-neotetraose showed the potential to increase IL-10 production 
in mice (282).  
Not only milk oligosaccharides, but also other prebiotic oligosaccharides like galacto- and 
fructooligosaccharides proved to affect the immune system. Oligofructose supplementation 
increased the IL-10 production in Peyer’s patches of the gut-associated lymphatic tissue and 
stimulated the cell activity of natural killer cells in rats (229). A mixture of galacto- and 
fructooligosaccharides, like it is used for supplementation of infant formula, influenced the 
 
Figure 3.2: C-type lectin receptor ligands (adapted 
from (276)). Exemplary glycan structures that bind to 
C-type lections like selectins, collectins and 
lymphocyte lectins. Monosaccharides are depicted by 
symbols representing sialic acid (purple rhombus), 
galactose (yellow circle), N-acetylglucosamine (blue 
square), fucose (red triangle). 
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occurrence of atopic dermatitis and allergy. Administered in the first six months of life, it led to a 
lower incidence of atopic dermatitis over this period (283). The occurrence of allergic manifestations 
and infections was decreased also beyond the treatment period until the age of two years (284). As 
the effect is persistent also after the intake of galacto- and fructooligosaccharides, it can probably be 
attributed to an indirect mechanism via longer-lasting changes in the microbiota, which had been 
induced by the prebiotics. 
These investigations demonstrate that human milk oligosaccharides and also other prebiotic 
oligosaccharides can influence the maturation and activation of the immune system directly, by 
selectin binding for example, or indirectly by increasing specific bacteria in the intestine, which 
themselves interact with immune cells. The immunologic functions of milk oligosaccharides are 
nowadays widely accepted. 
3.2 Fucosyllactose  
Fucosyllactose is the most abundant oligosaccharide in 
human milk (286). Also in this work, it received special 
attention and was selected for in vivo studies. It is a 
trisaccharide consisting of lactose with an added fucose. 
Fucose can be attached to milk oligosaccharides in α1-2, 
α1-3 and/or α1-4 linkage. In case of fucosyllactose, there 
are two possible structures. In 2FL, the fucose is bound to 
Gal in a α1-2 linkage, in 3-fucosyllactose (3FL) the fucose is 
attached to Glc in a α1-3-linkage. 2FL is the most abundant 
fucosylated milk oligosaccharide; 3FL is present in lower 
amounts (Figure 3.3).  
The type of fucosylation occurring at the different 
glycostructures of the human body, like milk 
oligosaccharides and also blood group antigens, is 
genetically determined. Fucosyltransferases are expressed by two different genes. The secretor gene 
(FUT2) encodes the α1-2-fucosyltransferase and the Lewis gene (FUT3) family the α1-3/4-
fucosyltransferase. Not every human being expresses both genes. Thus, four different groups 
according to their types of fucosylation can be distinguished: secretors and non-secretors who both 
can be either Lewis-positive or Lewis-negative. More than 20% of the human population are non-
secretors (287). Women of the non-secretor type do not contain 2FL in their breast milk (288). In 
 
Figure 3.3: Relative abundance of 
fucosylated oligosaccharides in human 
milk (cited from (285)). LNT, lacto-N-
tetraose; LNneoT, lacto-N-neo-tetraose; 
LNF I, lacto-N-fucopentaose I; 2’-FL, 2-
fucosyllactose; LDFH I, lacto-N-
difucohexaose I; LDFT, 
lactodifucotetraose; LNF II, lacto-N-
fucopentaose II; 3-FL, 3-fucosyllactose. 
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combination with Lewis-negative, also other fucosylated oligosaccharides are missing. Although, 
these fucosylated oligosaccharides are absent, non-secretors still have an amount of milk 
oligosaccharides of several g/l (48). Several advantages were reported for secretors compared to 
non-secretors, for example reduced overall mortality and death due to NEC and sepsis in preterm 
infants (287).  
The presence of 2-linked fucosyloligosaccharides, the typical secretor components in breast milk, is 
connected to several health benefits for the breast-fed newborn. Especially, its beneficial role in 
Campylobacter jejuni and norovirus infection has been thoroughly investigated. The role of 2-
fucosyloligosaccharides in Campylobacter jejuni infection was shown in several in vitro and in vivo 
studies (285). On the one hand, campylobacter binding to HEp2 cells could be inhibited by 2-
fucosyloligosaccharides. On the other hand, the binding could be initiated in case of Chinese hamster 
ovary cells that usually do not bind to Campylobacter jejuni by the transfection of the gene encoding 
human α1,2-fucosyltransferase (235). Mice were protected from campylobacter diarrhea if they 
were supplemented with neutral human milk oligosaccharides (235). In humans, low content of 2-
linked fucosyloligosaccharides in breast milk was associated with higher occurrence of diarrhea due 
to Campylobacter jejuni and also norovirus infection in the breast-fed child (289). 
In other studies, the dependency of norovirus infection on secretor status was tested (290-292). The 
infection with norovirus was 40 times more likely in secretors than in non-secretors (290) and milk of 
non-secretors was not able to inhibit the binding of norovirus to histo-blood group antigens in saliva 
samples (183, 257). This indicates a specific binding of norovirus to milk oligosaccharides containing 
α1,2-linked fucose. 
The prebiotic function of 2FL and 3FL was confirmed in bacterial cultures. When human milk 
oligosaccharides were incubated with the entire fecal microbiome isolated from several infants, 
these two were among the most consumed oligosaccharides. Consumption of 2FL and 3FL led to an 
increase of the amount of bifidobacteria and to a reduction of the number of Escherichia spp. and 
Clostridium perfringens (293). 
Whether fucosylated milk oligosaccharides have specific effects in gastrointestinal physiology, like 
sialylated milk oligosaccharides do (see 3.3), is currently unclear. In the course of this thesis, a study 
was conducted to answer the question if and to what extent dietary fucosyllactose influences the 
intestinal commensal microflora and the inflammatory response in mice. To reveal characteristics 
specific to the fucose linkage, 2FL as well as 3FL were included in the study. 
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3.3 The role of milk sialyllactose in intestinal bacterial colonization 
(Advances in Nutrition. 2012 May 1;3(3):483S-8S.) 
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Abstract 
Milk oligosaccharides influence the composition of intestinal microbiota and thereby mucosal 
inflammation. Some of the major milk oligosaccharides are α2,3-sialyllactose (3SL) and α2,6-
sialyllactose, which are mainly produced by the sialyltransferases ST3GAL4 and ST6GAL1, 
respectively. Recently, we showed that mice fed milk deficient in 3SL were more resistant to dextran 
sulfate sodium-induced colitis. By contrast, the exposure to milk containing or deficient in 3SL had no 
impact on the development of mucosal leukocyte populations. Milk 3SL mainly affected the 
colonization of the intestine by clostridial cluster IV bacteria. 
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Human milk contains up to 23 g/L oligosaccharides (294). These milk oligosaccharides consist of a 
lactose core elongated by a variety of carbohydrates, thereby yielding more than 200 distinct 
structures in human milk (295).The lactose core can be extended by the attachment of galactose 
(Gal), N-acetylglucosamine (GlcNAc), or repeats of Gal-GlcNAc. However, the main carbohydrates 
added to the lactose core are fucose and the sialic acid (Sia) N-acetylneuraminic acid. Accordingly, 
~70% and 28% of human milk oligosaccharides are fucosylated and sialylated, respectively (295). 
Sia 
The Sia family represents variants of a 9-carbon carboxylated carbohydrate backbone, which is often 
modified at the 4, 7, 8 and 9 positions (296). Sia occur in some bacteria (297) and vertebrates. Sia are 
commonly found as terminal monosaccharides in several classes of glycoconjugates, such as 
glycoproteins and glycosphingolipids. Gangliosides, which are a group of glycosphingolipids, are 
especially rich in Sia (298) and are involved in synaptogenesis and neural transmission (299). By 
contrast, the functional relevance of sialylated oligosaccharides in human milk is currently unknown. 
Because fucose and Sia are generally located at terminal positions, these carbohydrates essentially 
mediate the interaction of milk oligosaccharides with other molecules and cells. The effects of 
sialylated milk oligosaccharides have been documented in several biological assays. For example, the 
adhesion of leukocytes to endothelial cells can be inhibited by sialylated human milk oligosaccharides 
in vitro (279). Because milk oligosaccharides are partially absorbed in the intestine (300), they can 
occur in infants’ circulation at concentrations up to 125 mg/L (279), thus possibly accounting for 
lower infiltration of leukocytes into intestinal tissues. Acting as structural analogs for pathogen 
binding receptors (301), milk oligosaccharides prevent the adhesion of pathogenic bacteria to the 
epithelial surface in the gastrointestinal tract. For example, α2,3-sialyllactose (3SL) binds the 
ulcerogenic bacteria Helicobacter pylori, thereby decreasing the binding of the bacteria to 
duodenum-derived human cells (251). Similarly, fucosylated neutral oligosaccharides that do not 
contain Sia also exert anti-adhesive effects. Fucosylated oligosaccharides prevent the binding of 
major diarrhea-causing pathogens, including Campylobacter and major strains of caliciviruses to 
epithelial cells (235, 285, 289, 302, 303). 
Synthesis of sialylated oligosaccharides 
The structural diversity of human milk oligosaccharides is orchestrated by multiple 
glycosyltransferases expressed in the lactating mammary gland. Most of these glycosyltransferases 
are also active in other tissues and are involved in the biosynthesis of multiple types of 
glycoconjugates. Accordingly, the sialyltransferases involved in the sialylation of milk 
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oligosaccharides are broadly expressed and have roles in various developmental and physiological 
pathways. Four families of sialyltransferases have been characterized, which add Sia to glycan 
acceptors in 3 different linkages (Table 1). A group of 6 α2,3-sialyltransferases (ST3GAL1 to 6) 
transfer Sia α2,3-linked to β-Gal, 2 α2,6-sialyltransferases (ST6GAL1 and 2) transfer Sia α2,6-linked 
to β-Gal, whereas 6 α2,6-sialyltransferases (ST6GALNAC1 to 6) transfer Sia to GalNAc (α-N-
acetylgalactosamine). Finally, a group of 6 α2,8-sialyltransferases (ST8SIA1 to 6) elongate Sia through 
α2,8-linkage, thereby building polysialic acid chains (304-306). Such polysialic acid chains are 
commonly found on gangliosides and the glycoprotein neural cell adhesion molecule (N-CAM) (307), 
but they have never been found on milk oligosaccharides. Similarly, the enzymes of the ST6GalNAc 
family are mainly involved in the sialylation of O-glycan chains found on glycoproteins. 
Table 1. Mammalian sialyltransferase enzymes 
Family Sialyltransferase Principal substrates a References 
β-Galactoside α2,3-
sialyltransferases 
ST3GAL1 Galβ1,3GalNAc-(Protein)* (308) 
ST3GAL2 Galβ1,3GalNAc-(Lipid)* (309) 
ST3GAL3 Galβ1,3(4)GlcNAc- (310) 
ST3GAL4 Galβ1,4(3)GlcNAc- (310) 
ST3GAL5 Lac-Cer (311) 
ST3GAL6 Galβ1,4GlcNAc- (312) 
β-Galactoside α2,6-
sialyltransferases 
ST6GAL1 Galβ1,4GlcNAc- (313) 
ST6GAL2 Galβ1,4GlcNAc- (314) 
GalNAc α2,6-
sialyltransferases 
ST6GALNAC1 GalNAcα1,O-Ser/Thr (315) 
ST6GALNAC2 Galβ1,3GalNAcα1,O-Ser/Thr (316) 
ST6GALNAC3 NeuAcα2,3Galβ1,3GalNAc-(Lipid)* (317) 
ST6GALNAC4 NeuAcα2,3Galβ1,3GalNAc-(Protein)* (317) 
ST6GALNAC5 GM1b (318, 319) 
ST6GALNAC6 GM1b, GT1b, GD1a (320) 
α2,8-Sialyltransferases ST8SIA1 GM3 (321) 
ST8SIA2 N-glycan on N-CAM (322) 
ST8SIA3 NeuAcα2,3Galβ1,4GlcNAc- (323) 
ST8SIA4 N-glycan on N-CAM (324) 
ST8SIA5 GM1b, GT1b, GD1a, GD3 (325) 
ST8SIA6 NeuAcα2,3(6)Gal- (305) 
a From (304)  
* Preferential but not specific substrate.  
 
The sialylation of milk oligosaccharides is mediated by members of the ST3GAL and ST6GAL families. 
Both ST6GAL1 and 2 enzymes are theoretically capable of catalyzing α2,6-sialylated milk 
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oligosaccharides. However, in contrast to ST6GAL1, the ST6GAL2 enzyme showed no activity toward 
lactose and lacto-N-tetraose (304) whose sialylated forms belong to the most abundant acidic 
oligosaccharides in human milk (326). Our data confirmed that milk 6SL (α2,6-sialyllactose) in mouse 
milk is generated by the action of ST6GAL1 and not ST6GAL2 (327). The levels of ST6GAL1 transcripts 
were increased up to 20-fold in lactating mammary gland tissue, whereas ST6GAL2 transcript levels 
were only moderately increased. Furthermore, 6SL could not be detected in milk from mice lacking 
the ST6GAL1 gene (327). 
The ST6GAL1 gene is ubiquitously expressed in mammals and the corresponding enzyme acts on a 
broad range of glycoprotein and oligosaccharide acceptors (328). Investigations of ST6GAL1 KO 
(knockout) mice demonstrated the importance of this sialyltransferase in the activation of B 
lymphocytes and hence in immune functions (329). In addition, ST6GAL1 affects the maturation and 
functionality of DC (dendritic cells) as shown by increased DC maturation in the absence of α2,6-
sialylation (330). Several studies focusing on ST6GAL1 KO mice confirmed the role of α2,6-sialylation 
in immunity (331-333). 
In theory, several members of the ST3GAL family can account for the formation of α2,3-sialylated 
milk oligosaccharides. This ST3GAL family is divided into two subgroups. The first one consists of 
ST3GAL1 and 2. These two sialyltransferases prefer O-glycans of glycoproteins and glycosphingolipids 
as acceptor substrates (328). Both enzymes show a preference toward Galβ1,3GalNAc (type 3) 
disaccharides, but very low or no activity toward Galβ1,3GlcNAc (type 1) and Galβ1,4GlcNAc (type 2) 
structures found in milk oligosaccharides (309, 310). The characterization of ST3GAL1 KO mice 
demonstrated the involvement of this enzyme in the sialylation of T lymphocyte proteins (334, 335). 
The other ST3GAL subgroup includes the sialyltransferases ST3GAL3 to 6. ST3GAL3 and 4 prefer 
glycoproteins and oligosaccharides as acceptor substrates, whereas they hardly sialylate glycolipids 
(310). They show high activity toward type 1 and type 2 disaccharide structures. ST3GAL3 prefers 
type 1 over type 2 disaccharides, thus, it is responsible for the formation of the selectin ligand sialyl 
Lewis A on glycoproteins whose glycan backbone consists of Galβ1,3GlcNAc (type 1) disaccharides 
(310, 336). By contrast, ST3GAL4 prefers type 2 over type 1 disaccharides, indicating that this enzyme 
is involved in the biosynthesis of the sialyl Lewis X epitope on the Galβ1,4GlcNAc (type 2) backbone 
(336). The study of ST3GAL4 KO mice confirmed the importance of this sialyltransferase in the 
formation of selectin ligands, thereby affecting leukocyte trafficking and inflammation (337-339). 
The ST3GAL5 sialyltransferase synthesizes the ganglioside GM3 by transferring Sia to 
lactosylceramide. This sialyltransferase, also known as GM3 synthase, is not active toward other 
glycolipids, glycoproteins and oligosaccharides such as those found in milk (311). The ST3GAL6 
Introduction 
 
39 
 
enzyme preferentially transfers Sia to Galβ1,4GlcNAc (type 2) structures on glycoproteins and 
glycolipids (312), thereby forming, e.g., sialyl-paragloboside, which is the precursor of the sialyl Lewis 
X epitope on ceramide. The KO of the ST3GAL6 gene has not yet been described in the literature. 
Functional study of sialylated milk oligosaccharides 
Because of the tremendous structural complexity of human milk oligosaccharides, the attribution of 
functions to specific milk oligosaccharides has remained a challenging task. Therefore, the functional 
study of milk oligosaccharides in mice has 2 advantages. First, several glycosyltransferase gene KO 
models are available to address the role of specific milk oligosaccharides. Second, the oligosaccharide 
composition of mouse milk is far less complex than that of human milk (340, 341). In mouse milk, the 
main oligosaccharides besides lactose are the 2 sialyllactose 6SL and 3SL and trace amounts of α1,3-
fucosyllactose (341). 
To study the importance of 6SL and 3SL in mouse milk, we focused on the ST6GAL1 and ST3GAL4 KO 
mouse models, because these 2 sialyltransferases are involved in the formation of 6SL and 3SL in the 
lactating mammary gland, respectively (327). To identify the contribution of these 2 milk 
oligosaccharides on mucosal immunity and physiology, we applied a cross-fostering protocol, where 
newborn litters of normal wildtype mice and sialyltransferase KO mice were partially exchanged at 
birth (Fig. 1). Along this line, newborn wild-type and KO mice were fed either normal milk or milk 
deficient in 3SL or 6SL. Experiments revealed no impact of 3SL or 6SL on the leukocyte population 
and IgA secretion in ST6GAL1 and ST3GAL4 KO mice and cross-fostered mice (327). 
 
 
Figure 1. Schematic representation of the cross-fostering protocol between wild-type 
(WT) mice and sialyltransferase KO mice. Pregnancies were synchronized by time matings 
and newborns delivered simultaneously by WT and KO mothers were exchanged at birth. 
KO, knockout. 
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However, the investigation of 3SL and 6SL in mucosal immunity and physiology using ST6GAL1 and 
ST3GAL4 KO mice pointed to unexpected contributions of these milk oligosaccharides to the 
composition of intestinal microbiota. For example, analysis of 16S rDNA by real-time PCR showed 
that newborn mice fed 3SL-deficient milk had lower levels of clostridial cluster IV bacteria than 
littermates fed normal milk (327). Sequencing of 16S rDNA fragments obtained from TGGE 
fingerprints identified a species belonging to the family Ruminococcaceae, a group of clostridial 
cluster IV bacteria. The effect of 3SL on the colonization of the intestine may be multiple. The 
presence of 3SL in the milk may affect the adhesion of bacteria to sialylated structures expressed by 
the intestinal epithelium (342) or induce phase variation, which leads, e.g., to decreased type 1 
fimbriae expression of E. coli (343). Specific milk oligosaccharides such as 3SL may also be used as 
carbon source, thereby facilitating the colonization by bacteria capable of metabolizing Sia, as shown 
for E. coli, Vibrio cholera, Bacteroides fragilis, and other pathogenic and commensal bacteria (344-
346). Such a selective specificity toward 3SL supposes the expression of linkage-specific 
neuraminidases and transport systems by bacteria. Accordingly, clusters of NAN genes required for 
the catabolism of Sia are found in several pathogenic and commensal bacteria, including 
Ruminococcus gnavus (346). Thus, the ability of Ruminococcaceae to use Sia as carbon source could 
account for their enhanced growth in the presence of 3SL. Finally, sialylated milk oligosaccharides 
such as 3SL may influence the activation of innate immune responses by acting as ligands for pattern-
recognition receptors. Along this line, Lewis X-based milk oligosaccharides have been shown to affect 
the binding of HIV to the DC lectin DC-SIGN (347). 
The study of 3SL in ST3GAL4 KO mice revealed that Ruminococcaceae were especially sensitive to the 
absence of 3SL in milk. The gram-positive Ruminococcaceae are obligate anaerobes commonly found 
in the intestines of mammals, including mice and humans (348). Ruminococcaceae are capable of 
assimilating polysaccharides like cellulose and starch (349-351). The genomes of several 
Ruminococcus species have been sequenced and shown to contain multiple cellulases but also 
several enzymes enabling the fermentation of other carbohydrates (352). Ruminococcaceae are 
enriched in patients with inflammatory bowel disease (353-355), which supports their potential role 
as proinflammatory bacteria. 
The different microbiota composition resulting from exposure to milk containing 3SL or devoid of 3SL 
had a direct impact on the susceptibility of mice to acute colitis induced by dextran sulfate sodium 
(327). The presence of 3SL in milk decreased the resistance of mice toward dextran sulfate sodium. 
Several parameters such as body weight loss, colon length and epithelial permeability as well as 
histological examinations revealed that wild-type and ST3GAL4 KO mice fed milk containing 3SL were 
more susceptible to dextran sulfate sodium-induced colitis than ST3GAL4 KO and wild-type mice fed 
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3SL-deficient milk. In fact, the reconstitution of germfree mice with intestinal microbiota isolated 
from either wild-type or ST3GAL4 KO mice demonstrated that these reconstituted mice showed the 
same susceptibility to dextran sulfate sodium as their respective microbiota donor mice. These 
experiments underline the importance of individual milk oligosaccharides in shaping intestinal flora 
and thereby in influencing the severity of intestinal inflammatory responses. 
Next step: fucosylated oligosaccharides 
Whereas fucosylated oligosaccharides are prominent among human milk oligosaccharides, only trace 
amounts of α1,3-fucosyllactose can be detected in mouse milk (341). A transgenic mouse model was 
developed by Prieto et al. (341), in which the human FUT1 gene encoding the α1,2-
fucosyltransferase was expressed in lactating mammary glands. Transgenic expression of human 
α1,2-fucosyltransferase in mice led to the biosynthesis of α1,2-fucosylated lactose in their milk. In 
these transgenic mice, up to 34% of the total milk oligosaccharides was accounted by α1,2-linked 
fucosyllactose (341). 
The expression of human glycosyltransferases in mice opens new ways to study the physiological role 
of specific milk oligosaccharides in vivo. Similarly, murine glycosyltransferases that are not known to 
play a role in the milk oligosaccharide synthesis can be expressed in lactating mammary glands using 
transgenics technology. Accordingly, the expression of murine α1,3-galactosyltransferase in lactating 
mammary glands resulted in the occurrence of α1,3-galactosyllactose in mouse milk (340). 
Furthermore, the availability of chemically synthesized oligosaccharides in large amounts now allows 
testing the effect of such “new” oligosaccharides on intestinal microbiota by supplementation 
regimen. 
The commensal bacteria of the intestine can use milk oligosaccharides as a source of energy. 
Especially, Bifidobacteria and Bacteroides strains are able to grow on milk oligosaccharides as the 
sole carbon source (356, 357). Also, non-milk oligosaccharides like fructo-, galacto-, mannan-, chito- 
and xylooligosaccharides can influence the intestinal microbiota. Supplementation of mice with these 
oligosaccharides resulted in a change of the microbiota composition in favor of Bifidobacteria (358, 
359). Some bacterial strains like Bifidobacterium longum subsp. infantis and Bacteroides vulgatus 
show a preference for fucosylated milk oligosaccharides (356). Of note, fucosylated oligosaccharides 
are not present in mouse milk and Bifidobacteria are only minor constituents of the intestinal mouse 
microbiota. Supplementation of suckling mice with synthetic fucosylated oligosaccharides now allows 
testing the relationship between these oligosaccharides and the colonization of the mouse intestine 
by bacteria, such as Bifidobacteria. 
Introduction 
 
42 
 
Acknowledgements 
Adrienne Weiss was supported by a cooperative project grant of the Zurich Center for Integrative 
Human Physiology.  
Abbreviations 
3SL, α2,3-sialyllactose; 6SL, α2,6-sialyllactose; DC, dendritic cell; Gal, galactose; GalNAc, N-
acetylgalactosamine; GlcNAc, N-acetylglucosamine; KO, knockout; Sia, sialic acid 
Introduction 
 
43 
 
4 References 
1. Rautava, S., and W. A. Walker. 2009. Academy of Breastfeeding Medicine founder's lecture 
2008: breastfeeding--an extrauterine link between mother and child. Breastfeed Med. 4: 3-
10. 
2. Cizza, G., R. J. Brown, and K. I. Rother. 2012. Rising incidence and challenges of childhood 
diabetes. A mini review. J Endocrinol Invest. 35: 541-546. 
3. Patelarou, E., C. Girvalaki, H. Brokalaki, A. Patelarou, Z. Androulaki, and C. Vardavas. 2012. 
Current evidence on the associations of breastfeeding, infant formula, and cow's milk 
introduction with type 1 diabetes mellitus: a systematic review. Nutr Rev. 70: 509-519. 
4. Akobeng, A. K., A. V. Ramanan, I. Buchan, and R. F. Heller. 2006. Effect of breast feeding on 
risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch 
Dis Child. 91: 39-43. 
5. Greer, F. R., S. H. Sicherer, and A. W. Burks. 2008. Effects of early nutritional interventions on 
the development of atopic disease in infants and children: the role of maternal dietary 
restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed 
formulas. Pediatrics. 121: 183-191. 
6. Gdalevich, M., D. Mimouni, M. David, and M. Mimouni. 2001. Breast-feeding and the onset 
of atopic dermatitis in childhood: a systematic review and meta-analysis of prospective 
studies. J Am Acad Dermatol. 45: 520-527. 
7. Oddy, W. H., J. L. Sherriff, N. H. de Klerk, G. E. Kendall, P. D. Sly, L. J. Beilin, K. B. Blake, L. I. 
Landau, and F. J. Stanley. 2004. The relation of breastfeeding and body mass index to asthma 
and atopy in children: a prospective cohort study to age 6 years. Am J Public Health. 94: 
1531-1537. 
8. Oddy, W. H. 2009. The long-term effects of breastfeeding on asthma and atopic disease. Adv 
Exp Med Biol. 639: 237-251. 
9. Gdalevich, M., D. Mimouni, and M. Mimouni. 2001. Breast-feeding and the risk of bronchial 
asthma in childhood: a systematic review with meta-analysis of prospective studies. J 
Pediatr. 139: 261-266. 
10. Saarinen, U. M., and M. Kajosaari. 1995. Breastfeeding as prophylaxis against atopic disease: 
prospective follow-up study until 17 years old. Lancet. 346: 1065-1069. 
11. Nikolopoulou, A., and N. P. Kadoglou. 2012. Obesity and metabolic syndrome as related to 
cardiovascular disease. Expert Rev Cardiovasc Ther. 10: 933-939. 
12. Parikh, N. I., S. J. Hwang, E. Ingelsson, E. J. Benjamin, C. S. Fox, R. S. Vasan, and J. M. 
Murabito. 2009. Breastfeeding in infancy and adult cardiovascular disease risk factors. Am J 
Med. 122: 656-663 e651. 
13. Gillman, M. W., S. L. Rifas-Shiman, C. A. Camargo, Jr., C. S. Berkey, A. L. Frazier, H. R. Rockett, 
A. E. Field, and G. A. Colditz. 2001. Risk of overweight among adolescents who were 
breastfed as infants. JAMA. 285: 2461-2467. 
14. Owen, C. G., R. M. Martin, P. H. Whincup, G. D. Smith, and D. G. Cook. 2005. Effect of infant 
feeding on the risk of obesity across the life course: a quantitative review of published 
evidence. Pediatrics. 115: 1367-1377. 
15. Owen, C. G., R. M. Martin, P. H. Whincup, G. Davey-Smith, M. W. Gillman, and D. G. Cook. 
2005. The effect of breastfeeding on mean body mass index throughout life: a quantitative 
review of published and unpublished observational evidence. Am J Clin Nutr. 82: 1298-1307. 
16. Owen, C. G., R. M. Martin, P. H. Whincup, G. D. Smith, and D. G. Cook. 2006. Does 
breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of 
published evidence. Am J Clin Nutr. 84: 1043-1054. 
17. Huang, P. L. 2009. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2: 
231-237. 
Introduction 
 
44 
 
18. Owen, C. G., P. H. Whincup, K. Odoki, J. A. Gilg, and D. G. Cook. 2002. Infant feeding and 
blood cholesterol: a study in adolescents and a systematic review. Pediatrics. 110: 597-608. 
19. Martin, R. M., D. Gunnell, and G. D. Smith. 2005. Breastfeeding in infancy and blood pressure 
in later life: systematic review and meta-analysis. Am J Epidemiol. 161: 15-26. 
20. Owen, C. G., P. H. Whincup, J. A. Gilg, and D. G. Cook. 2003. Effect of breast feeding in 
infancy on blood pressure in later life: systematic review and meta-analysis. BMJ. 327: 1189-
1195. 
21. Kramer, M. S. 2010. "Breast is best": The evidence. Early Hum Dev. 86: 729-732. 
22. Anderson, J. W., B. M. Johnstone, and D. T. Remley. 1999. Breast-feeding and cognitive 
development: a meta-analysis. Am J Clin Nutr. 70: 525-535. 
23. Lucas, A., R. Morley, T. J. Cole, G. Lister, and C. Leeson-Payne. 1992. Breast milk and 
subsequent intelligence quotient in children born preterm. Lancet. 339: 261-264. 
24. Der, G., G. D. Batty, and I. J. Deary. 2006. Effect of breast feeding on intelligence in children: 
prospective study, sibling pairs analysis, and meta-analysis. BMJ. 333: 945. 
25. Clavano, N. R. 1982. Mode of feeding and its effect on infant mortality and morbidity. J Trop 
Pediatr. 28: 287-293. 
26. Ruiz-Palacios, G. M., J. J. Calva, L. K. Pickering, Y. Lopez-Vidal, P. Volkow, H. Pezzarossi, and 
M. S. West. 1990. Protection of breast-fed infants against Campylobacter diarrhea by 
antibodies in human milk. J Pediatr. 116: 707-713. 
27. Arifeen, S., R. E. Black, G. Antelman, A. Baqui, L. Caulfield, and S. Becker. 2001. Exclusive 
breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in 
Dhaka slums. Pediatrics. 108: E67. 
28. Koletzko, S., P. Sherman, M. Corey, A. Griffiths, and C. Smith. 1989. Role of infant feeding 
practices in development of Crohn's disease in childhood. BMJ. 298: 1617-1618. 
29. McGuire, W., and M. Y. Anthony. 2003. Donor human milk versus formula for preventing 
necrotising enterocolitis in preterm infants: systematic review. Arch Dis Child Fetal Neonatal 
Ed. 88: F11-14. 
30. Schanler, R. J. 2001. The use of human milk for premature infants. Pediatr Clin North Am. 48: 
207-219. 
31. Sisk, P. M., C. A. Lovelady, R. G. Dillard, K. J. Gruber, and T. M. O'Shea. 2007. Early human 
milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth 
weight infants. J Perinatol. 27: 428-433. 
32. Ballard, O., and A. L. Morrow. 2013. Human milk composition: nutrients and bioactive 
factors. Pediatr Clin North Am. 60: 49-74. 
33. Nommsen, L. A., C. A. Lovelady, M. J. Heinig, B. Lonnerdal, and K. G. Dewey. 1991. 
Determinants of energy, protein, lipid, and lactose concentrations in human milk during the 
first 12 mo of lactation: the DARLING Study. Am J Clin Nutr. 53: 457-465. 
34. Wojcik, K. Y., D. J. Rechtman, M. L. Lee, A. Montoya, and E. T. Medo. 2009. Macronutrient 
analysis of a nationwide sample of donor breast milk. J Am Diet Assoc. 109: 137-140. 
35. Michaelsen, K. F., L. Skafte, J. H. Badsberg, and M. Jorgensen. 1990. Variation in 
macronutrients in human bank milk: influencing factors and implications for human milk 
banking. J Pediatr Gastroenterol Nutr. 11: 229-239. 
36. Bauer, J., and J. Gerss. 2011. Longitudinal analysis of macronutrients and minerals in human 
milk produced by mothers of preterm infants. Clin Nutr. 30: 215-220. 
37. Landers, S., and B. T. Hartmann. 2013. Donor human milk banking and the emergence of milk 
sharing. Pediatr Clin North Am. 60: 247-260. 
38. Verordnung des Eidgenössischen Departements des Inneren (EDI) über Speziallebensmittel, 
Artikel 17, Absatz 3, Buchstabe b, (2012) 
39. Kunz, C., and B. Lonnerdal. 1992. Re-evaluation of the whey protein/casein ratio of human 
milk. Acta Paediatr. 81: 107-112. 
40. Gunn, T. R., and D. Stunzner. 1986. A comparative trial of casein or whey-predominant 
formulae in healthy infants. N Z Med J. 99: 843-846. 
Introduction 
 
45 
 
41. Lara-Villoslada, F., M. Olivares, and J. Xaus. 2005. The balance between caseins and whey 
proteins in cow's milk determines its allergenicity. J Dairy Sci. 88: 1654-1660. 
42. Balmer, S. E., and B. A. Wharton. 1989. Diet and faecal flora in the newborn: breast milk and 
infant formula. Arch Dis Child. 64: 1672-1677. 
43. Lien, E. L. 2003. Infant formulas with increased concentrations of alpha-lactalbumin. Am J 
Clin Nutr. 77: 1555S-1558S. 
44. Coppa, G. V., O. Gabrielli, P. Pierani, C. Catassi, A. Carlucci, and P. L. Giorgi. 1993. Changes in 
carbohydrate composition in human milk over 4 months of lactation. Pediatrics. 91: 637-641. 
45. Kunz, C., S. Rudloff, W. Baier, N. Klein, and S. Strobel. 2000. Oligosaccharides in human milk: 
structural, functional, and metabolic aspects. Annu Rev Nutr. 20: 699-722. 
46. Urashima, T., E. Taufik, K. Fukuda, and S. Asakuma. 2013. Recent advances in studies on milk 
oligosaccharides of cows and other domestic farm animals. Biosci Biotechnol Biochem. 77: 
455-466. 
47. Urashima, T., T. Saito, T. Nakamura, and M. Messer. 2001. Oligosaccharides of milk and 
colostrum in non-human mammals. Glycoconj J. 18: 357-371. 
48. Bode, L., and E. Jantscher-Krenn. 2012. Structure-function relationships of human milk 
oligosaccharides. Adv Nutr. 3: 383S-391S. 
49. Bruzzese, E., M. Volpicelli, M. Squaglia, A. Tartaglione, and A. Guarino. 2006. Impact of 
prebiotics on human health. Dig Liver Dis. 38 Suppl 2: S283-287. 
50. Boehm, G., J. Jelinek, B. Stahl, K. van Laere, J. Knol, S. Fanaro, G. Moro, and V. Vigi. 2004. 
Prebiotics in infant formulas. J Clin Gastroenterol. 38: S76-79. 
51. Koletzko, B., and M. Rodriguez-Palmero. 1999. Polyunsaturated fatty acids in human milk and 
their role in early infant development. J Mammary Gland Biol Neoplasia. 4: 269-284. 
52. Urwin, H. J., J. Zhang, Y. Gao, C. Wang, L. Li, P. Song, Q. Man, L. Meng, L. Froyland, E. A. Miles, 
P. C. Calder, and P. Yaqoob. 2012. Immune factors and fatty acid composition in human milk 
from river/lake, coastal and inland regions of China. Br J Nutr. 1-13. 
53. www.nestlebaby.com/au/baby_nutrition/products/Infant_Formula/.  [cited 03.02.2013]. 
54. www.milupa.de/mil/de/home/produkte/milchnahrung/milchnahrung.jsp.  [cited 03.02.13]. 
55. www.adapta-baby.ch/produkte/nutri-care.html.  [cited 03.02.2013]. 
56. Decsi, T., and B. Koletzko. 1994. Polyunsaturated fatty acids in infant nutrition. Acta Paediatr 
Suppl. 83: 31-37. 
57. GRAS determination for docosahexaenoic acid rich oil derived from tuna and arachidonic acid 
rich oil derived from Mortierella alpina, (2001). 
www.accessdata.fda.gov/scripts/fcn/gras_notices/grn000094a.pdf 
58. Riordan, J. 2005. Breastfeeding and human lactation. In. 3rd ed. Jones & Bartlett, Sudbury. 
104. 
59. Calder, P. C., S. Krauss-Etschmann, E. C. de Jong, C. Dupont, J. S. Frick, H. Frokiaer, J. Heinrich, 
H. Garn, S. Koletzko, G. Lack, G. Mattelio, H. Renz, P. T. Sangild, J. Schrezenmeir, T. M. Stulnig, 
T. Thymann, A. E. Wold, and B. Koletzko. 2006. Early nutrition and immunity - progress and 
perspectives. Br J Nutr. 96: 774-790. 
60. Spencer, S. P., and Y. Belkaid. 2012. Dietary and commensal derived nutrients: shaping 
mucosal and systemic immunity. Curr Opin Immunol. 24: 379-384. 
61. Buccigrossi, V., E. Nicastro, and A. Guarino. 2013. Functions of intestinal microflora in 
children. Curr Opin Gastroenterol. 29: 31-38. 
62. Newburg, D. S., and W. A. Walker. 2007. Protection of the neonate by the innate immune 
system of developing gut and of human milk. Pediatr Res. 61: 2-8. 
63. Lonnerdal, B. 2003. Nutritional and physiologic significance of human milk proteins. Am J Clin 
Nutr. 77: 1537S-1543S. 
64. Stromqvist, M., P. Falk, S. Bergstrom, L. Hansson, B. Lonnerdal, S. Normark, and O. Hernell. 
1995. Human milk kappa-casein and inhibition of Helicobacter pylori adhesion to human 
gastric mucosa. J Pediatr Gastroenterol Nutr. 21: 288-296. 
Introduction 
 
46 
 
65. Pellegrini, A., U. Thomas, N. Bramaz, P. Hunziker, and R. von Fellenberg. 1999. Isolation and 
identification of three bactericidal domains in the bovine alpha-lactalbumin molecule. 
Biochim Biophys Acta. 1426: 439-448. 
66. Maga, E. A., P. T. Desai, B. C. Weimer, N. Dao, D. Kultz, and J. D. Murray. 2012. Consumption 
of lysozyme-rich milk can alter microbial fecal populations. Appl Environ Microbiol. 78: 6153-
6160. 
67. Ibrahim, H. R., K. Imazato, and H. Ono. 2011. Human lysozyme possesses novel antimicrobial 
peptides within its N-terminal domain that target bacterial respiration. J Agric Food Chem. 
59: 10336-10345. 
68. Garofalo, R. 2010. Cytokines in human milk. J Pediatr. 156: S36-40. 
69. Buescher, E. S., and I. Malinowska. 1996. Soluble receptors and cytokine antagonists in 
human milk. Pediatr Res. 40: 839-844. 
70. Saarela, T., J. Kokkonen, and M. Koivisto. 2005. Macronutrient and energy contents of human 
milk fractions during the first six months of lactation. Acta Paediatr. 94: 1176-1181. 
71. Kent, J. C., L. R. Mitoulas, M. D. Cregan, D. T. Ramsay, D. A. Doherty, and P. E. Hartmann. 
2006. Volume and frequency of breastfeedings and fat content of breast milk throughout the 
day. Pediatrics. 117: e387-395. 
72. Gross, S. J., J. Geller, and R. M. Tomarelli. 1981. Composition of breast milk from mothers of 
preterm infants. Pediatrics. 68: 490-493. 
73. Daly, S. E., A. Di Rosso, R. A. Owens, and P. E. Hartmann. 1993. Degree of breast emptying 
explains changes in the fat content, but not fatty acid composition, of human milk. Exp 
Physiol. 78: 741-755. 
74. German, J. B. 2011. Dietary lipids from an evolutionary perspective: sources, structures and 
functions. Matern Child Nutr. 7 Suppl 2: 2-16. 
75. Bitman, J., L. M. Freed, M. C. Neville, D. L. Wood, P. Hamosh, and M. Hamosh. 1986. Lipid 
composition of prepartum human mammary secretion and postpartum milk. J Pediatr 
Gastroenterol Nutr. 5: 608-615. 
76. Szlagatys-Sidorkiewicz, A., D. Martysiak-Zurowska, G. Krzykowski, M. Zagierski, and B. 
Kaminska. 2013. Maternal Smoking Modulates Fatty Acid Profile of Breast Milk. Acta 
Paediatr. 
77. Giovannini, M., C. Agostoni, and P. C. Salari. 1991. The role of lipids in nutrition during the 
first months of life. J Int Med Res. 19: 351-362. 
78. Staellberg-Stenhagen, S., and L. Svennerholm. 1965. Fatty Acid Composition of Human Brain 
Sphingomyelins: Normal Variation with Age and Changes during Myelin Disorders. J Lipid Res. 
6: 146-155. 
79. Dziewulska, A., P. Dobrzyn, M. Jazurek, A. Pyrkowska, J. M. Ntambi, and A. Dobrzyn. 2012. 
Monounsaturated fatty acids are required for membrane translocation of protein kinase C-
theta induced by lipid overload in skeletal muscle. Mol Membr Biol. 29: 309-320. 
80. Moon, J. H., J. Y. Lee, S. B. Kang, J. S. Park, B. W. Lee, E. S. Kang, C. W. Ahn, H. C. Lee, and B. S. 
Cha. 2010. Dietary monounsaturated fatty acids but not saturated fatty acids preserve the 
insulin signaling pathway via IRS-1/PI3K in rat skeletal muscle. Lipids. 45: 1109-1116. 
81. Yaqoob, P. 2002. Monounsaturated fatty acids and immune function. Eur J Clin Nutr. 56 
Suppl 3: S9-S13. 
82. Le, H. D., J. A. Meisel, V. E. de Meijer, K. M. Gura, and M. Puder. 2009. The essentiality of 
arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot Essent Fatty Acids. 81: 
165-170. 
83. Innis, S. M. 2007. Fatty acids and early human development. Early Hum Dev. 83: 761-766. 
84. Heird, W. C., and A. Lapillonne. 2005. The role of essential fatty acids in development. Annu 
Rev Nutr. 25: 549-571. 
85. Lin, Y. H., A. Llanos, P. Mena, R. Uauy, N. Salem, Jr., and R. J. Pawlosky. 2010. Compartmental 
analyses of 2H5-alpha-linolenic acid and C-U-eicosapentaenoic acid toward synthesis of 
plasma labeled 22:6n-3 in newborn term infants. Am J Clin Nutr. 92: 284-293. 
Introduction 
 
47 
 
86. Weisinger, H. S., J. A. Armitage, B. G. Jeffrey, D. C. Mitchell, T. Moriguchi, A. J. Sinclair, R. S. 
Weisinger, and N. Salem, Jr. 2002. Retinal sensitivity loss in third-generation n-3 PUFA-
deficient rats. Lipids. 37: 759-765. 
87. Lauritzen, L., H. S. Hansen, M. H. Jorgensen, and K. F. Michaelsen. 2001. The essentiality of 
long chain n-3 fatty acids in relation to development and function of the brain and retina. 
Prog Lipid Res. 40: 1-94. 
88. Martinez, M. 1992. Tissue levels of polyunsaturated fatty acids during early human 
development. J Pediatr. 120: S129-138. 
89. Martinez, M., A. Ballabriga, and J. J. Gil-Gibernau. 1988. Lipids of the developing human 
retina: I. Total fatty acids, plasmalogens, and fatty acid composition of ethanolamine and 
choline phosphoglycerides. J Neurosci Res. 20: 484-490. 
90. Jamieson, E. C., K. A. Abbasi, F. Cockburn, J. Farquharson, R. W. Logan, and W. A. Patrick. 
1994. Effect of diet on term infant cerebral cortex fatty acid composition. World Rev Nutr 
Diet. 75: 139-141. 
91. Farquharson, J., F. Cockburn, W. A. Patrick, E. C. Jamieson, and R. W. Logan. 1992. Infant 
cerebral cortex phospholipid fatty-acid composition and diet. Lancet. 340: 810-813. 
92. Leaf, A. 2008. Historical overview of n-3 fatty acids and coronary heart disease. Am J Clin 
Nutr. 87: 1978S-1980S. 
93. Simopoulos, A. P. 2002. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am 
Coll Nutr. 21: 495-505. 
94. Endres, S., R. Lorenz, and K. Loeschke. 1999. Lipid treatment of inflammatory bowel disease. 
Curr Opin Clin Nutr Metab Care. 2: 117-120. 
95. McCall, T. B., D. O'Leary, J. Bloomfield, and C. A. O'Morain. 1989. Therapeutic potential of 
fish oil in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 3: 415-424. 
96. Salomon, P., A. A. Kornbluth, and H. D. Janowitz. 1990. Treatment of ulcerative colitis with 
fish oil n--3-omega-fatty acid: an open trial. J Clin Gastroenterol. 12: 157-161. 
97. Belluzzi, A., C. Brignola, M. Campieri, A. Pera, S. Boschi, and M. Miglioli. 1996. Effect of an 
enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med. 334: 1557-
1560. 
98. Caplan, M. S., and T. Jilling. 2001. The role of polyunsaturated fatty acid supplementation in 
intestinal inflammation and neonatal necrotizing enterocolitis. Lipids. 36: 1053-1057. 
99. Das, U. N. 2006. Can perinatal supplementation of long-chain polyunsaturated fatty acids 
prevent atopy, bronchial asthma and other inflammatory conditions? Med Sci Monit. 12: 
RA99-111. 
100. Lapillonne, A., S. Groh-Wargo, C. H. Gonzalez, and R. Uauy. 2013. Lipid needs of preterm 
infants: updated recommendations. J Pediatr. 162: S37-47. 
101. Haggarty, P. 2004. Effect of placental function on fatty acid requirements during pregnancy. 
Eur J Clin Nutr. 58: 1559-1570. 
102. Lapillonne, A., and C. L. Jensen. 2009. Reevaluation of the DHA requirement for the 
premature infant. Prostaglandins Leukot Essent Fatty Acids. 81: 143-150. 
103. Carnielli, V. P., M. Simonato, G. Verlato, I. Luijendijk, M. De Curtis, P. J. Sauer, and P. E. Cogo. 
2007. Synthesis of long-chain polyunsaturated fatty acids in preterm newborns fed formula 
with long-chain polyunsaturated fatty acids. Am J Clin Nutr. 86: 1323-1330. 
104. Jensen, R. G. 1999. Lipids in human milk. Lipids. 34: 1243-1271. 
105. Bokor, S., B. Koletzko, and T. Decsi. 2007. Systematic review of fatty acid composition of 
human milk from mothers of preterm compared to full-term infants. Ann Nutr Metab. 51: 
550-556. 
106. Jensen, R. G. 1996. The lipids in human milk. Prog Lipid Res. 35: 53-92. 
107. Ruan, C., X. Liu, H. Man, X. Ma, G. Lu, G. Duan, C. A. DeFrancesco, and W. E. Connor. 1995. 
Milk composition in women from five different regions of China: the great diversity of milk 
fatty acids. J Nutr. 125: 2993-2998. 
Introduction 
 
48 
 
108. Makrides, M., M. A. Neumann, and R. A. Gibson. 1996. Effect of maternal docosahexaenoic 
acid (DHA) supplementation on breast milk composition. Eur J Clin Nutr. 50: 352-357. 
109. Boris, J., B. Jensen, J. D. Salvig, N. J. Secher, and S. F. Olsen. 2004. A randomized controlled 
trial of the effect of fish oil supplementation in late pregnancy and early lactation on the n-3 
fatty acid content in human breast milk. Lipids. 39: 1191-1196. 
110. Insull, W., Jr., J. Hirsch, T. James, and E. H. Ahrens, Jr. 1959. The fatty acids of human milk. II. 
Alterations produced by manipulation of caloric balance and exchange of dietary fats. J Clin 
Invest. 38: 443-450. 
111. Martin, M. A., W. D. Lassek, S. J. Gaulin, R. W. Evans, J. G. Woo, S. R. Geraghty, B. S. Davidson, 
A. L. Morrow, H. S. Kaplan, and M. D. Gurven. 2012. Fatty acid composition in the mature 
milk of Bolivian forager-horticulturalists: controlled comparisons with a US sample. Matern 
Child Nutr. 8: 404-418. 
112. Valentine, C. J., G. Morrow, M. Pennell, A. L. Morrow, A. Hodge, A. Haban-Bartz, K. Collins, 
and L. K. Rogers. 2013. Randomized controlled trial of docosahexaenoic acid 
supplementation in midwestern U.S. Human milk donors. Breastfeed Med. 8: 86-91. 
113. Gottrand, F. 2008. Long-chain polyunsaturated fatty acids influence the immune system of 
infants. J Nutr. 138: 1807S-1812S. 
114. Serhan, C. N., N. Chiang, and T. E. Van Dyke. 2008. Resolving inflammation: dual anti-
inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 8: 349-361. 
115. Shimizu, T. 2009. Lipid mediators in health and disease: enzymes and receptors as 
therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol 
Toxicol. 49: 123-150. 
116. Norling, L. V., and M. Perretti. 2013. The role of omega-3 derived resolvins in arthritis. Curr 
Opin Pharmacol. 
117. Bagga, D., L. Wang, R. Farias-Eisner, J. A. Glaspy, and S. T. Reddy. 2003. Differential effects of 
prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 
expression and IL-6 secretion. Proc Natl Acad Sci U S A. 100: 1751-1756. 
118. Terano, T., J. A. Salmon, and S. Moncada. 1984. Biosynthesis and biological activity of 
leukotriene B5. Prostaglandins. 27: 217-232. 
119. Ricciotti, E., and G. A. FitzGerald. 2011. Prostaglandins and inflammation. Arterioscler Thromb 
Vasc Biol. 31: 986-1000. 
120. Legler, D. F., P. Krause, E. Scandella, E. Singer, and M. Groettrup. 2006. Prostaglandin E2 is 
generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 
receptors. J Immunol. 176: 966-973. 
121. Krause, P., M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler. 2009. 
Prostaglandin E(2) enhances T-cell proliferation by inducing the costimulatory molecules 
OX40L, CD70, and 4-1BBL on dendritic cells. Blood. 113: 2451-2460. 
122. Levy, B. D., C. B. Clish, B. Schmidt, K. Gronert, and C. N. Serhan. 2001. Lipid mediator class 
switching during acute inflammation: signals in resolution. Nat Immunol. 2: 612-619. 
123. Hammad, H., H. J. de Heer, T. Soullie, H. C. Hoogsteden, F. Trottein, and B. N. Lambrecht. 
2003. Prostaglandin D2 inhibits airway dendritic cell migration and function in steady state 
conditions by selective activation of the D prostanoid receptor 1. J Immunol. 171: 3936-3940. 
124. Basu, S. 2010. Bioactive eicosanoids: role of prostaglandin F(2alpha) and F(2)-isoprostanes in 
inflammation and oxidative stress related pathology. Mol Cells. 30: 383-391. 
125. Dorris, S. L., and R. S. Peebles, Jr. 2012. PGI2 as a regulator of inflammatory diseases. 
Mediators Inflamm. 2012: 926968. 
126. Nakahata, N. 2008. Thromboxane A2: physiology/pathophysiology, cellular signal 
transduction and pharmacology. Pharmacol Ther. 118: 18-35. 
127. Samuelsson, B., S. E. Dahlen, J. A. Lindgren, C. A. Rouzer, and C. N. Serhan. 1987. 
Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science. 237: 1171-
1176. 
Introduction 
 
49 
 
128. Austen, K. F. 2007. Additional functions for the cysteinyl leukotrienes recognized through 
studies of inflammatory processes in null strains. Prostaglandins Other Lipid Mediat. 83: 182-
187. 
129. Tager, A. M., J. H. Dufour, K. Goodarzi, S. D. Bercury, U. H. von Andrian, and A. D. Luster. 
2000. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a 
dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med. 192: 
439-446. 
130. Murray, J., C. Ward, J. T. O'Flaherty, I. Dransfield, C. Haslett, E. R. Chilvers, and A. G. Rossi. 
2003. Role of leukotrienes in the regulation of human granulocyte behaviour: dissociation 
between agonist-induced activation and retardation of apoptosis. Br J Pharmacol. 139: 388-
398. 
131. Sadik, C. D., and A. D. Luster. 2012. Lipid-cytokine-chemokine cascades orchestrate leukocyte 
recruitment in inflammation. J Leukoc Biol. 91: 207-215. 
132. Serhan, C. N. 2004. A search for endogenous mechanisms of anti-inflammation uncovers 
novel chemical mediators: missing links to resolution. Histochem Cell Biol. 122: 305-321. 
133. Weissmann, G., J. E. Smolen, and H. M. Korchak. 1980. Release of inflammatory mediators 
from stimulated neutrophils. N Engl J Med. 303: 27-34. 
134. Serhan, C. N., and N. A. Petasis. 2011. Resolvins and protectins in inflammation resolution. 
Chem Rev. 111: 5922-5943. 
135. Mas, E., K. D. Croft, P. Zahra, A. Barden, and T. A. Mori. 2012. Resolvins D1, D2, and other 
mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid 
supplementation. Clin Chem. 58: 1476-1484. 
136. Serhan, C. N., K. Gotlinger, S. Hong, and M. Arita. 2004. Resolvins, docosatrienes, and 
neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous 
epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid 
Mediat. 73: 155-172. 
137. Serhan, C. N. 2005. Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators 
of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids. 
73: 141-162. 
138. Gronert, K., A. Gewirtz, J. L. Madara, and C. N. Serhan. 1998. Identification of a human 
enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma 
and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med. 187: 1285-1294. 
139. Colgan, S. P., C. N. Serhan, C. A. Parkos, C. Delp-Archer, and J. L. Madara. 1993. Lipoxin A4 
modulates transmigration of human neutrophils across intestinal epithelial monolayers. J Clin 
Invest. 92: 75-82. 
140. Fiorucci, S., J. L. Wallace, A. Mencarelli, E. Distrutti, G. Rizzo, S. Farneti, A. Morelli, J. L. Tseng, 
B. Suramanyam, W. J. Guilford, and J. F. Parkinson. 2004. A beta-oxidation-resistant lipoxin 
A4 analog treats hapten-induced colitis by attenuating inflammation and immune 
dysfunction. Proc Natl Acad Sci U S A. 101: 15736-15741. 
141. Gewirtz, A. T., L. S. Collier-Hyams, A. N. Young, T. Kucharzik, W. J. Guilford, J. F. Parkinson, I. 
R. Williams, A. S. Neish, and J. L. Madara. 2002. Lipoxin a4 analogs attenuate induction of 
intestinal epithelial proinflammatory gene expression and reduce the severity of dextran 
sodium sulfate-induced colitis. J Immunol. 168: 5260-5267. 
142. Kure, I., S. Nishiumi, Y. Nishitani, T. Tanoue, T. Ishida, M. Mizuno, T. Fujita, H. Kutsumi, M. 
Arita, T. Azuma, and M. Yoshida. 2010. Lipoxin A(4) reduces lipopolysaccharide-induced 
inflammation in macrophages and intestinal epithelial cells through inhibition of nuclear 
factor-kappaB activation. J Pharmacol Exp Ther. 332: 541-548. 
143. Mangino, M. J., L. Brounts, B. Harms, and C. Heise. 2006. Lipoxin biosynthesis in 
inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 79: 84-92. 
144. Vong, L., J. G. Ferraz, N. Dufton, R. Panaccione, P. L. Beck, P. M. Sherman, M. Perretti, and J. 
L. Wallace. 2012. Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative 
colitis may promote mucosal homeostasis. PLoS One. 7: e39244. 
Introduction 
 
50 
 
145. Fiorucci, S., E. Distrutti, O. M. de Lima, M. Romano, A. Mencarelli, M. Barbanti, E. Palazzini, A. 
Morelli, and J. L. Wallace. 2003. Relative contribution of acetylated cyclo-oxygenase (COX)-2 
and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. 
FASEB J. 17: 1171-1173. 
146. Fiorucci, S., E. Distrutti, A. Mencarelli, A. Morelli, S. A. Laufor, G. Cirino, and J. L. Wallace. 
2003. Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids 
regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol. 139: 1351-
1359. 
147. Wallace, J. L., and S. Fiorucci. 2003. A magic bullet for mucosal protection...and aspirin is the 
trigger! Trends Pharmacol Sci. 24: 323-326. 
148. Fiorucci, S., O. M. de Lima, Jr., A. Mencarelli, B. Palazzetti, E. Distrutti, W. McKnight, M. Dicay, 
L. Ma, M. Romano, A. Morelli, and J. L. Wallace. 2002. Cyclooxygenase-2-derived lipoxin A4 
increases gastric resistance to aspirin-induced damage. Gastroenterology. 123: 1598-1606. 
149. Tjonahen, E., S. F. Oh, J. Siegelman, S. Elangovan, K. B. Percarpio, S. Hong, M. Arita, and C. N. 
Serhan. 2006. Resolvin E2: identification and anti-inflammatory actions: pivotal role of 
human 5-lipoxygenase in resolvin E series biosynthesis. Chem Biol. 13: 1193-1202. 
150. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel 
functional sets of lipid-derived mediators with antiinflammatory actions generated from 
omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and 
transcellular processing. J Exp Med. 192: 1197-1204. 
151. Schwab, J. M., N. Chiang, M. Arita, and C. N. Serhan. 2007. Resolvin E1 and protectin D1 
activate inflammation-resolution programmes. Nature. 447: 869-874. 
152. Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis, and C. N. 
Serhan. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the 
omega-3 lipid mediator resolvin E1. J Exp Med. 201: 713-722. 
153. Heufler, C., F. Koch, U. Stanzl, G. Topar, M. Wysocka, G. Trinchieri, A. Enk, R. M. Steinman, N. 
Romani, and G. Schuler. 1996. Interleukin-12 is produced by dendritic cells and mediates T 
helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J 
Immunol. 26: 659-668. 
154. Haworth, O., M. Cernadas, R. Yang, C. N. Serhan, and B. D. Levy. 2008. Resolvin E1 regulates 
interleukin 23, interferon-gamma and lipoxin A4 to promote the resolution of allergic airway 
inflammation. Nat Immunol. 9: 873-879. 
155. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and 
C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from omega-3 
eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. 
Proc Natl Acad Sci U S A. 102: 7671-7676. 
156. Campbell, E. L., C. F. MacManus, D. J. Kominsky, S. Keely, L. E. Glover, B. E. Bowers, M. Scully, 
W. J. Bruyninckx, and S. P. Colgan. 2010. Resolvin E1-induced intestinal alkaline phosphatase 
promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A. 
107: 14298-14303. 
157. Ishida, T., M. Yoshida, M. Arita, Y. Nishitani, S. Nishiumi, A. Masuda, S. Mizuno, T. Takagawa, 
Y. Morita, H. Kutsumi, H. Inokuchi, C. N. Serhan, R. S. Blumberg, and T. Azuma. 2010. Resolvin 
E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran 
sulfate sodium-induced colitis. Inflamm Bowel Dis. 16: 87-95. 
158. Salem, N., Jr., B. Litman, H. Y. Kim, and K. Gawrisch. 2001. Mechanisms of action of 
docosahexaenoic acid in the nervous system. Lipids. 36: 945-959. 
159. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. 
Moussignac. 2002. Resolvins: a family of bioactive products of omega-3 fatty acid 
transformation circuits initiated by aspirin treatment that counter proinflammation signals. J 
Exp Med. 196: 1025-1037. 
160. Sun, Y. P., S. F. Oh, J. Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P. Colgan, N. A. Petasis, and 
C. N. Serhan. 2007. Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical 
Introduction 
 
51 
 
assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem. 282: 
9323-9334. 
161. Spite, M., L. V. Norling, L. Summers, R. Yang, D. Cooper, N. A. Petasis, R. J. Flower, M. Perretti, 
and C. N. Serhan. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial 
sepsis. Nature. 461: 1287-1291. 
162. Duffield, J. S., S. Hong, V. S. Vaidya, Y. Lu, G. Fredman, C. N. Serhan, and J. V. Bonventre. 
2006. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol. 177: 5902-
5911. 
163. Bento, A. F., R. F. Claudino, R. C. Dutra, R. Marcon, and J. B. Calixto. 2011. Omega-3 fatty 
acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 
and resolvin D2 prevent experimental colitis in mice. J Immunol. 187: 1957-1969. 
164. Xu, Z. Z., and R. R. Ji. 2011. Resolvins are potent analgesics for arthritic pain. Br J Pharmacol. 
164: 274-277. 
165. Lima-Garcia, J. F., R. C. Dutra, K. da Silva, E. M. Motta, M. M. Campos, and J. B. Calixto. 2011. 
The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic 
properties in adjuvant-induced arthritis in rats. Br J Pharmacol. 164: 278-293. 
166. Dalli, J., J. W. Winkler, R. A. Colas, H. Arnardottir, C. Y. Cheng, N. Chiang, N. A. Petasis, and C. 
N. Serhan. 2013. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. 
Chem Biol. 20: 188-201. 
167. Serhan, C. N., K. Gotlinger, S. Hong, Y. Lu, J. Siegelman, T. Baer, R. Yang, S. P. Colgan, and N. 
A. Petasis. 2006. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural 
stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol. 176: 1848-
1859. 
168. Hong, S., K. Gronert, P. R. Devchand, R. L. Moussignac, and C. N. Serhan. 2003. Novel 
docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, 
human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem. 278: 14677-14687. 
169. Marcheselli, V. L., S. Hong, W. J. Lukiw, X. H. Tian, K. Gronert, A. Musto, M. Hardy, J. M. 
Gimenez, N. Chiang, C. N. Serhan, and N. G. Bazan. 2003. Novel docosanoids inhibit brain 
ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. 
J Biol Chem. 278: 43807-43817. 
170. Levy, B. D., P. Kohli, K. Gotlinger, O. Haworth, S. Hong, S. Kazani, E. Israel, K. J. Haley, and C. 
N. Serhan. 2007. Protectin D1 is generated in asthma and dampens airway inflammation and 
hyperresponsiveness. J Immunol. 178: 496-502. 
171. Ariel, A., P. L. Li, W. Wang, W. X. Tang, G. Fredman, S. Hong, K. H. Gotlinger, and C. N. Serhan. 
2005. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell 
apoptosis via lipid raft clustering. J Biol Chem. 280: 43079-43086. 
172. Le Huerou-Luron, I., S. Blat, and G. Boudry. 2010. Breast- v. formula-feeding: impacts on the 
digestive tract and immediate and long-term health effects. Nutr Res Rev. 23: 23-36. 
173. Laitinen, K., T. Arvola, E. Moilanen, A. M. Lampi, T. Ruuska, and E. Isolauri. 2005. 
Characterization of breast milk received by infants with gross blood in stools. Biol Neonate. 
87: 66-72. 
174. Lucas, A., and M. D. Mitchell. 1980. Prostaglandins in human milk. Arch Dis Child. 55: 950-
952. 
175. Laitinen, K., U. Hoppu, M. Hamalainen, K. Linderborg, E. Moilanen, and E. Isolauri. 2006. 
Breast milk fatty acids may link innate and adaptive immune regulation: analysis of soluble 
CD14, prostaglandin E2, and fatty acids. Pediatr Res. 59: 723-727. 
176. Laiho, K., A. M. Lampi, M. Hamalainen, E. Moilanen, V. Piironen, T. Arvola, S. Syrjanen, and E. 
Isolauri. 2003. Breast milk fatty acids, eicosanoids, and cytokines in mothers with and 
without allergic disease. Pediatr Res. 53: 642-647. 
177. Yang, R., N. Chiang, S. F. Oh, and C. N. Serhan. 2011. Metabolomics-lipidomics of eicosanoids 
and docosanoids generated by phagocytes. Curr Protoc Immunol. Chapter 14: Unit 14 26. 
Introduction 
 
52 
 
178. Wu, S., R. Grimm, J. B. German, and C. B. Lebrilla. 2011. Annotation and structural analysis of 
sialylated human milk oligosaccharides. J Proteome Res. 10: 856-868. 
179. Wu, S., N. Tao, J. B. German, R. Grimm, and C. B. Lebrilla. 2010. Development of an 
annotated library of neutral human milk oligosaccharides. J Proteome Res. 9: 4138-4151. 
180. Ruhaak, L. R., and C. B. Lebrilla. 2012. Analysis and role of oligosaccharides in milk. BMB Rep. 
45: 442-451. 
181. Rudloff, S., G. Pohlentz, C. Borsch, M. J. Lentze, and C. Kunz. 2012. Urinary excretion of in 
vivo (1)(3)C-labelled milk oligosaccharides in breastfed infants. Br J Nutr. 107: 957-963. 
182. Rudloff, S., and C. Kunz. 2012. Milk oligosaccharides and metabolism in infants. Adv Nutr. 3: 
398S-405S. 
183. Newburg, D. S., G. M. Ruiz-Palacios, and A. L. Morrow. 2005. Human milk glycans protect 
infants against enteric pathogens. Annu Rev Nutr. 25: 37-58. 
184. Urashima, T., S. Asakuma, F. Leo, K. Fukuda, M. Messer, and O. T. Oftedal. 2012. The 
predominance of type I oligosaccharides is a feature specific to human breast milk. Adv Nutr. 
3: 473S-482S. 
185. Thomson, A. M., and A. E. Black. 1975. Nutritional aspects of human lactation. Bull World 
Health Organ. 52: 163-177. 
186. Sela, D. A., and D. A. Mills. 2010. Nursing our microbiota: molecular linkages between 
bifidobacteria and milk oligosaccharides. Trends Microbiol. 18: 298-307. 
187. Bode, L. 2009. Human milk oligosaccharides: prebiotics and beyond. Nutr Rev. 67 Suppl 2: 
S183-191. 
188. Kobata, A. 2010. Structures and application of oligosaccharides in human milk. Proc Jpn Acad 
Ser B Phys Biol Sci. 86: 731-747. 
189. Tao, N., E. J. DePeters, S. Freeman, J. B. German, R. Grimm, and C. B. Lebrilla. 2008. Bovine 
milk glycome. J Dairy Sci. 91: 3768-3778. 
190. Nakamura, T., H. Kawase, K. Kimura, Y. Watanabe, M. Ohtani, I. Arai, and T. Urashima. 2003. 
Concentrations of sialyloligosaccharides in bovine colostrum and milk during the prepartum 
and early lactation. J Dairy Sci. 86: 1315-1320. 
191. Fong, B., K. Ma, and P. McJarrow. 2011. Quantification of bovine milk oligosaccharides using 
liquid chromatography-selected reaction monitoring-mass spectrometry. J Agric Food Chem. 
59: 9788-9795. 
192. Saavedra, J. M., and A. M. Dattilo. 2012. Early development of intestinal microbiota: 
implications for future health. Gastroenterol Clin North Am. 41: 717-731. 
193. Adlerberth, I., and A. E. Wold. 2009. Establishment of the gut microbiota in Western infants. 
Acta Paediatr. 98: 229-238. 
194. Bezirtzoglou, E., A. Tsiotsias, and G. W. Welling. 2011. Microbiota profile in feces of breast- 
and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 17: 
478-482. 
195. O'Hara, A. M., and F. Shanahan. 2006. The gut flora as a forgotten organ. EMBO Rep. 7: 688-
693. 
196. Johnson, C. L., and J. Versalovic. 2012. The human microbiome and its potential importance 
to pediatrics. Pediatrics. 129: 950-960. 
197. Dominguez-Bello, M. G., E. K. Costello, M. Contreras, M. Magris, G. Hidalgo, N. Fierer, and R. 
Knight. 2010. Delivery mode shapes the acquisition and structure of the initial microbiota 
across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 107: 11971-11975. 
198. Collado, M. C., M. Cernada, C. Bauerl, M. Vento, and G. Perez-Martinez. 2012. Microbial 
ecology and host-microbiota interactions during early life stages. Gut Microbes. 3: 352-365. 
199. Garrido, D., D. Barile, and D. A. Mills. 2012. A molecular basis for bifidobacterial enrichment 
in the infant gastrointestinal tract. Adv Nutr. 3: 415S-421S. 
200. Scholtens, P. A., R. Oozeer, R. Martin, K. B. Amor, and J. Knol. 2012. The early settlers: 
intestinal microbiology in early life. Annu Rev Food Sci Technol. 3: 425-447. 
Introduction 
 
53 
 
201. Collado, M. C., S. Delgado, A. Maldonado, and J. M. Rodriguez. 2009. Assessment of the 
bacterial diversity of breast milk of healthy women by quantitative real-time PCR. Lett Appl 
Microbiol. 48: 523-528. 
202. Martin, R., S. Langa, C. Reviriego, E. Jiminez, M. L. Marin, J. Xaus, L. Fernandez, and J. M. 
Rodriguez. 2003. Human milk is a source of lactic acid bacteria for the infant gut. J Pediatr. 
143: 754-758. 
203. Engfer, M. B., B. Stahl, B. Finke, G. Sawatzki, and H. Daniel. 2000. Human milk 
oligosaccharides are resistant to enzymatic hydrolysis in the upper gastrointestinal tract. Am 
J Clin Nutr. 71: 1589-1596. 
204. Gnoth, M. J., C. Kunz, E. Kinne-Saffran, and S. Rudloff. 2000. Human milk oligosaccharides are 
minimally digested in vitro. J Nutr. 130: 3014-3020. 
205. Yoshioka, H., K. Iseki, and K. Fujita. 1983. Development and differences of intestinal flora in 
the neonatal period in breast-fed and bottle-fed infants. Pediatrics. 72: 317-321. 
206. Zivkovic, A. M., J. B. German, C. B. Lebrilla, and D. A. Mills. 2011. Human milk glycobiome and 
its impact on the infant gastrointestinal microbiota. Proc Natl Acad Sci U S A. 108 Suppl 1: 
4653-4658. 
207. Harmsen, H. J., A. C. Wildeboer-Veloo, G. C. Raangs, A. A. Wagendorp, N. Klijn, J. G. Bindels, 
and G. W. Welling. 2000. Analysis of intestinal flora development in breast-fed and formula-
fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol 
Nutr. 30: 61-67. 
208. Knol, J., P. Scholtens, C. Kafka, J. Steenbakkers, S. Gro, K. Helm, M. Klarczyk, H. Schopfer, H. 
M. Bockler, and J. Wells. 2005. Colon microflora in infants fed formula with galacto- and 
fructo-oligosaccharides: more like breast-fed infants. J Pediatr Gastroenterol Nutr. 40: 36-42. 
209. Jeong, K., V. Nguyen, and J. Kim. 2012. Human milk oligosaccharides: the novel modulator of 
intestinal microbiota. BMB Rep. 45: 433-441. 
210. Zivkovic, A. M., and D. Barile. 2011. Bovine milk as a source of functional oligosaccharides for 
improving human health. Adv Nutr. 2: 284-289. 
211. Rinne, M. M., M. Gueimonde, M. Kalliomaki, U. Hoppu, S. J. Salminen, and E. Isolauri. 2005. 
Similar bifidogenic effects of prebiotic-supplemented partially hydrolyzed infant formula and 
breastfeeding on infant gut microbiota. FEMS Immunol Med Microbiol. 43: 59-65. 
212. Bezkorovainy, A. 1989. Ecology of bifidobacteria. In: Biochemistry and physiology of 
bifidobacteria. A. Bezkorovainy, Miller-Catchpole, R, editor. CRC Press, Cleveland. 29-72. 
213. Rivero-Urgell, M., and A. Santamaria-Orleans. 2001. Oligosaccharides: application in infant 
food. Early Hum Dev. 65 Suppl: S43-52. 
214. Turroni, F., F. Bottacini, E. Foroni, I. Mulder, J. H. Kim, A. Zomer, B. Sanchez, A. Bidossi, A. 
Ferrarini, V. Giubellini, M. Delledonne, B. Henrissat, P. Coutinho, M. Oggioni, G. F. Fitzgerald, 
D. Mills, A. Margolles, D. Kelly, D. van Sinderen, and M. Ventura. 2010. Genome analysis of 
Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan 
foraging. Proc Natl Acad Sci U S A. 107: 19514-19519. 
215. Sela, D. A., J. Chapman, A. Adeuya, J. H. Kim, F. Chen, T. R. Whitehead, A. Lapidus, D. S. 
Rokhsar, C. B. Lebrilla, J. B. German, N. P. Price, P. M. Richardson, and D. A. Mills. 2008. The 
genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk 
utilization within the infant microbiome. Proc Natl Acad Sci U S A. 105: 18964-18969. 
216. Marcobal, A., M. Barboza, J. W. Froehlich, D. E. Block, J. B. German, C. B. Lebrilla, and D. A. 
Mills. 2010. Consumption of human milk oligosaccharides by gut-related microbes. J Agric 
Food Chem. 58: 5334-5340. 
217. Asakuma, S., E. Hatakeyama, T. Urashima, E. Yoshida, T. Katayama, K. Yamamoto, H. 
Kumagai, H. Ashida, J. Hirose, and M. Kitaoka. 2011. Physiology of consumption of human 
milk oligosaccharides by infant gut-associated bifidobacteria. J Biol Chem. 286: 34583-34592. 
218. Locascio, R. G., M. R. Ninonuevo, S. R. Kronewitter, S. L. Freeman, J. B. German, C. B. Lebrilla, 
and D. A. Mills. 2009. A versatile and scalable strategy for glycoprofiling bifidobacterial 
consumption of human milk oligosaccharides. Microb Biotechnol. 2: 333-342. 
Introduction 
 
54 
 
219. Junick, J., and M. Blaut. 2012. Quantification of human fecal bifidobacterium species by use 
of quantitative real-time PCR analysis targeting the groEL gene. Appl Environ Microbiol. 78: 
2613-2622. 
220. Marcobal, A., M. Barboza, E. D. Sonnenburg, N. Pudlo, E. C. Martens, P. Desai, C. B. Lebrilla, 
B. C. Weimer, D. A. Mills, J. B. German, and J. L. Sonnenburg. 2011. Bacteroides in the infant 
gut consume milk oligosaccharides via mucus-utilization pathways. Cell Host Microbe. 10: 
507-514. 
221. Marcobal, A., and J. L. Sonnenburg. 2012. Human milk oligosaccharide consumption by 
intestinal microbiota. Clin Microbiol Infect. 18 Suppl 4: 12-15. 
222. LoCascio, R. G., M. R. Ninonuevo, S. L. Freeman, D. A. Sela, R. Grimm, C. B. Lebrilla, D. A. 
Mills, and J. B. German. 2007. Glycoprofiling of bifidobacterial consumption of human milk 
oligosaccharides demonstrates strain specific, preferential consumption of small chain 
glycans secreted in early human lactation. J Agric Food Chem. 55: 8914-8919. 
223. Xiao, J. Z., S. Takahashi, M. Nishimoto, T. Odamaki, T. Yaeshima, K. Iwatsuki, and M. Kitaoka. 
2010. Distribution of in vitro fermentation ability of lacto-N-biose I, a major building block of 
human milk oligosaccharides, in bifidobacterial strains. Appl Environ Microbiol. 76: 54-59. 
224. Kiyohara, M., A. Tachizawa, M. Nishimoto, M. Kitaoka, H. Ashida, and K. Yamamoto. 2009. 
Prebiotic effect of lacto-N-biose I on bifidobacterial growth. Biosci Biotechnol Biochem. 73: 
1175-1179. 
225. Barboza, M., D. A. Sela, C. Pirim, R. G. Locascio, S. L. Freeman, J. B. German, D. A. Mills, and C. 
B. Lebrilla. 2009. Glycoprofiling bifidobacterial consumption of galacto-oligosaccharides by 
mass spectrometry reveals strain-specific, preferential consumption of glycans. Appl Environ 
Microbiol. 75: 7319-7325. 
226. Knol, J., G. Boehm, M. Lidestri, F. Negretti, J. Jelinek, M. Agosti, B. Stahl, A. Marini, and F. 
Mosca. 2005. Increase of faecal bifidobacteria due to dietary oligosaccharides induces a 
reduction of clinically relevant pathogen germs in the faeces of formula-fed preterm infants. 
Acta Paediatr Suppl. 94: 31-33. 
227. Servin, A. L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial 
pathogens. FEMS Microbiol Rev. 28: 405-440. 
228. Ouwehand, A., E. Isolauri, and S. Salminen. 2002. The role of the intestinal microflora for the 
development of the immune system in early childhood. Eur J Nutr. 41 Suppl 1: I32-37. 
229. Watzl, B., S. Girrbach, and M. Roller. 2005. Inulin, oligofructose and immunomodulation. Br J 
Nutr. 93 Suppl 1: S49-55. 
230. Sharon, N. 1987. Bacterial lectins, cell-cell recognition and infectious disease. FEBS Lett. 217: 
145-157. 
231. Karlsson, K. A. 1995. Microbial recognition of target-cell glycoconjugates. Curr Opin Struct 
Biol. 5: 622-635. 
232. Andersson, B., O. Porras, L. A. Hanson, T. Lagergard, and C. Svanborg-Eden. 1986. Inhibition 
of attachment of Streptococcus pneumoniae and Haemophilus influenzae by human milk and 
receptor oligosaccharides. J Infect Dis. 153: 232-237. 
233. Coppa, G. V., S. Bruni, L. Zampini, T. Galeazzi, B. Facinelli, R. Capretti, A. Carlucci, and O. 
Gabrielli. 2003. Oligosaccharides of human milk inhibit the adhesion of Listeria 
monocytogenes to Caco-2 cells. Ital J Pediatr. 29: 61-68. 
234. Coppa, G. V., L. Zampini, T. Galeazzi, B. Facinelli, L. Ferrante, R. Capretti, and G. Orazio. 2006. 
Human milk oligosaccharides inhibit the adhesion to Caco-2 cells of diarrheal pathogens: 
Escherichia coli, Vibrio cholerae, and Salmonella fyris. Pediatr Res. 59: 377-382. 
235. Ruiz-Palacios, G. M., L. E. Cervantes, P. Ramos, B. Chavez-Munguia, and D. S. Newburg. 2003. 
Campylobacter jejuni binds intestinal H(O) antigen (Fuc alpha 1, 2Gal beta 1, 4GlcNAc), and 
fucosyloligosaccharides of human milk inhibit its binding and infection. J Biol Chem. 278: 
14112-14120. 
236. Newburg, D. S. 2009. Neonatal protection by an innate immune system of human milk 
consisting of oligosaccharides and glycans. J Anim Sci. 87: 26-34. 
Introduction 
 
55 
 
237. Idanpaan-Heikkila, I., P. M. Simon, D. Zopf, T. Vullo, P. Cahill, K. Sokol, and E. Tuomanen. 
1997. Oligosaccharides interfere with the establishment and progression of experimental 
pneumococcal pneumonia. J Infect Dis. 176: 704-712. 
238. Cravioto, A., A. Tello, H. Villafan, J. Ruiz, S. del Vedovo, and J. R. Neeser. 1991. Inhibition of 
localized adhesion of enteropathogenic Escherichia coli to HEp-2 cells by immunoglobulin 
and oligosaccharide fractions of human colostrum and breast milk. J Infect Dis. 163: 1247-
1255. 
239. Hong, P., M. R. Ninonuevo, B. Lee, C. Lebrilla, and L. Bode. 2009. Human milk 
oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-
integrin (DC-SIGN). Br J Nutr. 101: 482-486. 
240. Newburg, D. S., L. K. Pickering, R. H. McCluer, and T. G. Cleary. 1990. Fucosylated 
oligosaccharides of human milk protect suckling mice from heat-stabile enterotoxin of 
Escherichia coli. J Infect Dis. 162: 1075-1080. 
241. Brassart, D., A. Woltz, M. Golliard, and J. R. Neeser. 1991. In vitro inhibition of adhesion of 
Candida albicans clinical isolates to human buccal epithelial cells by Fuc alpha 1----2Gal beta-
bearing complex carbohydrates. Infect Immun. 59: 1605-1613. 
242. Idota, T., H. Kawakami, Y. Murakami, and M. Sugawara. 1995. Inhibition of cholera toxin by 
human milk fractions and sialyllactose. Biosci Biotechnol Biochem. 59: 417-419. 
243. Stins, M. F., N. V. Prasadarao, L. Ibric, C. A. Wass, P. Luckett, and K. S. Kim. 1994. Binding 
characteristics of S fimbriated Escherichia coli to isolated brain microvascular endothelial 
cells. Am J Pathol. 145: 1228-1236. 
244. Virkola, R., J. Parkkinen, J. Hacker, and T. K. Korhonen. 1993. Sialyloligosaccharide chains of 
laminin as an extracellular matrix target for S fimbriae of Escherichia coli. Infect Immun. 61: 
4480-4484. 
245. Devaraj, N., M. Sheykhnazari, W. S. Warren, and V. P. Bhavanandan. 1994. Differential 
binding of Pseudomonas aeruginosa to normal and cystic fibrosis tracheobronchial mucins. 
Glycobiology. 4: 307-316. 
246. Bouchara, J. P., M. Sanchez, A. Chevailler, A. Marot-Leblond, J. C. Lissitzky, G. Tronchin, and 
D. Chabasse. 1997. Sialic acid-dependent recognition of laminin and fibrinogen by Aspergillus 
fumigatus conidia. Infect Immun. 65: 2717-2724. 
247. Gambaryan, A. S., A. B. Tuzikov, V. E. Piskarev, S. S. Yamnikova, D. K. Lvov, J. S. Robertson, N. 
V. Bovin, and M. N. Matrosovich. 1997. Specification of receptor-binding phenotypes of 
influenza virus isolates from different hosts using synthetic sialylglycopolymers: non-egg-
adapted human H1 and H3 influenza A and influenza B viruses share a common high binding 
affinity for 6'-sialyl(N-acetyllactosamine). Virology. 232: 345-350. 
248. Matrosovich, M. N., A. S. Gambaryan, A. B. Tuzikov, N. E. Byramova, L. V. Mochalova, A. A. 
Golbraikh, M. D. Shenderovich, J. Finne, and N. V. Bovin. 1993. Probing of the receptor-
binding sites of the H1 and H3 influenza A and influenza B virus hemagglutinins by synthetic 
and natural sialosides. Virology. 196: 111-121. 
249. Stehle, T., Y. Yan, T. L. Benjamin, and S. C. Harrison. 1994. Structure of murine polyomavirus 
complexed with an oligosaccharide receptor fragment. Nature. 369: 160-163. 
250. Mysore, J. V., T. Wigginton, P. M. Simon, D. Zopf, L. M. Heman-Ackah, and A. Dubois. 1999. 
Treatment of Helicobacter pylori infection in rhesus monkeys using a novel antiadhesion 
compound. Gastroenterology. 117: 1316-1325. 
251. Simon, P. M., P. L. Goode, A. Mobasseri, and D. Zopf. 1997. Inhibition of Helicobacter pylori 
binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides. Infect 
Immun. 65: 750-757. 
252. Martin-Sosa, S., M. J. Martin, and P. Hueso. 2002. The sialylated fraction of milk 
oligosaccharides is partially responsible for binding to enterotoxigenic and uropathogenic 
Escherichia coli human strains. J Nutr. 132: 3067-3072. 
253. Schwertmann, A., H. Schroten, J. Hacker, and C. Kunz. 1999. S-fimbriae from Escherichia coli 
bind to soluble glycoproteins from human milk. J Pediatr Gastroenterol Nutr. 28: 257-263. 
Introduction 
 
56 
 
254. Feizi, T., and R. W. Loveless. 1996. Carbohydrate recognition by Mycoplasma pneumoniae 
and pathologic consequences. Am J Respir Crit Care Med. 154: S133-136. 
255. Liukkonen, J., S. Haataja, K. Tikkanen, S. Kelm, and J. Finne. 1992. Identification of N-
acetylneuraminyl alpha 2-->3 poly-N-acetyllactosamine glycans as the receptors of sialic acid-
binding Streptococcus suis strains. J Biol Chem. 267: 21105-21111. 
256. Ashkenazi, S., D. S. Newburg, and T. G. Cleary. 1991. The effect of human milk on the 
adherence of enterohemorrhagic E. coli to rabbit intestinal cells. Adv Exp Med Biol. 310: 173-
177. 
257. Jiang, X., P. Huang, W. Zhong, M. Tan, T. Farkas, A. L. Morrow, D. S. Newburg, G. M. Ruiz-
Palacios, and L. K. Pickering. 2004. Human milk contains elements that block binding of 
noroviruses to human histo-blood group antigens in saliva. J Infect Dis. 190: 1850-1859. 
258. Lesman-Movshovich, E., B. Lerrer, and N. Gilboa-Garber. 2003. Blocking of Pseudomonas 
aeruginosa lectins by human milk glycans. Can J Microbiol. 49: 230-235. 
259. Ramphal, R., C. Carnoy, S. Fievre, J. C. Michalski, N. Houdret, G. Lamblin, G. Strecker, and P. 
Roussel. 1991. Pseudomonas aeruginosa recognizes carbohydrate chains containing type 1 
(Gal beta 1-3GlcNAc) or type 2 (Gal beta 1-4GlcNAc) disaccharide units. Infect Immun. 59: 
700-704. 
260. Yolken, R. H., J. A. Peterson, S. L. Vonderfecht, E. T. Fouts, K. Midthun, and D. S. Newburg. 
1992. Human milk mucin inhibits rotavirus replication and prevents experimental 
gastroenteritis. J Clin Invest. 90: 1984-1991. 
261. Crane, J. K., S. S. Azar, A. Stam, and D. S. Newburg. 1994. Oligosaccharides from human milk 
block binding and activity of the Escherichia coli heat-stable enterotoxin (STa) in T84 
intestinal cells. J Nutr. 124: 2358-2364. 
262. Angeloni, S., J. L. Ridet, N. Kusy, H. Gao, F. Crevoisier, S. Guinchard, S. Kochhar, H. Sigrist, and 
N. Sprenger. 2005. Glycoprofiling with micro-arrays of glycoconjugates and lectins. 
Glycobiology. 15: 31-41. 
263. Sharon, N., and I. Ofek. 2000. Safe as mother's milk: carbohydrates as future anti-adhesion 
drugs for bacterial diseases. Glycoconj J. 17: 659-664. 
264. Mouricout, M., J. M. Petit, J. R. Carias, and R. Julien. 1990. Glycoprotein glycans that inhibit 
adhesion of Escherichia coli mediated by K99 fimbriae: treatment of experimental 
colibacillosis. Infect Immun. 58: 98-106. 
265. Lee, W. H., P. Pathanibul, J. Quarterman, J. H. Jo, N. S. Han, M. J. Miller, Y. S. Jin, and J. H. Seo. 
2012. Whole cell biosynthesis of a functional oligosaccharide, 2'-fucosyllactose, using 
engineered Escherichia coli. Microb Cell Fact. 11: 48. 
266. Ruffing, A., and R. R. Chen. 2006. Metabolic engineering of microbes for oligosaccharide and 
polysaccharide synthesis. Microb Cell Fact. 5: 25. 
267. Ukkonen, P., K. Varis, M. Jernfors, E. Herva, J. Jokinen, E. Ruokokoski, D. Zopf, and T. Kilpi. 
2000. Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, 
double-blind, placebo-controlled trial. Lancet. 356: 1398-1402. 
268. Parente, F., C. Cucino, A. Anderloni, G. Grandinetti, and G. Bianchi Porro. 2003. Treatment of 
Helicobacter pylori infection using a novel antiadhesion compound (3'sialyllactose sodium 
salt). A double blind, placebo-controlled clinical study. Helicobacter. 8: 252-256. 
269. Schumacher, G., G. Bendas, B. Stahl, and C. Beermann. 2006. Human milk oligosaccharides 
affect P-selectin binding capacities: in vitro investigation. Nutrition. 22: 620-627. 
270. Srichai, M. B., and R. Zent. 2010. Integrin Structure and Function. In: Cell-Extracellular Matrix 
Interactions in Cancer. R. Zent and A. Pozzi, editors. Springer Science+Business Media, New 
York. 19-41. 
271. Stewart, P. L., and G. R. Nemerow. 2007. Cell integrins: commonly used receptors for diverse 
viral pathogens. Trends Microbiol. 15: 500-507. 
272. Carden, D. L., and D. N. Granger. 2000. Pathophysiology of ischaemia-reperfusion injury. J 
Pathol. 190: 255-266. 
Introduction 
 
57 
 
273. Peters, M. J., G. Dixon, K. T. Kotowicz, D. J. Hatch, R. S. Heyderman, and N. J. Klein. 1999. 
Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils 
primed for adhesion, phagocytosis and intracellular killing. Br J Haematol. 106: 391-399. 
274. Bode, L., S. Rudloff, C. Kunz, S. Strobel, and N. Klein. 2004. Human milk oligosaccharides 
reduce platelet-neutrophil complex formation leading to a decrease in neutrophil beta 2 
integrin expression. J Leukoc Biol. 76: 820-826. 
275. Kunz, C., and S. Rudloff. 2008. Potential anti-inflammatory and anti-infectious effects of 
human milk oligosaccharides. Adv Exp Med Biol. 606: 455-465. 
276. Kolarich, D., B. Lepenies, and P. H. Seeberger. 2012. Glycomics, glycoproteomics and the 
immune system. Curr Opin Chem Biol. 16: 214-220. 
277. Foxall, C., S. R. Watson, D. Dowbenko, C. Fennie, L. A. Lasky, M. Kiso, A. Hasegawa, D. Asa, 
and B. K. Brandley. 1992. The three members of the selectin receptor family recognize a 
common carbohydrate epitope, the sialyl Lewis(x) oligosaccharide. J Cell Biol. 117: 895-902. 
278. Rudloff, S., C. Stefan, G. Pohlentz, and C. Kunz. 2002. Detection of ligands for selectins in the 
oligosaccharide fraction of human milk. Eur J Nutr. 41: 85-92. 
279. Bode, L., C. Kunz, M. Muhly-Reinholz, K. Mayer, W. Seeger, and S. Rudloff. 2004. Inhibition of 
monocyte, lymphocyte, and neutrophil adhesion to endothelial cells by human milk 
oligosaccharides. Thromb Haemost. 92: 1402-1410. 
280. Eiwegger, T., B. Stahl, J. Schmitt, G. Boehm, M. Gerstmayr, J. Pichler, E. Dehlink, C. Loibichler, 
R. Urbanek, and Z. Szepfalusi. 2004. Human milk--derived oligosaccharides and plant-derived 
oligosaccharides stimulate cytokine production of cord blood T-cells in vitro. Pediatr Res. 56: 
536-540. 
281. Velupillai, P., and D. A. Harn. 1994. Oligosaccharide-specific induction of interleukin 10 
production by B220+ cells from schistosome-infected mice: a mechanism for regulation of 
CD4+ T-cell subsets. Proc Natl Acad Sci U S A. 91: 18-22. 
282. Terrazas, L. I., K. L. Walsh, D. Piskorska, E. McGuire, and D. A. Harn, Jr. 2001. The schistosome 
oligosaccharide lacto-N-neotetraose expands Gr1(+) cells that secrete anti-inflammatory 
cytokines and inhibit proliferation of naive CD4(+) cells: a potential mechanism for immune 
polarization in helminth infections. J Immunol. 167: 5294-5303. 
283. Moro, G., S. Arslanoglu, B. Stahl, J. Jelinek, U. Wahn, and G. Boehm. 2006. A mixture of 
prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six 
months of age. Arch Dis Child. 91: 814-819. 
284. Arslanoglu, S., G. E. Moro, J. Schmitt, L. Tandoi, S. Rizzardi, and G. Boehm. 2008. Early dietary 
intervention with a mixture of prebiotic oligosaccharides reduces the incidence of allergic 
manifestations and infections during the first two years of life. J Nutr. 138: 1091-1095. 
285. Morrow, A. L., G. M. Ruiz-Palacios, X. Jiang, and D. S. Newburg. 2005. Human-milk glycans 
that inhibit pathogen binding protect breast-feeding infants against infectious diarrhea. J 
Nutr. 135: 1304-1307. 
286. Thurl, S., M. Munzert, J. Henker, G. Boehm, B. Muller-Werner, J. Jelinek, and B. Stahl. 2010. 
Variation of human milk oligosaccharides in relation to milk groups and lactational periods. 
Br J Nutr. 104: 1261-1271. 
287. Morrow, A. L., J. Meinzen-Derr, P. Huang, K. R. Schibler, T. Cahill, M. Keddache, S. G. Kallapur, 
D. S. Newburg, M. Tabangin, B. B. Warner, and X. Jiang. 2011. Fucosyltransferase 2 non-
secretor and low secretor status predicts severe outcomes in premature infants. J Pediatr. 
158: 745-751. 
288. Grollman, E. F., and V. Ginsburg. 1967. Correlation between secretor status and the 
occurrence of 2'-fucosyllactose in human milk. Biochem Biophys Res Commun. 28: 50-53. 
289. Newburg, D. S., G. M. Ruiz-Palacios, M. Altaye, P. Chaturvedi, J. Meinzen-Derr, L. Guerrero 
Mde, and A. L. Morrow. 2004. Innate protection conferred by fucosylated oligosaccharides of 
human milk against diarrhea in breastfed infants. Glycobiology. 14: 253-263. 
Introduction 
 
58 
 
290. Lindesmith, L., C. Moe, S. Marionneau, N. Ruvoen, X. Jiang, L. Lindblad, P. Stewart, J. 
LePendu, and R. Baric. 2003. Human susceptibility and resistance to Norwalk virus infection. 
Nat Med. 9: 548-553. 
291. Hutson, A. M., F. Airaud, J. LePendu, M. K. Estes, and R. L. Atmar. 2005. Norwalk virus 
infection associates with secretor status genotyped from sera. J Med Virol. 77: 116-120. 
292. Thorven, M., A. Grahn, K. O. Hedlund, H. Johansson, C. Wahlfrid, G. Larson, and L. Svensson. 
2005. A homozygous nonsense mutation (428G-->A) in the human secretor (FUT2) gene 
provides resistance to symptomatic norovirus (GGII) infections. J Virol. 79: 15351-15355. 
293. Yu, Z. T., C. Chen, D. E. Kling, B. Liu, J. M. McCoy, M. Merighi, M. Heidtman, and D. S. 
Newburg. 2013. The principal fucosylated oligosaccharides of human milk exhibit prebiotic 
properties on cultured infant microbiota. Glycobiology. 23: 169-177. 
294. Coppa, G. V., P. Pierani, L. Zampini, I. Carloni, A. Carlucci, and O. Gabrielli. 1999. 
Oligosaccharides in human milk during different phases of lactation. Acta Paediatr Suppl. 88: 
89-94. 
295. Ninonuevo, M. R., Y. Park, H. Yin, J. Zhang, R. E. Ward, B. H. Clowers, J. B. German, S. L. 
Freeman, K. Killeen, R. Grimm, and C. B. Lebrilla. 2006. A strategy for annotating the human 
milk glycome. J Agric Food Chem. 54: 7471-7480. 
296. Varki, A. 1992. Diversity in the sialic acids. Glycobiology. 2: 25-40. 
297. Severi, E., D. W. Hood, and G. H. Thomas. 2007. Sialic acid utilization by bacterial pathogens. 
Microbiology. 153: 2817-2822. 
298. Brunngraber, E. G., L. A. Witting, C. Haberland, and B. Brown. 1972. Glycoproteins in Tay-
sachs disease: isolation and carbohydrate composition of glycopeptides. Brain Res. 38: 151-
162. 
299. Schnaar, R. L. Brain gangliosides in axon-myelin stability and axon regeneration. FEBS Lett. 
584: 1741-1747. 
300. Rudloff, S., G. Pohlentz, L. Diekmann, H. Egge, and C. Kunz. 1996. Urinary excretion of lactose 
and oligosaccharides in preterm infants fed human milk or infant formula. Acta Paediatr. 85: 
598-603. 
301. Shoaf-Sweeney, K. D., and R. W. Hutkins. 2009. Adherence, anti-adherence, and 
oligosaccharides preventing pathogens from sticking to the host. Adv Food Nutr Res. 55: 101-
161. 
302. Newburg, D. S. 1997. Do the binding properties of oligosaccharides in milk protect human 
infants from gastrointestinal bacteria? J Nutr. 127: 980S-984S. 
303. Morrow, A. L., G. M. Ruiz-Palacios, M. Altaye, X. Jiang, M. L. Guerrero, J. K. Meinzen-Derr, T. 
Farkas, P. Chaturvedi, L. K. Pickering, and D. S. Newburg. 2004. Human milk oligosaccharides 
are associated with protection against diarrhea in breast-fed infants. J Pediatr. 145: 297-303. 
304. Takashima, S., S. Tsuji, and M. Tsujimoto. 2002. Characterization of the second type of 
human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Galbeta 
1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human 
sialyltransferase genes. J Biol Chem. 277: 45719-45728. 
305. Takashima, S., H. K. Ishida, T. Inazu, T. Ando, H. Ishida, M. Kiso, S. Tsuji, and M. Tsujimoto. 
2002. Molecular cloning and expression of a sixth type of alpha 2,8-sialyltransferase (ST8Sia 
VI) that sialylates O-glycans. J Biol Chem. 277: 24030-24038. 
306. Tsuji, S., A. K. Datta, and J. C. Paulson. 1996. Systematic nomenclature for sialyltransferases. 
Glycobiology. 6: v-vii. 
307. Angata, K., and M. Fukuda. 2003. Polysialyltransferases: major players in polysialic acid 
synthesis on the neural cell adhesion molecule. Biochimie. 85: 195-206. 
308. Lee, Y. C., N. Kurosawa, T. Hamamoto, T. Nakaoka, and S. Tsuji. 1993. Molecular cloning and 
expression of Gal beta 1,3GalNAc alpha 2,3-sialyltransferase from mouse brain. Eur J 
Biochem. 216: 377-385. 
Introduction 
 
59 
 
309. Lee, Y. C., N. Kojima, E. Wada, N. Kurosawa, T. Nakaoka, T. Hamamoto, and S. Tsuji. 1994. 
Cloning and expression of cDNA for a new type of Gal beta 1,3GalNAc alpha 2,3-
sialyltransferase. J Biol Chem. 269: 10028-10033. 
310. Kono, M., Y. Ohyama, Y. C. Lee, T. Hamamoto, N. Kojima, and S. Tsuji. 1997. Mouse beta-
galactoside alpha 2,3-sialyltransferases: comparison of in vitro substrate specificities and 
tissue specific expression. Glycobiology. 7: 469-479. 
311. Kono, M., S. Takashima, H. Liu, M. Inoue, N. Kojima, Y. C. Lee, T. Hamamoto, and S. Tsuji. 
1998. Molecular cloning and functional expression of a fifth-type alpha 2,3-sialyltransferase 
(mST3Gal V: GM3 synthase). Biochem Biophys Res Commun. 253: 170-175. 
312. Okajima, T., S. Fukumoto, H. Miyazaki, H. Ishida, M. Kiso, K. Furukawa, and T. Urano. 1999. 
Molecular cloning of a novel alpha2,3-sialyltransferase (ST3Gal VI) that sialylates type II 
lactosamine structures on glycoproteins and glycolipids. J Biol Chem. 274: 11479-11486. 
313. Hamamoto, T., M. Kawasaki, N. Kurosawa, T. Nakaoka, Y. C. Lee, and S. Tsuji. 1993. Two step 
single primer mediated polymerase chain reaction. Application to cloning of putative mouse, 
beta-galactoside alpha 2,6-sialyltransferase cDNA. Bioorg Med Chem. 1: 141-145. 
314. Takashima, S., S. Tsuji, and M. Tsujimoto. 2003. Comparison of the enzymatic properties of 
mouse beta-galactoside alpha2,6-sialyltransferases, ST6Gal I and II. J Biochem. 134: 287-296. 
315. Kurosawa, N., S. Takashima, M. Kono, Y. Ikehara, M. Inoue, Y. Tachida, H. Narimatsu, and S. 
Tsuji. 2000. Molecular cloning and genomic analysis of mouse GalNAc alpha2, 6-
sialyltransferase (ST6GalNAc I). J Biochem. 127: 845-854. 
316. Kurosawa, N., M. Inoue, Y. Yoshida, and S. Tsuji. 1996. Molecular cloning and genomic 
analysis of mouse Galbeta1, 3GalNAc-specific GalNAc alpha2,6-sialyltransferase. J Biol Chem. 
271: 15109-15116. 
317. Lee, Y. C., M. Kaufmann, S. Kitazume-Kawaguchi, M. Kono, S. Takashima, N. Kurosawa, H. Liu, 
H. Pircher, and S. Tsuji. 1999. Molecular cloning and functional expression of two members 
of mouse NeuAcalpha2,3Galbeta1,3GalNAc GalNAcalpha2,6-sialyltransferase family, 
ST6GalNAc III and IV. J Biol Chem. 274: 11958-11967. 
318. Okajima, T., S. Fukumoto, H. Ito, M. Kiso, Y. Hirabayashi, T. Urano, and K. Furukawa. 1999. 
Molecular cloning of brain-specific GD1alpha synthase (ST6GalNAc V) containing 
CAG/Glutamine repeats. J Biol Chem. 274: 30557-30562. 
319. Ikehara, Y., N. Shimizu, M. Kono, S. Nishihara, H. Nakanishi, T. Kitamura, H. Narimatsu, S. 
Tsuji, and M. Tatematsu. 1999. A novel glycosyltransferase with a polyglutamine repeat; a 
new candidate for GD1alpha synthase (ST6GalNAc V)(1). FEBS Lett. 463: 92-96. 
320. Okajima, T., H. H. Chen, H. Ito, M. Kiso, T. Tai, K. Furukawa, and T. Urano. 2000. Molecular 
cloning and expression of mouse GD1alpha/GT1aalpha/GQ1balpha synthase (ST6GalNAc VI) 
gene. J Biol Chem. 275: 6717-6723. 
321. Yamamoto, A., M. Haraguchi, S. Yamashiro, S. Fukumoto, K. Furukawa, K. Takamiya, M. 
Atsuta, and H. Shiku. 1996. Heterogeneity in the expression pattern of two ganglioside 
synthase genes during mouse brain development. J Neurochem. 66: 26-34. 
322. Kojima, N., Y. Yoshida, and S. Tsuji. 1995. A developmentally regulated member of the 
sialyltransferase family (ST8Sia II, STX) is a polysialic acid synthase. FEBS Lett. 373: 119-122. 
323. Yoshida, Y., N. Kojima, N. Kurosawa, T. Hamamoto, and S. Tsuji. 1995. Molecular cloning of 
Sia alpha 2,3Gal beta 1,4GlcNAc alpha 2,8-sialyltransferase from mouse brain. J Biol Chem. 
270: 14628-14633. 
324. Yoshida, Y., N. Kojima, and S. Tsuji. 1995. Molecular cloning and characterization of a third 
type of N-glycan alpha 2,8-sialyltransferase from mouse lung. J Biochem. 118: 658-664. 
325. Kono, M., Y. Yoshida, N. Kojima, and S. Tsuji. 1996. Molecular cloning and expression of a 
fifth type of alpha2,8-sialyltransferase (ST8Sia V). Its substrate specificity is similar to that of 
SAT-V/III, which synthesize GD1c, GT1a, GQ1b and GT3. J Biol Chem. 271: 29366-29371. 
326. Kunz, C., S. Rudloff, A. Hintelmann, G. Pohlentz, and H. Egge. 1996. High-pH anion-exchange 
chromatography with pulsed amperometric detection and molar response factors of human 
milk oligosaccharides. J Chromatogr B Biomed Appl. 685: 211-221. 
Introduction 
 
60 
 
327. Fuhrer, A., N. Sprenger, E. Kurakevich, L. Borsig, C. Chassard, and T. Hennet. Milk sialyllactose 
influences colitis in mice through selective intestinal bacterial colonization. J Exp Med. 207: 
2843-2854. 
328. Takashima, S. 2008. Characterization of mouse sialyltransferase genes: their evolution and 
diversity. Biosci Biotechnol Biochem. 72: 1155-1167. 
329. Hennet, T., D. Chui, J. C. Paulson, and J. D. Marth. 1998. Immune regulation by the ST6Gal 
sialyltransferase. Proc Natl Acad Sci U S A. 95: 4504-4509. 
330. Crespo, H. J., M. G. Cabral, A. V. Teixeira, J. T. Lau, H. Trindade, and P. A. Videira. 2009. Effect 
of sialic acid loss on dendritic cell maturation. Immunology. 128: e621-631. 
331. Zeng, J., H. M. Joo, B. Rajini, J. P. Wrammert, M. Y. Sangster, and T. M. Onami. 2009. The 
generation of influenza-specific humoral responses is impaired in ST6Gal I-deficient mice. J 
Immunol. 182: 4721-4727. 
332. Grewal, P. K., M. Boton, K. Ramirez, B. E. Collins, A. Saito, R. S. Green, K. Ohtsubo, D. Chui, 
and J. D. Marth. 2006. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and 
Shp-1 recruitment in normal and pathogenic immune signaling. Mol Cell Biol. 26: 4970-4981. 
333. Ghosh, S., C. Bandulet, and L. Nitschke. 2006. Regulation of B cell development and B cell 
signalling by CD22 and its ligands alpha2,6-linked sialic acids. Int Immunol. 18: 603-611. 
334. Priatel, J. J., D. Chui, N. Hiraoka, C. J. Simmons, K. B. Richardson, D. M. Page, M. Fukuda, N. 
M. Varki, and J. D. Marth. 2000. The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte 
homeostasis by modulating O-glycan biosynthesis. Immunity. 12: 273-283. 
335. Van Dyken, S. J., R. S. Green, and J. D. Marth. 2007. Structural and mechanistic features of 
protein O glycosylation linked to CD8+ T-cell apoptosis. Mol Cell Biol. 27: 1096-1111. 
336. Carvalho, A. S., A. Harduin-Lepers, A. Magalhaes, E. Machado, N. Mendes, L. T. Costa, R. 
Matthiesen, R. Almeida, J. Costa, and C. A. Reis. Differential expression of alpha-2,3-
sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a 
and sialyl Lewis x in gastrointestinal carcinoma cells. Int J Biochem Cell Biol. 42: 80-89. 
337. Ellies, L. G., M. Sperandio, G. H. Underhill, J. Yousif, M. Smith, J. J. Priatel, G. S. Kansas, K. Ley, 
and J. D. Marth. 2002. Sialyltransferase specificity in selectin ligand formation. Blood. 100: 
3618-3625. 
338. Sperandio, M., D. Frommhold, I. Babushkina, L. G. Ellies, T. S. Olson, M. L. Smith, B. 
Fritzsching, E. Pauly, D. F. Smith, R. Nobiling, O. Linderkamp, J. D. Marth, and K. Ley. 2006. 
Alpha 2,3-sialyltransferase-IV is essential for L-selectin ligand function in inflammation. Eur J 
Immunol. 36: 3207-3215. 
339. Frommhold, D., A. Ludwig, M. G. Bixel, A. Zarbock, I. Babushkina, M. Weissinger, S. 
Cauwenberghs, L. G. Ellies, J. D. Marth, A. G. Beck-Sickinger, M. Sixt, B. Lange-Sperandio, A. 
Zernecke, E. Brandt, C. Weber, D. Vestweber, K. Ley, and M. Sperandio. 2008. 
Sialyltransferase ST3Gal-IV controls CXCR2-mediated firm leukocyte arrest during 
inflammation. J Exp Med. 205: 1435-1446. 
340. Kelder, B., R. Erney, J. Kopchick, R. Cummings, and P. Prieto. 2001. Glycoconjugates in human 
and transgenic animal milk. Adv Exp Med Biol. 501: 269-278. 
341. Prieto, P. A., P. Mukerji, B. Kelder, R. Erney, D. Gonzalez, J. S. Yun, D. F. Smith, K. W. 
Moremen, C. Nardelli, M. Pierce, and et al. 1995. Remodeling of mouse milk glycoconjugates 
by transgenic expression of a human glycosyltransferase. J Biol Chem. 270: 29515-29519. 
342. Sakarya, S., and S. Oncu. 2003. Bacterial adhesins and the role of sialic acid in bacterial 
adhesion. Med Sci Monit. 9: RA76-82. 
343. Sohanpal, B. K., S. El-Labany, M. Lahooti, J. A. Plumbridge, and I. C. Blomfield. 2004. 
Integrated regulatory responses of fimB to N-acetylneuraminic (sialic) acid and GlcNAc in 
Escherichia coli K-12. Proc Natl Acad Sci U S A. 101: 16322-16327. 
344. Almagro-Moreno, S., and E. F. Boyd. 2009. Sialic acid catabolism confers a competitive 
advantage to pathogenic vibrio cholerae in the mouse intestine. Infect Immun. 77: 3807-
3816. 
Introduction 
 
61 
 
345. Chang, D. E., D. J. Smalley, D. L. Tucker, M. P. Leatham, W. E. Norris, S. J. Stevenson, A. B. 
Anderson, J. E. Grissom, D. C. Laux, P. S. Cohen, and T. Conway. 2004. Carbon nutrition of 
Escherichia coli in the mouse intestine. Proc Natl Acad Sci U S A. 101: 7427-7432. 
346. Almagro-Moreno, S., and E. F. Boyd. 2009. Insights into the evolution of sialic acid catabolism 
among bacteria. BMC Evol Biol. 9: 118. 
347. Naarding, M. A., I. S. Ludwig, F. Groot, B. Berkhout, T. B. Geijtenbeek, G. Pollakis, and W. A. 
Paxton. 2005. Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to 
CD4+ T lymphocytes. J Clin Invest. 115: 3256-3264. 
348. Collins, M. D., P. A. Lawson, A. Willems, J. J. Cordoba, J. Fernandez-Garayzabal, P. Garcia, J. 
Cai, H. Hippe, and J. A. Farrow. 1994. The phylogeny of the genus Clostridium: proposal of 
five new genera and eleven new species combinations. Int J Syst Bacteriol. 44: 812-826. 
349. Herbeck, J. L., and M. P. Bryant. 1974. Nutritional features of the intestinal anaerobe 
Ruminococcus bromii. Appl Microbiol. 28: 1018-1022. 
350. Leitch, E. C., A. W. Walker, S. H. Duncan, G. Holtrop, and H. J. Flint. 2007. Selective 
colonization of insoluble substrates by human faecal bacteria. Environ Microbiol. 9: 667-679. 
351. Wang, R. F., W. W. Cao, and C. E. Cerniglia. 1997. PCR detection of Ruminococcus spp. in 
human and animal faecal samples. Mol Cell Probes. 11: 259-265. 
352. Suen, G., D. M. Stevenson, D. C. Bruce, O. Chertkov, A. Copeland, J. F. Cheng, C. Detter, J. C. 
Detter, L. A. Goodwin, C. S. Han, L. J. Hauser, N. N. Ivanova, N. C. Kyrpides, M. L. Land, A. 
Lapidus, S. Lucas, G. Ovchinnikova, S. Pitluck, R. Tapia, T. Woyke, J. Boyum, D. Mead, and P. J. 
Weimer. Complete genome of the cellulolytic ruminal bacterium Ruminococcus albus 7. J 
Bacteriol. 193: 5574-5575. 
353. Andoh, A., S. Sakata, Y. Koizumi, K. Mitsuyama, Y. Fujiyama, and Y. Benno. 2007. Terminal 
restriction fragment length polymorphism analysis of the diversity of fecal microbiota in 
patients with ulcerative colitis. Inflamm Bowel Dis. 13: 955-962. 
354. Martinez-Medina, M., X. Aldeguer, F. Gonzalez-Huix, D. Acero, and L. J. Garcia-Gil. 2006. 
Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as 
revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm 
Bowel Dis. 12: 1136-1145. 
355. Prindiville, T., M. Cantrell, and K. H. Wilson. 2004. Ribosomal DNA sequence analysis of 
mucosa-associated bacteria in Crohn's disease. Inflamm Bowel Dis. 10: 824-833. 
356. Marcobal, A., M. Barboza, J. W. Froehlich, D. E. Block, J. B. German, C. B. Lebrilla, and D. A. 
Mills. Consumption of human milk oligosaccharides by gut-related microbes. J Agric Food 
Chem. 58: 5334-5340. 
357. Ward, R. E., M. Ninonuevo, D. A. Mills, C. B. Lebrilla, and J. B. German. 2007. In vitro 
fermentability of human milk oligosaccharides by several strains of bifidobacteria. Mol Nutr 
Food Res. 51: 1398-1405. 
358. Pan, X. D., F. Q. Chen, T. X. Wu, H. G. Tang, and Z. Y. Zhao. 2009. Prebiotic oligosaccharides 
change the concentrations of short-chain fatty acids and the microbial population of mouse 
bowel. J Zhejiang Univ Sci B. 10: 258-263. 
359. Petersen, A., A. Bergstrom, J. B. Andersen, M. Hansen, S. J. Lahtinen, A. Wilcks, and T. R. 
Licht. Analysis of the intestinal microbiota of oligosaccharide fed mice exhibiting reduced 
resistance to Salmonella infection. Benef Microbes. 1: 271-281. 
 
  
62 
 
Results 
5 High levels of selected anti-inflammatory and pro-resolving lipid mediators 
and declining docosahexaenoic acid levels in human milk during the first 
month of lactation  
(Manuscript submitted to Lipids in Health and Disease) 
 
Gisela Adrienne Weiss1,2,3, Heinz Troxler1, Glynis Klinke1,2, Daniela Rogler4, Christian Braegger4, Martin 
Hersberger1,2 
 
1Clinical Chemistry and Biochemistry, Children’s Research Center, University Children’s Hospital 
Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland 
2Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland 
3Institute of Physiology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland 
4Gastroenterology and Nutrition, University Children’s Hospital Zurich, Steinwiesstrasse 75, 8032 
Zurich, Switzerland 
 
Abbreviated title: Lipid mediators and fatty acids in human milk 
 
Corresponding author: Martin Hersberger 
University Children's Hospital Zürich 
Steinwiesstrasse 75 
CH-8032 Zürich 
Switzerland 
Phone: +41 44 266 7541 
Fax: +41 44 266 7169 
Email: martin.hersberger@kispi.uzh.ch 
Results 
 
63 
 
5.1 Abstract 
Background 
The fatty acid mixture of human milk is ideal for the newborn but little is known about its 
composition in the first few weeks of lactation. Of special interest are the levels of long-chain PUFAs 
(LCPUFAs), since these are essential for the newborn’s development. Additionally, the LCPUFAs 
arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are precursors 
for lipid mediators which regulate inflammation.  
Methods 
We determined the composition of 94 human milk samples from 30 mothers over the first month of 
lactation for fatty acids using GC-MS and quantified lipid mediators using HPLC-MS/MS.  
Results 
Over the four weeks period, DHA levels decreased, while levels of γC18:3 and αC18:3 steadily 
increased. Intriguingly, we found high concentrations of lipid mediators and their hydroxy fatty acid 
precursors in human milk, including pro-inflammatory leukotriene B4 (LTB4) and anti-inflammatory 
and pro-resolving lipoxin A4 (LXA4), resolvin D1 (RvD1) and resolvin E1 (RvE1). Lipid mediator levels 
were stable with the exception of two direct precursors.  
Conclusions 
Elevated levels of DHA right after birth might represent higher requirements of the newborn and the 
high content of anti-inflammatory and pro-resolving lipid mediators and their precursors may 
indicate their role in neonatal immunity and may be one of the reasons for the advantage of human 
milk over infant formula. 
Key words 
Human milk, omega-3 fatty acids, DHA, EPA, 17-HDHA, 18-HEPE, 15-HETE, resolvins, lipoxins, 
leukotrienes 
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5.2 Background 
Human milk fat is the main energy source for the breast-fed newborn and provides specific fatty 
acids that are required for the newborn’s development. The fatty acid composition of human milk 
has been assessed in several studies showing differences between term and preterm milk (105, 360-
363) and the influence of diet on the fatty acid composition (364-366). There is also indication for a 
change in fatty acid composition over the lactation period (363, 367-376). 
Especially, LCPUFAs fulfill several essential functions in the newborns. For example, the omega-6 
LCPUFA AA and the omega-3 LCPUFA DHA are crucial for brain and nervous system development 
(377, 378), the visual system (379) and for early human growth in general (380). In addition, the fatty 
acid profile of human milk has been associated with the development of atopy and with allergic 
diseases in children (175, 381-383). 
The supply of LCPUFAs by human milk to the newborn determines the fatty acid composition of 
several lipid compartments including plasma lipids and the cellular membrane (384). The fatty acid 
composition of the membrane influences not only membrane properties but also immune-regulatory 
processes through the metabolization of free and membrane bound LCPUFAs to lipid mediators 
(385). These lipid mediators are signaling molecules that initiate and resolve inflammation and they 
derive from oxygenation of the omega-6 fatty acid AA and the two omega-3 fatty acids DHA and EPA 
(115, 386). Oxygenation of AA, DHA and EPA occurs in a concerted action of lipoxygenases, 
cyclooxygenases and cytochrome-P-450 dependent oxygenases to result in the pro-inflammatory 
leukotrienes and the anti-inflammatory lipoxins from AA and resolvins and protectins from DHA and 
EPA (115, 386, 387). Apart from being anti-inflammatory, lipoxins, resolvins and protectins also 
initiate inflammation-resolving actions like recruitment of nonphlogistic monocytes and clearance of 
apoptotic polymorphonuclear neutrophils by macrophages (388-390). Due to their potent immune-
regulatory functions, these lipid mediators are thought to play a role in chronic inflammatory 
diseases like atherosclerosis, rheumatoid arthritis and inflammatory bowel disease (387, 391-393). 
We therefore surmised that a supply of anti-inflammatory and pro-resolving lipid mediators to the 
newborn by breast milk could be one of the explanations for the lower incidence of intestinal 
inflammation in breast-fed compared to formula-fed infants (25, 28). 
Only limited information is available on the fatty acid composition of human milk over the first few 
weeks of lactation (373-376), and the presence of leukotrienes, lipoxins and resolvins in human milk 
has not been investigated yet. In this study, we present the milk fatty acid profile and the profile for 
selected bioactive lipid mediators and their precursors in human milk over the first month of 
lactation. 
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5.3 Results 
Quantification of fatty acid composition in human milk 
Thirteen fatty acids containing 16 to 24 carbon atoms (Tab. 1 and Fig. 1) were analysed and 
quantified in human milk with a specific and selective GC-MS method. For each analyte, the 
calibration was linear with R²>0.98 and the observed fatty acid concentrations in breast milk were 
within the working range (See Supplementary Tab. 1, Additional file 3). Intra-assay coefficients of 
variation are stated in supplementary table 1 (Additional file 3). 
Table 1: Fatty acids analyzed in human milk 
State of saturation Fatty acid 
Lipid number 
(C:D)a 
Saturated Palmitic acid C16:0 
Stearic acid C18:0 
Arachidic acid C20:0 
Behenic acid C22:0 
Lignoceric acid C24:0 
Monounsaturated Palmitoleic acid C16:1 
Oleic acid C18:1 
Omega-6 
polyunsaturated 
Linoleic acid C18:2 
γ-Linolenic acid γC18:3 
Arachidonic acid C20:4 
Omega-3 
polyunsaturated 
α-Linolenic acid αC18:3 
Eicosapentaenoic acid C20:5 
Docosahexaenoic acid C22:6 
a C, number of carbon atoms; D, number of double bonds 
 
Figure 1: Gas-chromatogram of fatty acid standard substances. Fatty acids in standard mixture were 
methylated according to the sample preparation procedure prior to injection into the GC-MS system. For 
nomenclature of the fatty acids see table 1. 
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Fatty acid composition of human milk over the first month of lactation 
The lactational age of the collected human milk samples ranged from 1 to 30 days postpartum. For 
statistical analysis, the samples were divided into six groups according to their lactational age (Tab. 
2). The major fatty acids in human milk were C18:1, C16:0, C18:2 and C18:0 in descending order. 
Other fatty acids were present with quantities lower than 5% of total fatty acids. The relative content 
was stable over the first month of lactation for the saturated fatty acids C16:0 to C22:0. Only C24:0  
showed a significant decrease (Tab. 2). The amounts of the monounsaturated fatty acids C16:1 and 
C18:1 were stable over the observed time period. In contrast, the amount of most PUFAs changed  
over time (Fig. 2). The amount of DHA decreased to approximately half of the initial quantity 
(p<0.0001, Tab. 2), while its precursor αC18:3 increased over the same period. Similarly, the amount 
of AA showed a trend to decrease over time (p=0.094) while its precursor γC18:3 increased. Albeit 
these changes in the concentration of the PUFAs, the ratio of omega-6 (C18:2, γC18:3, AA) to omega-
3 (αC18:3, EPA, DHA) fatty acids in human milk did not change significantly over the first four weeks 
of lactation.  
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Table 2: Total fatty acid composition (%) of human milk over time of lactation 
Fatty acid 
Time of lactation (days after birth) 
R² P 
1-5 
N=15 
6-10 
N=27 
11-15 
N=23 
16-20 
N=16 
21-25 
N=6 
26-30 
N=7 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
C16:0 23.96 
3.47 
20.75 
2.41 
21.96 
2.55 
21.95 
2.59 
21.90 
2.60 
21.92 
4.02 
0.12 0.63 
C18:0 6.91 
1.59 
6.06 
1.31 
7.73 
1.90 
7.34 
1.69 
6.85 
0.67 
7.64 
1.36 
0.23 0.37 
C20:0 0.17 
0.06 
0.11 
0.03 
0.15 
0.04 
0.14 
0.05 
0.12 
0.03 
0.12 
0.03 
0.36 0.10 
C22:0 0.22 
0.18 
0.13 
0.04 
0.15 
0.06 
0.12 
0.04 
0.13 
0.04 
0.17 
0.03 
0.16 0.27 
C24:0 0.29 
0.12 
0.17 
0.07 
0.20 
0.10 
0.16 
0.09 
0.14 
0.05 
0.18 
0.05 
0.48 0.011 
C16:1 3.35 
0.87 
4.55 
1.35 
3.66 
1.17 
4.30 
1.81 
4.27 
1.21 
3.67 
0.89 
0.02 0.74 
C18:1 46.29 
5.42 
48.21 
3.94 
45.76 
5.28 
44.92 
3.80 
46.26 
5.17 
43.96 
2.50 
0.46 0.51 
C18:2 14.42 
3.09 
16.10 
3.24 
16.58 
3.97 
17.16 
3.37 
16.72 
3.45 
18.43 
2.80 
0.83 0.13 
γC18:3 0.09 
0.03 
0.10 
0.02 
0.10 
0.04 
0.11 
0.04 
0.11 
0.02 
0.13 
0.02 
0.81 0.040 
C20:4  
(AA) 
2.09 
0.96 
1.82 
0.91 
1.56 
0.62 
1.79 
0.83 
1.49 
0.41 
1.48 
0.49 
0.73 0.094 
αC18:3 1.07 
0.44 
1.04 
0.23 
1.41 
0.62 
1.34 
0.58 
1.47 
0.33 
1.82 
0.48 
0.85 0.0024 
C20:5 
(EPA) 
0.08 
0.02 
0.06 
0.02 
0.06 
0.03 
0.07 
0.01 
0.07 
0.02 
0.07 
0.01 
0.06 0.77 
C22:6 
(DHA) 
1.15 
0.42 
0.99 
0.33 
0.79 
0.25 
0.71 
0.32 
0.59 
0.11 
0.56 
0.22 
0.96 <0.0001 
n6/n3 7.58 
1.73 
8.92 
2.40 
8.31 
1.50 
9.47 
3.11 
8.81 
2.53 
8.27 
1.00 
0.12 0.59 
M, mean % of total fatty acids; SD, standard deviation; R², coefficient of determination of linear 
trendline; P, p-value for linear trend (ANOVA). 
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Figure 2: Changes in omega-6 and omega-3 fatty acids in human milk over the first month of lactation. Relative 
amount of the omega-6 PUFA (E) AA (C20:4) and its precursors (A) C18:2 and (C) γC18:3. Relative amount of the 
omega-3 PUFA (F) DHA (C22:6) and its precursors (D) αC18:3 and (B) EPA (C20:5). For an overview on PUFA 
fatty acid biosynthesis see figure 3. 
 
Results 
 
69 
 
Quantification of selected lipid mediators and precursors in human milk 
To determine the concentration of the 
selected lipid mediators in human breast 
milk, a HPLC-MS/MS method was 
developed analyzing LTB4, LXA4, RvE1 and 
RvD1 and the four hydroxy fatty acids 17-
hydroxydocosahexaenoic acid (17-HDHA), 
18-hydroxyeicosapentaenoic acid (18-
HEPE), 15-hydroxyeicosatetraenoic acid (15-
HETE) and 12-hydroxyeicosatetraenoic acid 
(12-HETE) (Figs. 3 and 4). For each 
compound, several transitions were 
scanned (See Supplementary Tab. 2, 
Additional file 3) and one transition per 
analyte was selected as quantifier ion. For 
each lipid mediator and hydroxy fatty acid, 
the fragmentation pattern of the analyte 
from human milk was comparable to the fragmentation pattern of the corresponding standard 
substance (See Supplementary figure 1, Additional file 1 and Supplementary figure 2, Additional file 
2). For each analyte, the calibration was linear with R²>0.98 and the observed lipid mediator 
concentrations in breast milk were within the working range. 
 
Figure 4: Chromatogram of lipid mediators and related precursor 
hydroxy fatty acids. 5 µl of a 0.1 ng/µl standard mixture was injected 
into the HPLC-MS/MS system. Cps, counts per second. 
 
Figure 3: Simplified scheme for the biosynthesis of the 
selected measured lipid mediators. LTB4, LXA4, RvE1 and 
RvD1 are produced from the two essential omega-6 and 
omega-3 fatty acid pathways via the corresponding 
intermediate mono-hydroxy fatty acids. 
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Lipid mediator concentrations of human milk over the first month of lactation 
The breast milk concentration of the lipid mediators LTB4, LXA4, RvE1 and RvD1 showed mean values 
(and ranges) of 9 ng/ml (0.01 to 24.5 ng/ml) for LTB4, 21 ng/ml (0.1 to 54.1 ng/ml) for LXA4, 6 ng/ml 
(0.03 to 41.5 ng/ml) for RvE1 and 10 ng/ml (0.01 to 44.5 ng/ml) for RvD1, and was stable over the 
period of one month for all lipid mediators (Tab. 3). The mean concentrations of the precursor 
hydroxy fatty acids were higher than the concentrations of the more bioactive forms with the 
exception of 18-HEPE, which was observed at similar concentrations to the resulting lipid mediator 
RvE1 at the beginning of lactation. Over the observed four weeks of lactation, 18-HEPE increased in 
concentration, although not significantly (p=0.063). In contrast, the 17-HDHA content of human 
breast milk decreased. It was more than three times higher in the first five days postpartum than 
three weeks postpartum (Fig. 5), which followed the change in DHA content of the human breast 
milk. The concentrations of 12-HETE and 15-HETE were stable over the observed time period. 
 
Figure 5: Changes in the concentration of the precursor hydroxy fatty acids over the first month of lactation. 
Concentrations of (A) 18-HEPE (precursor of RvE1) and (B) 17-HDHA (precursor of RvD1) were measured in 
human milk over the first month of lactation. 
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Table 3: Concentration (ng/ml) of lipid mediators and precursors in human milk over time 
of lactation 
 
Compound 
Time of lactation (days after birth) 
R² P 
1-5 
N=11-14 
6-10 
N=20-23 
11-15 
N=20-21 
16-20 
N=13-14 
21-25 
N=6 
26-30 
N=6-7 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
M 
SD 
LTB4 9.48 10.01 10.19 8.47 9.31 7.78 0.51 0.44 
8.59 4.43 5.28 6.31 5.64 3.34 
LXA4 15.55 25.02 22.11 16.65 19.53 22.04 0.02 0.19 
16.87 14.68 13.11 14.06 10.11 12.60 
RvE1 4.24 5.23 8.15 4.60 12.57 5.67 0.19 0.13 
5.76 3.91 11.45 4.08 15.20 5.65 
RvD1 9.42 12.46 12.37 6.48 9.53 9.99 0.08 0.58 
11.68 7.34 9.28 6.24 4.64 5.06 
17-HDHA 53.38 40.73 34.04 22.72 14.76 28.27 0.71 0.0035 
37.80 25.41 22.61 20.94 6.61 25.50 
18-HEPE 7.20 7.29 8.99 6.28 9.80 8.30 0.18 0.063 
5.02 2.63 3.92 4.54 6.60 3.29 
15-HETE 28.38 24.19 26.90 25.35 22.80 26.04 0.22 0.60 
16.44 12.86 11.72 17.85 8.33 19.65 
12-HETE 43.90 38.46 36.71 28.12 28.75 23.63 0.95 0.39 
26.61 29.11 15.99 19.37 15.80 11.55 
M, mean; SD, standard deviation; R², coefficient of determination of linear trendline; P, p-value for linear trend 
(ANOVA). 
5.4 Discussion  
In this study, we examined the fatty acid and the derived lipid mediator profiles of human breast milk 
over the first month of lactation. While most of the fatty acids showed stable concentrations over 
the four weeks of lactation, the concentrations of the omega-6 fatty acid AA and of the omega-3 
fatty acid DHA decreased over time. Concomitantly, the amount of the precursor fatty acids for both 
of these very long-chain PUFAs increased. Human breast milk also contains a considerable amount of 
lipid mediators and its precursor hydroxy fatty acids. While we did not observe a change in 
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concentration for the lipid mediators over the investigated lactation period, the DHA metabolite 17-
HDHA decreased in parallel to the DHA concentration. 
The most surprising finding of this study was the high concentration of bioactive lipid mediators and 
their precursors in human milk. The levels of these analytes in human milk have not been reported so 
far. All of the investigated lipid mediators LTB4, LXA4, RvE1 and RvD1 were found at considerable 
concentrations, which were higher than the concentrations reported for plasma of healthy 
individuals. While human breast milk contains in average 8 ng/ml of the pro-inflammatory LTB4, the 
level for LTB4 was reported to be 100 times lower in plasma with concentrations of approximately 34 
pg/ml (394). Similarly, the concentration for the anti-inflammatory lipid mediators is higher in human 
breast milk. While breast milk contains in average 18 ng/ml LXA4, the plasma levels were reported to 
be 100 times lower ranging from 10 to 26 pg/ml (395). Also, RvD1 levels are 100 times lower in 
plasma than in human breast milk with 31 pg/ml (135) and 9 ng/ml, respectively. The levels for RvE1 
are 10 times higher in human breast milk than in plasma with 6 ng/ml and 0.1 to 0.4 ng/ml of RvE1, 
respectively (152). There is also a 10-100 times increase in the concentration of the precursors for 
these lipid mediators. While we detected 12-HETE, 15-HETE, 18-HEPE and 17-HDHA mean 
concentrations in human breast milk in the range of 5-40 ng/ml, these hydroxy fatty acids were 
measured in the low nanomolar range in human whole blood with concentrations ranging from 0.1 
to 4.10 ng/ml (135, 396). Thus, there seems to be an enrichment of the lipid mediators and its 
precursors in human breast milk, similar to the enrichment previously observed for some of the 
prostaglandins (174). 
Our data also suggest a preferred accumulation of anti-inflammatory and pro-resolving lipid 
mediators in human milk as seen by the bioactive products of AA. This fatty acid can be converted 
into pro- and anti-inflammatory lipid mediators like LTB4 and LXA4, respectively (397). In human 
milk, the average content of anti-inflammatory LXA4 is double as high as for the pro-inflammatory 
LTB4, while in human whole blood the concentration of LXA4 seems to be lower than the 
concentration of LTB4 (394, 395). In addition, there are high concentrations of the precursor hydroxy 
fatty acids for the anti-inflammatory and pro-resolving lipid mediators present in human breast milk. 
At least some of the precursors also have potent anti-inflammatory and pro-resolving effects, which 
may derive from a direct effect or through its metabolism to the lipid mediators. 
Several studies have shown that the lipid mediators LXA4, RvE1 and RvD1 have potent anti-
inflammatory and pro-resolving effects in experimental mouse models of intestinal colitis (140, 155-
157, 163). In addition, also 17-HDHA the precursor for RvD1 was shown to reduce inflammation in 
dextran sulfate sodium induced colitis in mice (163). It is therefore tempting to speculate that these 
high levels of lipid mediators and their precursors in human milk might affect the immune regulation 
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of the gastrointestinal tract in the newborn. In this line, the concentrations measured in human 
breast milk for RvD1 and LXA4 meet the concentrations necessary to effect human leukocytes in an 
anti-inflammatory and pro-resolving manner (398, 399). For example, LXA4 and RvE1 were shown to 
suppress neutrophil infiltration and to promote phagocytosis of bacteria and apoptotic neutrophils 
by macrophages in the nanomolar range (151, 152, 388, 400).  
The concentrations of the measured lipid mediators did not change over the first month of lactation 
in contrast to the two precursor hydroxy fatty acids 17-HDHA and 18-HEPE. While the concentration 
of 18-HEPE slightly increases during lactation, the concentration of 17-HDHA decreases in parallel to 
the decrease of its precursor fatty acid DHA. The breast milk concentrations of the lipid mediator 
products RvE1 and RvD1 do not show the same temporal pattern, which is in agreement with the just 
in time generation of these inflammatory regulators during an acute inflammation (397). Similarly, 
the concentrations of all the lipid mediators investigated in this study are constant in breast milk over 
the first month of lactation. Hence, an effect of degradation during storage can be excluded, since all 
samples were stored for the same time period. However, it is not clear why the intermediate 
precursor fatty acids investigated are present in such high concentrations in human breast milk. 
Possibly, these fatty acids are supplied as pre-metabolized lipid mediators for a final conversion to 
the more potent lipid mediators in the newborn’s intestine. Considering the high concentration of 
these anti-inflammatory and pro-resolving hydroxy fatty acids and lipid mediators in human breast 
milk, we presume a potential role in lowering the overall inflammation in breast-fed infants, 
suggesting a possible reason for the lower incidence of inflammatory diseases in breast-fed 
compared to formula-fed children (401-403). In addition, these lipid mediators may be involved in 
gastrointestinal pain reception in newborns, since RvE1 and RvD1 have been shown to reduce 
inflammatory pain in mice (404). 
The average fatty acid profile found in our study is similar to the fatty acid compositions reported 
before (360, 363, 365, 372, 381, 405). Considering the profile over the first month of lactation, the 
relative content in milk is stable for most fatty acids, while the concentration of specific LCPUFAs 
changes over this period. 
Similar results were found in recent studies in which human milk with equal lactational age was 
analyzed and which presented the same decrease of DHA and AA over time, while the precursor fatty 
acids C18:2, γC18:3 and αC18:3 increased during the same period (364, 372). It was previously 
speculated that the increase in the precursors C18:2, γC18:3 and αC18:3 might compensate for the 
declining levels of DHA and AA in human breast milk, which may come from the depletion of the 
maternal DHA stores (87). Alternatively, the high relative amounts of DHA and AA in the beginning of 
lactation may well be a mechanism to compensate for the lower absolute fat content of human 
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breast milk in the beginning of lactation (405, 406). This may assure a stable supply of DHA and AA to 
the newborn suggesting a regulation of the fatty acid secretion by the mammary gland, which is not 
only dependent on the maternal DHA intake and plasma levels. 
DHA and AA are important for the neonatal development. Especially DHA has a high abundance in 
the brain and retina where it is accumulated predominantly in the last trimester of pregnancy and 
during the first year after birth (407). Before birth, most of the accumulated DHA is delivered from 
the mother by transplacental transfer (408). After birth, human milk is the only exogenous source of 
DHA for the breast-fed child. The endogenous de novo production of the newborn and the DHA 
stores in adipose tissue alone are not sufficient to maintain DHA homeostasis (85). Infants fed 
formula without DHA showed reduced DHA stores in their tissue six months after birth and showed 
only half the accumulation rate for DHA in the brain compared to breast-fed infants (409). At the 
same time, breast-fed infants further increased their DHA stores also in non-brain tissues. Hence, the 
newborn’s need for DHA is eminent and elevated DHA levels in human milk right after birth may 
represent the high requirement for DHA at that time. 
Preterm infants are born with a lower DHA status, because they did not complete intrauterine DHA 
accumulation (410). The importance of DHA for the development is underlined by the higher DHA 
content of human preterm milk (105) and by the elevated activity of enzymes required for LCPUFA 
production in preterm infants (411). This suggests that the fatty acid composition of human milk is 
part of the natural mechanism to regulate the infant’s DHA status. 
DHA and AA are on the one hand vital for neuronal and visual functions, and on the other hand 
pivotal for the neonatal development of the immune system. Several studies confirmed that the DHA 
status is linked to various immune processes (412-416) and that several LCPUFAs have the potential 
to influence the immune system. For example, atopic sensitization of the newborn is associated to 
the α-linolenic acid and omega-3 fatty acid supply (417) and a higher tissue status of omega-3 fatty 
acids results in reduced inflammation and less tissue injury in a colitis model in mice (418). The latter 
was shown in transgenic mice expressing fat-1, the enzyme responsible for the endogenous 
production of the omega-3 and omega-6 LCPUFAs DHA and AA from the essential PUFAs. As 
mentioned before, these LCPUFAs are the precursors of the lipid mediators and the metabolism of 
these LCPUFAs to the corresponding lipid mediators may play a role in the protective effect of the 
LCPUFAs in innate and adaptive immune responses (419-421). Hence, our results suggest that human 
milk may be an important regulator of neonatal immunity by providing not only the precursors, but 
also the bioactive forms of these lipid mediators. 
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5.5 Conclusions 
We investigated human milk to identify components that are responsible for the beneficial effect of 
human milk on neonatal health. Our results confirm a considerable amount of DHA and AA in human 
milk with higher levels in the beginning of lactation. Since the nutrient composition of human milk 
reflects the ideal mixture to satisfy the newborn’s needs, this likely mirrors the neonatal DHA and AA 
requirements. Moreover, we demonstrate the presence of bioactive lipid mediators in human milk 
which affect atopy and inflammation and therefore influence neonatal immunity. Our results support 
an addition of DHA and AA to infant formula which is often done nowadays, but still is not standard 
practice. The high content of anti-inflammatory lipid mediators and its precursors in human breast 
milk may indicate the crucial role of lipid mediators in neonatal immunity and may be a reason for 
the advantage of human breast milk over infant formula. 
5.6 Materials and Methods 
Sample collection and preparation for fatty acid analysis 
94 human milk samples were obtained from 30 mothers and the lactational age was recorded. 
Samples were stored at -20 °C for approximately 120 days. Sample preparation for total fatty acid 
analysis was essentially done according to Moser et al. (422). 125 µl of human milk was diluted 1:2 
with ultrapure water (ELGA Purelab Ultra, Labtec Service AG, Wohlen, Switzerland) and subjected to 
protein precipitation with 1 ml methanol-methylene chloride (3:1, v/v). 20 µg d3-C17:0 (Cambridge 
Isotope Laboratories, Inc., Andover, MA, USA) and 0.8 µg d3-C22:0 (Dr. Ehrenstorfer GmbH, 
Augsburg, Germany) were added as internal standards. Fatty acid methyl esters were prepared by 
the addition of 200 µl acetyl chloride and subsequent incubation at 75 °C for one hour. The reaction 
was neutralized with 4 ml 7% K2CO3, and fatty acid methyl esters were extracted with 2 ml hexane. 
After centrifugation at 2500 rpm for 20 min, 1.6 ml of the hexane layer was dried under nitrogen and 
redissolved in 280 µl heptane for injection into the GC-MS system. Calibration curves were obtained 
with defatted cow’s milk spiked with known concentrations of fatty acid standards, thereby defining 
the individual working range for each fatty acid (See Supplementary Tab. 1, Additional file 3). 
GC-MS of fatty acid methyl esters 
One µl sample was injected into a Finnigan PolarisQ ion trap GC-MS system (Thermo Quest, Austin, 
TX, USA). The injector temperature was 280 °C and fatty acid methyl esters were separated on a 30 
m BGB-1701 column (BGB Analytik AG, Boeckten, Switzerland). The initial oven temperature of 50 °C 
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was hold for 8 min and then increased gradually by 5 °C/min reaching a final temperature of 280 °C. 
The ion source temperature and transfer line temperature was 230 °C and 300 °C, respectively. 
Analytes were detected as positive ions in full scan mode from 50 to 650 m/z. Specific mass traces 
were extracted for the quantification of each analyte (See Supplementary Tab. 1, Additional file 3). 
Fatty acids were identified by comparison of retention time and mass spectrum with authentic 
standards.  
Sample preparation for analysis of lipid mediators and their precursors 
85 of the human milk samples were stored at -20 °C for approximately 330 days. The analyte 
extraction method was adapted from Yang et al. (177). Two volumes of ice cold methanol and 3 ng of 
deuterated LTB4 (d4-LTB4; Enzo Life Sciences AG, Lausen, Switzerland) as internal standard were 
added to 1 ml human milk.  The samples were centrifuged for 20 min at 2500 rpm and the 
supernatant was diluted with 5 ml ultrapure water. The diluted supernatant was loaded on a C18 
solid phase extraction (SPE) column (Grace, Deerfield, IL, USA) prewashed with 5 ml 90% methanol 
and 5 ml 5% methanol. After sample loading, the SPE column was washed with 2x5 ml 5% methanol 
and the analytes were eluted with 3 ml 90% methanol. The eluate was dried under nitrogen and 
redissolved in 100 µl 35% methanol (2 mM ammonium acetate). The sample was filtered with a 0.2 
µm syringe filter (BGB Analytik AG, Boeckten, Switzerland) and 5 µl were injected into a HPLC-MS/MS 
system. Calibration curves were obtained by lipid mediator standard addition to human milk at the 
concentrations 0, 15, 30, 45, 60, 75 and 90 ng/ml. 
HPLC-MS/MS of lipid mediators and hydroxy fatty acids 
Analytes were separated using a HPLC system (UltiMate® HPLC, LC Packings, Dionex, Olten, 
Switzerland) with a C18 column (Luna 3u C18(2) 100A, 150x0.3 mm; Phenomenex, Brechbühler AG, 
Schlieren, Switzerland). A gradient was run over 10 min from 35% to 80% methanol (2 mM 
ammonium acetate) and was kept constant for 25 min at a flow rate of 4 µl/min. The column was 
rinsed with 100% methanol and equilibrated with 35% methanol (2 mM ammonium acetate). 
Analytes of interest were detected on a Sciex 4000 QTRAP mass spectrometer (AB SCIEX GmbH, Zug, 
Switzerland) in the negative ion mode. The transitions were scanned in multiple reaction monitoring 
mode and are stated in supplementary table 2 (Additional file 3). The optimized MS parameters were 
defined as: Electrospray ionization (ESI), curtain gas (CUR) = 10, nebulizer gas (GS1) = 20, auxiliary gas 
(GS2) = 0, ionspray voltage (IS) = -4500 V, collision gas (CAD) = medium, entrance potential (EP) = -10 
V, cell exit potential = -11 to -5 V, dwell time = 100 msec. Declustering potential (DP) and collision 
energy (CE) were optimized individually for each analyte (See Supplementary Tab. 2, Additional file 
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3). Fragmentation patterns for each analyte as standard substance as well as isolated from human 
milk were obtained by product ion scans at MS parameter settings defined above. 
Data analysis 
Statistical analysis was done using Microsoft Office Excel. To estimate the difference between 
groups, analysis of variance (ANOVA) with subsequent trend analysis was used. All values are 
presented as mean with standard deviation or as indicated. Two-sided p-values < 0.05 were 
considered significant. 
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5.8 Supplemental data 
 
Supplementary figure 1: Fragmentation spectra of lipid mediator standard substances and lipid mediators 
from human milk. Spectra were obtained as product ion scans at collision energy specified in Supplementary 
table 2, Additional file 3. Quantifier and qualifier product ions selected for each analyte are given in 
Supplementary table 2, Additional file 3. (A) Fragmentation of LTB4 standard and (B) LTB4 from human milk as 
products of 335 m/z; (C) Fragmentation of LXA4 standard and (D) LXA4 from human milk as products of 351 
m/z; (E) Fragmentation of RvE1 standard and (F) RvE1 from human milk as products of 349; (G) Fragmentation 
of RvD1 standard and (H) RvD1 from human milk as products of 375. Rel. Int., Relative Intensity; m/z, mass per 
charge; Da, Dalton. 
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Supplementary figure 2: Fragmentation spectra of hydroxy fatty acid standard substances and hydroxy fatty 
acids from human milk. Spectra were obtained as product ion scans at collision energy specified in 
Supplementary table 2, Additional file 3. Quantifier and qualifier product ions selected for each analyte are 
given in Supplementary table 2, Additional file 3. (A) Fragmentation of 12-HETE standard and (B) 12-HETE from 
human milk as products of 319 m/z; (C) Fragmentation of 15-HETE standard and (D) 15-HETE from human milk 
as products of 319 m/z; (E) Fragmentation of 18-HEPE standard and (F) 18-HEPE from human milk as products 
of 317; (G) Fragmentation of 17-HDHA standard and (H) 17-HDHA from human milk as products of 343. Rel. 
Int., Relative Intensity; m/z, mass per charge; Da, Dalton. 
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Supplementary table I: Extracted mass traces and working range for fatty acid analysis 
 
Fatty acid 
Lipid 
number 
(C:D)a 
Extracted mass traces 
(m/z) 
Working 
range 
(µg/ml) 
Intra-assay 
coefficient of 
variation (%) 
N=6 
Palmitic acid C16:0 87, 143, 270 1.2 - 2200 8.0 
Stearic acid C18:0 143, 199, 298 2.5 - 1200 12.6 
Arachidic acid C20:0 143, 283, 326 2.3 - 34 10.5 
Behenic acid C22:0 311, 354 3.5 - 60 20.2 
Lignoceric acid C24:0 143, 199, 382 3.4 - 75 16.8 
Palmitoleic acid C16:1 67, 81, 96 5.2 - 250 3.4 
Oleic acid C18:1 166, 222, 264 7.4 - 4000 2.6 
Linoleic acid C18:2 164, 220, 262 8.1 - 3000 1.9 
γ-Linolenic acid γC18:3 79, 292 0.1 - 16 12.4 
Arachidonic acid C20:4 79, 91 4.5 - 250 7.0 
α-Linolenic acid αC18:3 79, 91 1.9 - 180 15.2 
Eicosapentaenoic acid C20:5 79, 91, 384.5 1.7 - 16 12.2 
Docosahexaenoic acid C22:6 79, 91 7.1 - 120 13.0 
d3-Margaric acid 
d3-Behenic acid 
d3-C17:0 
d3-C22:0 
188, 244, 287 
202, 216, 258, 314, 357 
  
a 
C, number of carbon atoms; D, number of double bonds 
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Supplementary table II: Scanned transitions for lipid mediator analysis 
 
 
Compound Scanned transition (m/z) 
Collision Energy 
(eV) 
Declustering 
potential (V) 
Intra-assay 
coefficient of 
variation (%) 
N= 6 or 7 
LTB4 335→317 
335→195 (Quantifier ion) 
-24 
-24 
-85 
-85 
6.0 
LXA4 351→235 
351→217 
351→115 (Quantifier ion) 
-28 
-20 
-20 
-30 
-30 
-30 
4.2 
RvE1 349→331 
349→205 
349→195 (Quantifier ion) 
349→161 
-20 
-24 
-24 
-24 
-30 
-30 
-30 
-30 
17.5 
RvD1 375→277 
375→233 (Quantifier ion) 
375→215 
-18 
-18 
-18 
-60 
-60 
-60 
11.0 
17-HDHA 343→281 (Quantifier ion) 
343→245 
343→201 
-20 
-20 
-20 
-60 
-60 
-60 
9.9 
18-HEPE 317→255 
317→195 
317→167 (Quantifier ion) 
-25 
-25 
-25 
-60 
-60 
-60 
7.8 
15-HETE 319→257 
319→219 
319→175 (Quantifier ion) 
-27 
-27 
-27 
-80 
-80 
-80 
21.4 
12-HETE 319→301 
319→257 
319→179 (Quantifier ion) 
-23 
-23 
-23 
-80 
-80 
-80 
18.6 
d4-LTB4 
(Internal 
Standard) 
339→277 
339→197 (Quantifier ion) 
-20 
-20 
-60 
-60 
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6 Correlative association between human milk oligosaccharides and infant 
microbiota in humans 
(Results are currently not submitted for publication) 
6.1 Materials and Methods 
Human milk and feces samples 
Human milk was collected from one woman daily over the first three weeks of lactation to analyze 
changes over this period. Samples were stored at -20 °C until analysis. For studying associations 
between milk oligosaccharides and infant microbiota, breast milk and feces samples were provided 
by the University Children’s Hospital Zurich and the Hospital Zollikerberg (Zurich, Switzerland) in the 
course of an observational clinical study (423, 424). The study protocols were approved by the Ethics 
Committee of the Canton of Zurich and written informed consent was obtained from all subjects. 
Seven women provided human milk samples at three time points after birth: 4-5 days, 9-13 days and 
25-29 days. Breast milk was collected using a hospital-grade electrical breast pump. All children were 
delivered vaginally at term and were exclusively breast-fed. Of five corresponding children, a feces 
sample was collected at each collection point. Milk samples were stored at -20 °C until analysis. Feces 
samples were stored at -80 °C prior to 16S DNA extraction. 
Sample preparation for milk oligosaccharide analysis 
Human milk samples of 100 µl were centrifuged at 17000 x g for 5 min to separate milk fat. 80 µl of 
the medium phase were subjected to protein precipitation by addition of 9 volumes of methanol and 
incubation at 4 °C on ice over night. Samples were centrifuged at 17000 x g for 30 min. Supernatants 
were dried down and redissolved in 1 ml 2% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA). Milk 
oligosaccharides were purified on a triphasic column consisting of AG 50W cation exchange resin 
(Bio-Rad), Sep Pak C18 SPE columns (Waters) and Supelclean™ Envi Carb™ SPE sorbent (Sigma-
Aldrich). Samples were loaded after a precycle of 9 ml 2% ACN, 0.1% TFA and 6 ml 50% ACN, 0.1% 
TFA and conditioning with 6 ml 2% ACN, 0.1% TFA. After washing with 9 ml 2% ACN, 0.1% TFA, milk 
oligosaccharides were eluted with 6 ml 50% ACN, 0.1% TFA. Eluates were concentrated under 
nitrogen, freeze-dried and washed three times with 50 µl methanol. Purified milk oligosaccharides 
were redissolved in 100 µl ultrapure water and injected on a P-2 gel column (220 mm, 10 mm ID, 
Supelco Omnifit Column Kit) using a LaChrom HPLC (Merck Hitachi) for partial removal of lactose by 
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size exclusion chromatography. Ultrapure water was used as solvent at a flowrate of 0.15 ml/min. 
Analytes eluting from P-2 gel column in the first 70 min were collected, freeze-dried and redissolved 
in 50 µl ultrapure water. 
Quantification of milk oligosaccharides 
Purified milk oligosaccharides were separated by high-performance anion exchange chromatography 
(HPAEC) and detected by pulsed amperometric detection (PAD) (Dionex). Samples were diluted 1:100 
and 20 µl were injected on a CarboPac PA200 column (Dionex). After an initial 5 min of 100 mM 
sodium hydroxide (NaOH), a linear sodium acetate (NaOAc) gradient was run over 40 min reaching 
150 mM NaOAc. Flow rate was 0.35 ml/min. The column was rinsed with 1 M NaOAc, 100 mM NaOH 
and equilibrated with 100 mM NaOH. For peak identification, 30 sec-fractions were collected and 
desalted online. Milk oligosaccharides were identified by molecular mass and fragmentation pattern 
measured by matrix-assisted laser desorption/ionization-time of flight-tandem mass spectrometry 
(MALDI-TOF-MS/MS). 3SL and 6SL and lacto-N-tetraose I and lacto-N-tetraose II (lacto-N-neo-
tetraose) were distinguished by comparing retention times with standard substances on the 
CarboPac PA200 column. Quantification was done via peak area. Amounts are given relative to peak 
area of lacto-N-tetraose I. 
Glucose units (GU) were determined by comparing retention times with partially hydrolyzed dextran. 
Partial hydrolysis of dextran was done by incubation of 10 µg dextran with 100 µl 0.1 M TFA at 100 °C 
for 120 min, subsequent drying down, washing with methanol (4 times 50 µl) and redissoving in 100 
µl ultrapure water and 10 µl were injected into the HPAEC-PAD system. 
Structural identification by MALDI-TOF-MS/MS 
30-sec fractions were dried down and milk oligosaccharides were labeled with 2-aminobenzamide (2-
AB) by adding 20 µl of 0.35 M 2-AB, 1 M sodium cyanoborohydride (NaCNBH4) in acetic acid 
(HAc)/dimethyl sulfoxide (DMSO) (3:7, v:v). After incubation for 120 min at 65 °C, 380 µl ACN was 
added and the sample was subjected to paper disk clean up on 4-7 µm filter (Whatman). Samples 
were loaded on filter preconditioned with 450 µl ultrapure water and 2 times 450 µl ACN. After 
washing with 6 times 450 µl 95% ACN, milk oligosaccharides were eluted with 3 times 50 µl ultrapure 
water. Eluates were freeze-dried and redissolved in 25 µl 2% ACN, 0.1% TFA. Desalting was done with 
HyperSep Hypercarb Columns Tips (Thermo Scientific) preconditioned with 5 times 20 µl 50% ACN, 
0.1% TFA and 3 times 20 µl 2% ACN, 0.1% TFA. After sample loading, tips were washed with 10 times 
20 µl 2% ACN, 0.1% TFA and milk oligosaccharides were eluted with 2 times 10 µl 50% ACN, 0.1% 
TFA. Samples are dried down and redissolved in 10 µl ultrapure water. 1 µl sample and 1 µl matrix 
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(2,5-dihydroxybenzoic acid in water-ACN (1:1, v:v), 1 mM NaCl) were spotted on a stainless steel 
target and recrystallized with ethanol. 
MALDI-TOF-MS/MS analysis was performed on an ABI 4800 MALDI tandem time-of-flight mass 
spectrometer. Mass spectra were obtained in positive reflector ion mode by averaging 300 laser 
shots scanned across the sample surface for MS-scans and averaging scans of 1000 laser shots for 
MS/MS-scans. The annotation of fragments was assisted by the GlycoWorkbench tool (425). 
Microbiological analysis 
Total DNA was isolated from 0.1 to 0.3 g of infant feces samples using a FastDNA SPIN kit for soil (MP 
Biomedicals) according to the manufacturer’s instructions. DNA concentrations were measured by 
NanoDrop (Witec AG) and 100 ng DNA was subjected to PCR. The V2-V3 region of 16S ribosomal DNA 
was amplified using the primers HDA1-GC 5’-
CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGGACTCCTACGGGAGGCAGCAGT-3’ and HDA2 
5’-TTACCGCGGCTGCTGGCA-3’ at a temperature of 56 °C for strand annealing. After an initial 
denaturation at 94 °C for 4 min, 30 cycles of 30 s at 94 °C, 30 s at 56°C and 1 min at 72 °C followed. 
Agarose gel electrophosis was used to verify the quality of the PCR products. The separation of the 
amplified 16S ribosomal DNA by denaturing gradient gel electrophoresis (DGGE) and the bacterial 
identification by sequencing of the separated DNA was done as described in chapter 7 under 
materials and methods. 
6.2 Results  
Analysis of oligosaccharides from human milk 
Oligosaccharides extracted from human milk were separated and structurally analyzed. Fourteen 
structures could be assigned to prominent peaks in the milk oligosaccharide chromatogram (Figure 
6.1). The most prominent oligosaccharide after lactose was fucosyllactose, followed by lacto-N-
fucopentaose and lacto-N-tetraose I. Lacto-N-tetraose II, lacto-N-fucoseptaose, 6SL and 3SL were 
present in moderate amounts. Relatively low contents were shown for lacto-N-hexaose, lacto-N-
fucononaose, lacto-N-octaose, lacto-N-fucoundecaose and two sialyl-lacto-N-tetraoses. The two 
sialyl-lacto-N-tetraoses showed different retention times, but the Sia linkage could not be 
determined via fragmentation or comparison to retention times of standard substances. Thus, they 
were distinguished by their GU 10.3 and 10.8 determined by retention time comparison to partially 
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hydrolyzed dextran. The amount of lacto-N-tetraose I was selected as reference value in quantitative 
evaluations due to its prominence and stable amount in all analyzed human milk samples. 
 
Figure 6.1: Milk oligosaccharides identified in human breast milk. Oligosaccharides 
extracted from human milk were analyzed by HPAEC-PAD and identified by MALDI-TOF-
MS/MS.  
 
Changes in milk oligosaccharides over lactation  
The eight most prominent milk oligosaccharides were selected for quantification in milk samples 
collected daily from one woman over the first three weeks postpartum. Fucosyllactose could not be 
detected in any of the samples. As other fucosylated oligosaccharides were present, the 
corresponding mother seemed to be a Lewis-positive non-secretor. The composition of milk 
oligosaccharides changed significantly during the first two weeks after birth. Relative amounts of five 
of the measured milk oligosaccharides are highest directly after birth and decrease over the first two 
weeks postpartum (Figure 6.2A, B, D, E, F). After this initial decrease, the content of 3SL and 6SL and 
sialyl-lacto-N-tetraose (GU 10.3) stabilized or rose again, respectively (Figure 6.2D, E, F). In contrast, 
lacto-N-fucoseptaose increased in the first two weeks postpartum almost 2-fold (Figure 6.2C). The 
trend for sialyl-lacto-N-tetraose (GU 10.8) was unclear (Figure 6.2G).  
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Figure 6.2: Relative amount of milk oligosaccharides over the first three weeks of lactation. Milk 
oligosaccharides in daily milk samples of one woman were analyzed by HPAEC-PAD. Values are given as 
percentages of the amount of lacto-N-tetraose I. For monosaccharide key, see Figure 7.1. GU, glucose units. 
Fucosyllactose might influence the microbiota composition 
Milk oligosaccharides were quantified in milk samples collected from seven different mothers at 
three time points during the first four weeks after birth (Figure 6.3). The previously observed decline 
in milk oligosaccharides over the first weeks postpartum was confirmed in the seven mothers 
participating in this study. For all of them, the relative amount of lacto-N-tetraose II, lacto-N-
fucopentaose, 6SL and sialyl-lacto-N-tetraose (GU 10.3) decreased over the first four weeks 
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postpartum (Figure 6.3B, C, E, G). The relative amount of 3SL declined in human milk of four mothers, 
while it was stable for three women (Figure 6.3F). Lacto-N-fucoseptaose increased over the observed 
time period for six out of seven mothers (Figure 6.3D). Fucosyllactose and sialyl-lacto-N-tetraose (GU 
10.8) showed no trend over time (Figure 6.3A, H). But for these two milk oligosaccharides, either 
generally low or high amounts were observed. Mothers 1, 4, 8 and 15 have more than 2-fold lower 
fucosyllactose concentrations than mothers 12, 16 and 18. For sialyl-lacto-N-tetraose (GU 10.8), the 
relative amount is approximately 2-fold higher for mothers 12, 15, 16 and 18 than for mothers 1, 4 
and 8. 
 
Figure 6.3: Milk oligosaccharides over the first four weeks of lactation in breast milk of seven women. 
Relative amounts of milk oligosaccharides were analyzed in three samples per mother at three different time 
points of lactation by HPAEC-PAD. For monosaccharide key, see Figure 7.1. GU, glucose units. 
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The variation in the infant gut microbiota was analyzed at the same time points for five (children 8, 
16, 12, 15 and 18) out of seven corresponding breast-fed newborns. It was examined, if the presence 
of individual bacterial species in the infant feces depends on the amount of individual milk 
oligosaccharides in the mother’s breast milk. Inter-individual differences in the amount of 
fucosyllactose correlated with the presence of Bifidobacterium spp. in the gut of the breast-fed child. 
In contrast to mother 8 and 15, the content of fucosyllactose in mother 16, 12 and 18 was high 
(Figure 6.4). Bifidobacterium spp. could be identified in children 16, 12 and 18, but not in 8 and 15. 
The presence of Bifidobacterium spp. seemed to be associated with the amount of fucosyllactose 
present in the milk. 
 
Figure 6.4: Relative amount of fucosyllactose in human milk and presence of 
Bifidobacteria spp. in infant feces. Red horizontal bars mark women with low 
fucosyllactose content, green bars mark women with high fucosyllactose content. 
16S ribosomal DNA was isolated from infant feces and separated by DGGE. 
Bacterial species were identified by sequencing. Each lane represents DNA of fecal 
bacteria from one infant sample. The three feces samples per child are ordered by 
lactational age (4-6, 9-13 and 25-29 days postpartum) from left to right The band in 
the green boxes represents a member of the family Bifidobacteria. The red boxes 
mark children where this species is absent. M, marker. 
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6.3 Discussion 
The composition of eight prominent oligosaccharides in human milk was observed in several mothers 
over three or four weeks after birth. The relative amount of most milk oligosaccharides decreased in 
this time period. Only lacto-N-fucoseptaose increased in concentration, whereas fucosyllactose and 
sialyl-lacto-N-tetraose (GU 10.8) showed rather inter-individual differences than intra-individual 
changes over the first month of lactation. A general decrease of neutral as well as acidic milk 
oligosaccharides as a whole has been reported for the first three month of lactation (286, 294, 426-
428). In some studies, this decrease occurs after a concentration maximum in the first week (286, 
429). While most individual structures decrease, a stable level of fucosyllactose, as seen in our study, 
has been shown for the first 30 days postpartum (430). Generally, the milk oligosaccharide 
composition and its lactational change vary greatly depending on genetic factors like expression of 
the secretor and Lewis genes as well as on regional factors (426, 430). However, the higher 
oligosaccharide concentration at the onset of lactation might support multiple aspects of the 
newborn’s early development considering the prebiotic, pathogen- and receptor-binding activities of 
milk oligosaccharides. 
One of the milk oligosaccharides showing great intra-individual differences was fucosyllactose, which 
was represented in human milk from secretors by the second largest peak after lactose. If the fucose 
is α1,2- or α1,3-linked could not be determined by MALDI-TOF-MS/MS. Because of its high 
concentration, this fucosyllactose can be assumed to represent 2FL, the usually most abundant 
oligosaccharide in human milk of secretors (286). This milk oligosaccharide was the only one whose 
concentration in human milk positively correlated with the occurrence of a bacterial species 
identified as member of the family Bifidobacteria in the feces of the corresponding infant. Aside from 
acting as inhibitor of intestinal pathogen-binding, e. g. of Campylobacter jejuni (303) and stable toxin 
of Escherichia coli (289), 2FL has been described as important prebiotic for human microbiota (293, 
431). In vitro, 2FL promotes the growth especially of bifidobacteria, as shown with the two strains 
Bifidobacterium longum and Bifidobacterium longum spp. infantis (293). The latter proved to be the 
one out of five tested Bifidobacterium species that grew best on extracted human milk 
oligosaccharides (357). This growth advantage might be due to an α1,2-fucosidase activity that was 
detected for Bifidobacterium longum spp. infantis (432) as well as Bifidobacterium bifidum but not 
for 16 other tested fecal bacteria (433). This α1,2-fucosidase activity might cause the enhanced 
growth of the Bifidobacteria species detected in our study under high levels of 2FL. The sample size 
of five examined mother-infant-couples does not allow drawing general conclusions about growth-
promoting effects of fucosyllactose, but it demonstrates a possible association that demands further 
investigations in order to define the role of 2FL in the microbial colonization of the intestine. 
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7.1 Abstract  
The oligosaccharides 2-fucosyllactose and 3-fucosyllactose are major constituents of human breast 
milk but are not found in mouse milk. Milk oligosaccharides have a prebiotic action, thus affecting 
the colonization of the infant intestine by microbiota. To determine the specific effect of 
fucosyllactose exposure on intestinal microbiota and impact on mucosal immunity in mice, we 
supplemented newborn mice orally with pure 2-fucosyllactose and 3-fucosyllactose. Exposure to 2-
fucosyllactose and 3-fucosyllactose increased the levels of the bacterial family Porphyromonadaceae 
in the intestinal gut, more precisely members of the genus Barnesiella as analyzed by 16S 
pyrosequencing. The ability of Barnesiella to utilize fucosyllactose as energy source was confirmed in 
bacterial cultures. Whereas Barnesiella intestinihominis and Barnesiella viscericola did not grow on 
fucose alone, they proliferated in presence of 2-fucosyllactose and 3-fucosyllactose following the 
secretion of linkage-specific fucosidase enzymes that liberated lactose. The change in intestinal 
microbiota mediated by fucosyllactose supplementation affected the susceptibility of mice to 
dextran sulfate sodium-induced colitis, as shown by increased resistance of mice subjected to 2-
fucosyllactose supplementation for six weeks. This study underlines the ability of specific milk 
oligosaccharides to change the composition of intestinal microbiota and thereby to shape an 
intestinal milieu resilient to inflammatory diseases. 
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7.2 Introduction 
Oligosaccharides are a major constituent of human breast milk. Milk oligosaccharides are built up by 
multiple glycosyltransferases expressed in the secretory mammary gland by extending the lactose 
core, thereby forming close to 200 various structures (295). Milk oligosaccharides do not deliver 
energy to the newborn since the human gut lacks the glycosidase machinery required to break down 
these complex carbohydrates. Rather, milk oligosaccharides have a prebiotic action providing a 
nutrient milieu for the microbiotic colonization of the intestine (221), thereby influencing the 
development of the mucosal immune system of the breastfed infant (434). Milk oligosaccharides 
shape the intestinal flora by providing fermentable carbohydrates to selected bacterial groups and by 
acting as soluble receptors preventing the adhesion of other bacteria (252, 301, 435). The 
remarkable diversity of milk oligosaccharides hampers the attribution of specific functions to 
individual structures. To date, only few studies unraveled the biological impact of single milk 
oligosaccharides. For example, lacto-N-fucopentaose III was shown to induce the production of 
interleukin-10 and prostaglandin E2 in spleen cells (281). Disialyllacto-N-tetraose was shown to lower 
the incidence of necrotizing enterocolitis in rats (436). Finally, 3-sialyllactose was shown to influence 
the intestinal abundance of clostridial cluster IV bacteria in mice and hence, their susceptibility to 
dextran sulfate sodium (DSS)-induced colitis (437). 
Fucosyllactose is a major constituent of human milk oligosaccharides (45), whereas only trace 
amounts are found in mouse milk (341). Fucosyllactose occurs as Fuc(α1-2)Gal(β1-4)Glc also called 2-
fucosyllactose (2FL) and Fuc(α1-3)[Gal(β1-4)]Glc called 3-fucosyllactose (3FL). 2FL is similar to the 
blood group H-antigen and 3FL to the Lewis-X antigen found on glycoproteins and glycolipids (438). 
2FL accounts for 20% of total human milk oligosaccharides and 3FL for less than 1% (439). The 
abundance of 2FL in human milk suggests an evolutionary pressure pertaining to the development of 
beneficial effects on infant physiology. Along this way, ex vivo and in vivo studies showed that 2FL 
inhibits mucosal attachment and intestinal colonization of Campylobacter jejuni, hence lowering the 
incidence of diarrhea (235, 303). Fucosyllactose also provides a protected source of lactose to 
bacteria expressing fucosidase enzymes, such as bifidobacteria and Bacteroides, whereas Escherichia 
coli and Clostridium perfringens cannot utilize 2FL as nutrient (440). 
The potential of specific oligosaccharides to influence intestinal colonization by commensal 
microbiota in vivo is not known. To address the potential contribution of fucosyllactose in shaping 
the distribution of intestinal microbiota, we supplemented newborn mice with 2FL and 3FL, which 
are naturally not found in mouse milk. The lack of fucosylated oligosaccharides in mouse milk may 
decrease the selection of fucosidase-expressing bacteria. The exposure of infant mice to soluble 2FL 
  
and 3FL may also impair the adhesion of bacteria to fucosylated glycans in the gastrointestinal 
mucosa, or interfere with the bacterial regulation of host
the effect on intestinal microbial colonization, the question as to whether fucosyllactose 
supplementation has an impact on the susceptibility towards inflammatory diseases was addressed 
using the DSS-induced colitis model. 
7.3 Results 
Microbiota variation after three
To determine whether early exposure to exogenous fucosyllactose influenced the microbiotic 
colonization of the intestine, we first compared three supplementation regimens. Mice were eith
fed daily with 2FL or 3FL for three weeks from birth until weaning, for three weeks after weaning, or 
for six weeks from birth (Fig. 1). 
Before weaning, 2FL and 3FL were given orally in addition
maternal milk. The microbiological diversity in feces samples was first examined by denat
gradient gel electrophoresis (DGGE) of amplified bacterial 16S rRNA gene fragments. By the time of 
weaning, the DGGE profiles obtained from 2FL
similar with only few DNA bands specifically found in s
shown). The main difference was represented by a band corresponding to bacteria from the family of 
Lachnospiraceae observed 2FL-supplemented mice. The DGGE profiles obtained from DNA samples 
isolated at six weeks of age showed more pronounced changes as exemplified by prominent bands 
representing members of the family of 
Porphyromonadaceae was strongest in mice
supplemented with 2FL and 3FL for three weeks after weaning also showed increased 
Porphyromonadaceae yet to a lesser extent than
Because of the limited sensitivity of
microbial composition of DNA samples 
Figure 1: Fucosyllactose supplementation protocol.
increasing daily amounts. Fucosyllactose supplementation after weaning w
An average daily consumption of 4.5 ml drinking water per day and mouse resulted in a daily f
intake of 7.2 mg. 2.75% DSS was added to drinki
-derived fucosylated glycans
 
 and six weeks of supplementation 
The latter protocol was referred to as long-term supplementation.
 to the natural feeding of the pups through 
-, 3FL-supplemented mice and control mice were very 
ingle supplementation groups (data not 
Porphyromonadaceae (Fig. 2)
 supplemented with 2FL for six weeks, whereas mice 
 mice exposed to 2FL or 3FL for the whole period. 
 DGGE to quantify microbial diversity, we have
using high-throughput sequencing. 
 Fucosyllactose was fed orally until weaning with 
as administered by drinking water. 
ng water from day 45 to day 50. 
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Each sample was analyzed at coverage ranging from 6898 to 16171 16sDNA sequences. The grouping 
of sequences at the level of bacterial families confirmed the results obtained by DGGE. Mice 
supplemented with 2FL from birth for three weeks showed increased levels of Lachnospiraceae (Fig. 
3A) whereas other bacterial families did not vary significantly after exposure to 2FL and 3FL (Table 1). 
 
Figure 2: DGGE of bacterial 16S rDNA isolated from feces samples at age of six weeks. Bacterial variation 
between 2FL-, 3FL-supplemented and control mice were compared. Duration of 2FL- or 3FL- supplementation is 
indicated as 3-6 weeks or 0-6 weeks. Each lane represents DNA of fecal bacteria from one mouse. The lower 
band in the box (indicated by arrows) represents a member of the family Porphyromonadaceae. M, marker; C, 
control. 
 
 
Reciprocally, the abundance of Alcaligenaceae strongly decreased in 2FL supplemented mice, while 
remaining unchanged in 3FL supplemented mice. The dominant bacterial families identified at three 
weeks of age were Porphyromonadaceae and Bacteroidaceae, which accounted for respectively 39% 
and 16% of sequence coverage in control mice. The dominance of these bacterial families in the 
murine gut were confirmed by Bailey et al. (442), who assigned approximately 30% of identified 
sequences to each of these two families. Wohlgemuth et al. also identified Porphyromonadaceae as 
the most abundant family with 37% of sequences, while they assigned 9% of sequences to 
Bacteroidaceae (443). After weaning at three weeks of age, the transition from breast milk to solid 
chow leads to several adjustments in the distribution of intestinal microbiota in control and 
fucosyllactose-supplemented mice (Table 1). The family of Porphyromonadaceae remained dominant 
in all mouse groups at six weeks of age, yet with a sharp increase in 2FL- and 3FL-supplemented mice 
(Fig. 3B). The analysis of bacterial sequences at the genus level showed that Barnesiella accounted 
for the observed increase in Porphyromonadaceae bacteria (Table 2). At the age of six weeks, varying 
amounts of Barnesiella were observed in the three mouse groups (Fig. 3C). Whereas Barnesiella 
summed up to 58.3% of identified genera in 2FL supplemented mice, Barnesiella reached 
respectively 47.0% and 39.6% of genera in 3FL supplemented mice and control mice. 
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Fucosyllactose utilization by Barnesiella 
Two species of Barnesiella, namely Barnesiella viscericola isolated from chicken caecum and 
Barnesiella intestinihominis from human faeces have been characterized and cultivated to date (444, 
445). The Barnesiella sequences obtained in the present study showed up to 93% identity with the 
reference 16S rRNA sequence of Barnesiella intestinihominis and Barnesiella viscericola. The 
enrichment of Barnesiella found in fucosyllactose-supplemented mice suggested that these bacteria 
are able to utilize fucosyllactose as carbon source. To address this question, we have monitored the 
growth of Barnesiella viscericola and Barnesiella intestinihominis in vitro in culture medium 
containing glucose, lactose, fucose, 2FL or 3FL as sole energy source. As expected, both Barnesiella 
species grew in medium containing glucose and lactose (Fig. 4A-D). By contrast, Barnesiella failed to 
grow in presence of fucose, indicating that they cannot utilize this deoxy-hexose as carbon source 
(Fig. 4E, F). 
Table 1: Relative abundance of bacterial families in 2FL- or 3FL-supplemented and control mice at the age of 
3 and 6 weeks. Values are mean% (standard deviation). N=5 per group. Only families that are present with a 
mean value of more than 0.2% in at least one group are displayed. 
 After 3 weeks After 6 weeks 
 2FL 3FL Control 2FL 3FL Control 
Alcaligenaceae 0.5 (0.4) 6.2 (4.1) 6.9 (9.4) 2.1 (0.5) 2.2 (2.2) 1.6 (1.0) 
Anaeroplasmataceae 0.0 (0.1) 2.1 (2.6) 2.7 (3.0) 3.2 (1.5) 0.9 (0.7) 3.4 (3.4) 
Bacteroidaceae 27.1 (13.7) 24.4 (16.4) 15.6 (9.5) 5.2 (1.8) 7.3 (2.0) 8.4 (10.1) 
Coriobacteriaceae 0.1 (0.1) 0.3 (0.2) 0.1 (0.2) 0.1 (0.0) 0.2 (0.1) 0.1 (0.1) 
Deferribacteraceae 0.0 (0.0) 0.2 (0.3) 0.3 (0.3) 0.1 (0.1) 0.0 (0.0) 0.6 (0.7) 
Erysipelotrichaceae 0.1 (0.1) 1.8 (1.9) 2.2 (2.8) 0.7 (0.3) 2.1 (1.2) 0.9 (1.3) 
Helicobacteraceae 1.7 (1.1) 2.1 (1.9) 5.1 (3.8) 2.7 (1.0) 2.7 (0.9) 2.4 (1.2) 
Incertae Sedis XIV 0.2 (0.4) 0.1 (0.1) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
Lachnospiraceae 17.4 (8.9) 5.5 (1.4) 4.7 (3.4) 3.9 (1.0) 5.1 (2.5) 9.4 (6.2) 
Lactobacillaceae 2.2 (1.0) 4.7 (4.4) 3.2 (2.3) 1.3 (1.5) 1.1 (1.4) 0.6 (0.9) 
Mycoplasmataceae 0.7 (0.7) 0.2 (0.2) 0.7 (0.7) 0.4 (0.1) 0.5 (0.4) 0.1 (0.1) 
Porphyromonadaceae 35.4 (9.0) 34.8 (9.9) 38.8 (8.7) 61.8 (3.8) 54.8 (4.8) 37.6 (14.9) 
Prevotellaceae 5.1 (3.0) 3.2 (1.0) 4.4 (3.5) 3.7 (0.8) 3.7 (0.8) 4.9 (3.2) 
Rikenellaceae 5.4 (2.1) 7.0 (4.7) 9.4 (5.6) 6.3 (0.8) 6.2 (2.9) 6.3 (2.1) 
Ruminococcaceae 3.8 (1.7) 7.1 (4.0) 5.0 (2.2) 8.4 (1.6) 13.1 (3.8) 23.7 (21.1) 
Verrucomicrobiaceae 0.0 (0.0) 0.0 (0.0) 0.7 (1.4) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
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The addition of either 2FL or 3FL in the growth 
medium pointed to the differential utilization of 
both forms of fucosyllactose by Barnesiella 
viscericola and Barnesiella intestinihominis. 
Whereas Barnesiella intestinihominis was able to 
grow in 2FL- but not in 3FL-containing medium 
(Fig. 4 G, I), the reverse phenotype was observed 
for Barnesiella viscericola, which grew in 
presence of 3FL but not in presence of 2FL (Fig. 
4H, J). Note worthily, the growth of Barnesiella 
intestinihominis in presence of 2FL was delayed, 
suggesting that the utilization of the 
oligosaccharide as energy source required the 
expression of a putative fucosidase. During the 
growth experiments, the cellular morphology of 
Barnesiella was monitored by Gram staining to 
confirm the purity of the two strains in culture 
(Supplementary fig. 1). 
DSS-induced colitis in fucosyllactose 
supplemented mice 
We finally investigated whether the changes in 
intestinal microbiota mediated by 2FL and 3FL 
supplementation affected the susceptibility of 
mice towards local inflammation. We therefore 
treated mice with DSS to induce acute colitis. 
Loss of body weight was assessed to monitor the 
severity of the inflammatory response in the 
different mouse groups. Supplementation of 2FL 
and 3FL during lactation or for three weeks after 
weaning had no influence on the body weight loss induced by DSS uptake (Fig. 5A, B). By contrast, 
2FL supplementation for six weeks decreased the severity of DSS-induced colitis (Fig. 5C). Similarly, 
long-term 3FL supplementation led to reduced weight loss, although to a lesser extent than 2FL 
supplementation. The difference between the supplementation groups was mainly observed in male 
mice, which responded more strongly to DSS than females (Fig. 5D). Accordingly, male mice exposed 
 
Figure 3: Individual bacterial species associated with 
fucosyllactose supplementation. Relative abundances 
of the family Lachnospiraceae (A), the family 
Porphyromonadaceae (B) and the genus Barnesiella 
(C) were determined in feces samples of long-term 
supplemented and control mice at 3 and 6 weeks of 
age by pyrosequencing. C, control. N = 5 per group; *, 
Significance with P < 0.05 by t-test; #, trend with P < 
0.1 by t-test. 
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to 2FL and 3FL maintained higher body weight values than control mice, indicating a protective effect 
of the oligosaccharides towards exposure to DSS. The correlation of DSS sensitivity with the amount 
of Barnesiella bacteria in the intestine suggests that this bacterial genus confers anti-inflammatory 
properties in the context of DSS challenge. 
 
Table 2: Relative abundance of bacterial genera in 2FL- or 3FL-supplemented and control mice at 
the age of 3 and 6 weeks. Values are mean% (standard deviation). N=5 per group. Only genera that 
are present with a mean value of more than 0.2% in at least one group are displayed. 
 After 3 weeks After 6 weeks 
 2FL 3FL Control 2FL 3FL Control 
Akkermansia 0.0 (0.0) 0.1 (0.0) 0.8 (1.7) 0.0 (0.0) 0.0 (0.1) 0.0 (0.0) 
Alistipes 8.0 (3.7) 8.4 (5.8) 10.8 (7.5) 8.5 (0.9) 7.6 (3.1) 10.5 (1.8) 
Allobaculum 0.0 (0.0) 0.6 (0.5) 0.0 (0.0) 0.7 (0.5) 1.6 (1.2) 0.4 (0.8) 
Anaeroplasma 0.1 (0.1) 3.1 (3.8) 3.6 (4.0) 4.7 (2.1) 1.3 (1.2) 6.6 (5.6) 
Bacteroides 42.5 (20.9) 34.1 (21.7) 20.2 (11.1) 7.7 (2.7) 11.2 (3.5) 15.0 (15.5) 
Barnesiella 17.4 (8.0) 16.3 (7.3) 25.4 (5.4) 58.3 (5.4) 47.0 (10.2) 39.6 (16.1) 
Blautia 0.4 (0.7) 0.1 (0.2) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
Butyricicoccus 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.2 (0.2) 0.0 (0.1) 0.4 (0.6) 
Coprobacillus 0.1 (0.1) 0.7 (0.9) 1.4 (1.5) 0.2 (0.1) 0.5 (0.4) 0.4 (0.4) 
Helicobacter 2.5 (1.7) 2.8 (2.4) 6.1 (4.8) 3.7 (1.4) 3.8 (1.3) 4.4 (3.5) 
Lactobacillus 3.6 (2.1) 7.0 (6.9) 4.4 (3.2) 1.9 (2.1) 1.8 (2.4) 1.1 (1.5) 
Marvinbryantia 0.0 (0.0) 0.1 (0.1) 0.0 (0.0) 0.1 (0.0) 0.1 (0.1) 0.3 (0.2) 
Mucispirillum 0.0 (0.0) 0.4 (0.4) 0.4 (0.4) 0.1 (0.1) 0.0 (0.1) 1.7 (2.2) 
Odoribacter 0.2 (0.1) 0.0 (0.0) 0.8 (0.8) 0.6 (0.2) 0.0 (0.0) 0.9 (0.5) 
Oscillibacter 2.3 (1.1) 1.1 (1.0) 1.1 (0.9) 1.8 (0.4) 1.9 (1.1) 3.6 (2.6) 
Parabacteroides 13.9 (6.4) 13.1 (4.9) 11.4 (6.5) 4.1 (2.2) 13.3 (7.5) 5.0 (6.4) 
Paraprevotella 0.0 (0.0) 0.0 (0.0) 0.3 (0.6) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
Parasutterella 0.4 (0.4) 6.3 (4.2) 7.3 (10.0) 1.6 (0.3) 2.7 (2.9) 2.7 (1.6) 
Prevotella 6.1 (3.4) 3.6 (1.1) 3.9 (2.3) 4.2 (0.9) 4.4 (1.0) 5.3 (1.9) 
Roseburia 0.1 (0.1) 0.7 (0.6) 0.1 (0.2) 0.1 (0.1) 0.3 (0.2) 0.0 (0.1) 
TM7 genera  
incertae sedis 
0.4 (0.4) 0.5 (0.4) 0.1 (0.2) 0.5 (0.4) 0.8 (0.6) 0.4 (0.4) 
Ureaplasma 1.1 (1.2) 0.3 (0.3) 0.9 (0.9) 0.6 (0.2) 0.7 (0.6) 0.2 (0.2) 
Xylanibacter 0.4 (0.2) 0.3 (0.3) 0.2 (0.1) 0.3 (0.2) 0.3 (0.1) 0.9 (0.7) 
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Figure 4: Selective growth of Barnesiella intestinihominis (left panel) and Barnesiella viscericola (right 
panel) with different sugar substrates. The two Barnesiella strains were incubated in YCFA medium 
supplemented with (A, B) glucose, (C, D) lactose, (E, F) fucose, (G, H) 2FL or (I, J) 3FL. Proliferation was 
measured spectrophotometrically at 600 nm. Values are mean and standard deviation of two experiments 
each carried out in triplicate. 
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Figure 5: Susceptibility to acute colitis of fucosyllactose supplemented mice. Acute colitis in fucosyllactose-
supplemented and control mice was induced by DSS treatment at the age of six weeks. Treatment with DSS in 
drinking water was started on day 0. On day 5, treatment was ended by changing to normal drinking water. 
Loss of body weight was monitored during DSS treatment and 2 subsequent days in mice supplemented (A) 
for 3 weeks until weaning, (B) for 3 weeks after weaning and (C) for 6 weeks (long-term supplementation). (A) 
and (C) present pooled data from two independent experiments. C, control. *, P < 0.05 vs. control by t-test; 
**, P < 0.001 vs. control by t-test. (D) Body weight loss of male and female mice is compared on day 7 after 
start of DSS treatment of long-term supplemented mice. Graph shows pooled data from two independent 
experiments. For males, n = 8, 9 and 9, for females, n = 10, 4 and 7 (2FL, 3FL and control (C) group, 
respectively). *, P < 0.05 by one-way ANOVA; ***, P < 0.0001 by one-way ANOVA. 
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7.4 Discussion 
Our study demonstrated that the exposure of young mice to the fucosyllactose isoforms 2FL and 3FL, 
which are absent in mouse milk, affects the composition of intestinal microbiota. Specifically, the 
amount of Barnesiella increased after six weeks of fucosyllactose supplementation. Barnesiella, a 
genus of the family of Porphyromonadaceae, order Bacteroidales, was one of the most abundant 
microbiota detected in mouse intestine. Already by three weeks of age, it accounted for up to 25% of 
total intestinal microbiota. At the age of six weeks, this proportion increased to around 40% for 
control mice, whereas the abundance of Barnesiella rose close to 60% in 2FL-supplemented mice. 
Members of the order Bacteroidales contribute to carbohydrate degradation and prevent by 
competition the colonization of the intestine by pathogenic bacteria (446). Specifically, Barnesiella 
are able to eliminate and protect against the intestinal dominance of antibiotic-resistant pathogenic 
bacteria which can be observed in hospitalized patients (447). The abundance of Barnesiella 
correlates with the amount of several immunoregulatory cells. The higher the amount of Barnesiella 
in the colon, the more marginal zone B cells and invariant natural killer T cells were enumerated in 
spleen and liver (448). Furthermore, a direct association between a change in microbiota in favor of 
Barnesiella and the resistance to arthritis has been demonstrated in mice (449). Arthritis-resistant 
mice were characterized by microbiota enriched in Barnesiella, Bifidobacterium and Parabacteroides 
spp. with Barnesiella being the most abundant genus. In the development of colitis in IL-10-/- mice, 
higher levels of a Barnesiella phylotype correlated with lower activity levels of the disease (450). In 
the last years, many new sequences were isolated from human and animal intestine and assigned to 
the genus Barnesiella (451, 452). It still remains to be determined how the abundance of Barnesiella 
is linked to inflammatory diseases of the gastrointestinal tract. 
As demonstrated in the present study, Barnesiella intestinihominis and Barnesiella viscericola can 
utilize fucosyllactose as energy source. This phenotype was contingent on the expression of linkage-
specific fucosidases based on the respective specific utilization of 2FL and 3FL by both Barnesiella 
species. Barnesiella intestinihominis had been previously tested negative (444) and Barnesiella 
viscericola positive for α-fucosidase (445), although the linkage specificity of this activity was not 
addressed. The expression of glycosidases able to cleave carbohydrates capping lactose brings a 
selective advantage for bacteria competing for energy in the densely populated gastrointestinal 
environment. The gut of the breast-fed newborn is enriched for Bacteroides and Bifidobacterium 
species that possess α-fucosidase and α-sialidase activity (220, 221, 432, 453). Since α-fucosidase and 
α-sialidase conduct the first step of metabolizing milk oligosaccharides by removing terminal 
monosaccharides, the expression of these two enzymes leads to the successful intestinal 
establishment of species such as Bifidobacterium infantis, Bifidobacterium bifidum, Bacteroides 
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fragilis, Bacteroides thetaiotaomicron in the breast-fed child (214, 215, 220). Bacteria that do not 
exhibit α-fucosidase or α-sialidase activity, e.g. Bifidobacterium adolescentis and Bifidobacterium 
animalis, are not able to grow solely on milk oligosaccharides, and therefore, do not belong to the 
typical infant-associated microbiota (454). Little is known about the carbohydrate metabolizing 
activity of Barnesiella, but the feeding of obese mice with oligofructose has been shown to increase 
the abundance of Barnesiella by 26% (455). 
The differential susceptibility of mice towards DSS-induced colitis indicated that the shift in microbial 
composition elicited by 2FL and 3FL supplementation had a significant biological impact on the health 
of the treated animal. The decreased susceptibility to DSS correlated with the levels of Barnesiella in 
2FL and 3FL supplemented mice, suggesting that Barnesiella could render the intestinal milieu less 
prone to inflammation. The protective effect of 2FL supplementation was strongest in male mice, 
whereas long-term supplemented female mice did not differ significantly in their reaction to DSS 
from female controls. Future experiments will examine whether the distribution of specific bacterial 
groups such as Barnesiella present gender differences after fucosyllactose supplementation. Along 
this line, differences in the intestinal microbiome of male vs. female mice were reported in the 
context of an arthritis susceptibility study, in which male mice had higher amounts of Barnesiella 
viscericola than female mice (449). 
Our study demonstrated that supplementation with specific human milk oligosaccharides influenced 
the development of intestinal microbiota in mice as shown by the changes in abundance of 
Barnesiella.  Although Barnesiella belongs to the major bacterial genera in mice, their representation 
in human microbiota is minor (446, 456) and changes in Barnesiella have not been associated with 
resistance to gastrointestinal disorders in humans. Nevertheless, supplementation of 2FL might be of 
interest for children whose mothers lack 2FL in breast milk. Approximately 20% of Caucasians have a 
genetic inability to express α1,2-fucosyltransferase activity. In women, this results in the lack of α1,2-
linked fucose on milk oligosaccharides, thereby to 2FL deficiency in milk (45, 288). Since α1,2-
fucosylated oligosaccharides inhibit the attachment of several enteric pathogens, the absence of 
these glycans is associated with different infectious diseases (183, 235, 285, 457). Current research 
focuses on the synthesis of fucosyllactose by Escherichia coli (265) or with the help of bacterial 
enzymes (458, 459) for the production of food additives. To prevent disadvantages of children of so 
called non-secretors, especially in the context of necrotizing enterocolitis, the supplementation of 
2FL might become a possible treatment. 
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7.5 Materials and Methods 
Fucosyllactose supplementation in mice 
Newborn C57BL/6 mice were supplemented orally with 500 mM 2FL and 3FL (Glycom) daily from day 
1 to day 20 after birth starting with 5 μl, increasing by 2.5 µl every 2-3 days reaching a daily amount 
of 25 µl on day 20. Sterile water was given as negative control. For supplementation after weaning, 
2FL and 3FL were administered in drinking water (3.3 mM) from day 21 to day 45. Fresh feces were 
collected on day 21 and day 45 and immediately stored at -80 °C until further analysis. 
DSS-induced colitis 
From day 45 postpartum, 2.75% (wt/vol) of DSS (MP Biomedicals, Cat. no. 0216011090) was added to 
drinking water for 5 days followed by 2 days of normal drinking water until mice were sacrificed. 
Body weight was monitored daily. Animals reaching less than 85% of the initial body weight were 
euthanized immediately. Experiments were performed in compliance with the Swiss Animal 
Protection Ordinance and approved by the local veterinary authority (Kantonales Veterinäramt 
Zürich, Switzerland). 
Bacterial DNA extraction and amplification 
DNA was isolated from feces samples using the QIAamp DNA Stool Mini kit (QIAGEN, Cat. no. 51504) 
according to the manufacturers’ instructions. DNA concentrations of extracts were measured by 
NanoDrop (Witec AG). Aliquots of 100 ng of extracted DNA were subjected to PCR using the 16S 
rDNA universal primers HDA1-GC 5’-
CGCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGGGGGGACTCCTACGGGAGGCAGCAGT-3’ and HDA2 
5’-TTACCGCGGCTGCTGGCA-3’at 56 °C for strand annealing. Initial denaturation at 94 °C for 4 min was 
followed by 30 cycles of 30 s at 94 °C, 30 s at 56 °C and 1 min at 72 °C.  The quality of PCR products 
were verified by agarose gel electrophoresis. 
DGGE and species identification 
Amplified 16S rDNA fragments were separated by DGGE using an INGENYphorU (Ingeny International 
BV) system equipped with 6% polyacrylamide gels in range of 30 to 55% denaturant, where 100% 
denaturant is equivalent to 7 M urea and 40% formamide. Electrophoresis was performed at 130 V 
for 4.5 h at 60 °C. Polyacrylamide gels were stained with GelRed™ nucleic acid stain (Biotium, Cat. no. 
41003) for 45 min, destained in ultrapure water and viewed under UV. Bands of interest were 
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excised from gels and lysed in ultrapure water. Extracted DNA was re-amplified using the same 
primers and PCR conditions. To purify the bacterial DNA, PCR products were re-loaded on a 
denaturant gradient gel followed by excision and lysis of selected bands. DNA samples recovered 
from lysed bands of the second DGGE were re-amplified by PCR prior to purification by QIAquick PCR 
purification kit (QIAGEN, Cat. no. 28104) and sequenced (Microsynth AG, Switzerland). Species 
identification was performed using the Ribosomal Microbiome Database Project classifier tool (460). 
Pyrosequencing and data processing 
The V5-V6 region of 16S rDNA was amplified from feces DNA samples using specifically designed 
primers and amplicons were pyrosequenced using a Roche 454 GS-FLX system by DNAVision in 
Gosselies, Belgium. Bacterial diversity was determined at phylum, family and genus levels. Sequences 
were aligned to 16S ribosomal RNA of Barnesiella intestinihominis and Barnesiella viscericola with 
BLASTN 2.2.27+ (461). The GenBank accession numbers for the 16S rRNA sequences of Barnesiella 
intestinihominis and Barnesiella viscericola are AB267809.1 and AB370251.1, respectively. 
Bacterial culture 
Strains of Barnesiella viscericola and Barnesiella intestinihominis were obtained from Leibniz-Institut, 
Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH (Braunschweig, 
Germany). The cellular morphology was inspected visually by microscopy (DM1000 10X/20 
microscope, Leica). Substrate utilization was determined by adding sterilized, O2-free sugar solutions 
of glucose, lactose, fucose, 2FL or 3FL to a final concentration of 2.44 g/l to yeast extract, casitone, 
fatty acid (YCFA) medium (462). YCFA medium was dispensed in 8 ml aliquots in Hungate tubes 
sealed with butyl rubber septa. Short chain fatty acids were added to the medium in the final 
concentrations of 32.4 mM acetate, 4.7 mM butyrate, 8.7 mM propionate, 1 mM n-valeric acid, and 
1.2 mM isobutyric acid. YCFA medium was prepared and maintained anaerobically using CO2. 
Inoculated tubes were incubated at 37° C. Growth was measured spectrophotometrically at 600 nm. 
Statistical analysis 
Values are presented as mean% with standard deviation or as indicated. Comparisons of means were 
done by t-test or one-way ANOVA using SPSS 20. P-values lower than 0.05 were considered 
significant. 
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7.7 Supplemental data 
 
Supplementary figure 1: Cell morphology of Barnesiella strains. Purity of the bacterial strains was tested by 
Gram staining for Barnesiella intestinihominis (left panel) and for Barnesiella viscericola (right panel) (A, B) 
before substrate utilization tests and (C, D) after four times of subsequent inoculation in YCFA medium. Bar = 
20 µm. 
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General Discussion 
8 Discussion 
In this work, human milk was examined on different levels. First, content and lactational changes of 
fatty acids, selected lipid mediators and milk oligosaccharides were determined. Second, the impact 
of specific milk oligosaccharides, two isoforms of fucosyllactose, on the intestinal microbiota was 
investigated. The results indicate that the amount of certain milk oligosaccharides and specific fatty 
acids of human milk change over lactation, especially in the first weeks after birth. The 
developmentally important fatty acid DHA shows higher relative amounts at the beginning of 
lactation, like most of the measured milk oligosaccharides do. A decrease of oligosaccharides over 
longer periods of lactation such as one year (429) and four month (44, 463) has been reported 
before. These higher concentrations right after birth demonstrates the importance of DHA and milk 
oligosaccharides especially in early development. While DHA is needed for brain and retina 
development, milk oligosaccharides might support the initially immature immune system of the 
newborn infant. 
The hypothesis of increased immune support by human milk early after birth is supported by the fact 
that the concentrations of many other protective milk components are also elevated at the beginning 
of lactation. Levels of immunoglobulins, lactoferrin and lysozyme are higher in colostrum, the milk of 
the first one to three days, than in mature milk (464, 465). Higher concentrations of secretory IgA 
and other immune factors positively correlate with higher DHA levels in breast milk (52). Thus, higher 
levels of both are seen in colostrum as well as in preterm milk (466, 467). Hence, the mammary gland 
seems to adjust its milk production in case the newborn has higher requirements. Higher levels of 
DHA and other protective factors in preterm milk fulfill the increased demands for these components 
of the preterm child (102, 105, 468). Preterm human milk not only provides significantly more DHA, 
but also significantly higher amounts of milk oligosaccharides than term milk (439, 469). This suggests 
a particular relevance of milk oligosaccharides for the preterm infant harboring an immature, not yet 
fully functioning immune system and an intestinal microbiota different to the one of a term infant 
(470). 
A woman’s individual milk oligosaccharide composition presumably affects the colonization of her 
infants’ gut by bacteria. As our results indicate, especially fucosylated oligosaccharides like 
fucosyllactose might play a role in the growth of bifidobacteria. 2FL is the most abundant 
oligosaccharide in human milk and was shown to be preferentially consumed by cultured fecal 
microbiota that were supplemented with purified human milk oligosaccharides (293). Among 
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selected milk oligosaccharides, 2FL best promoted the growth of two representative bifidobacteria 
species of the infant gut, Bifidobacterium longum spp. infantis and Bifidobacterium longum. In 
contrast, Escherichia coli and Clostridium perfringens hardly utilized this oligosaccharide for energy 
consumption. 2FL belongs in general to the group of milk oligosaccharides that are rapidly fermented 
by microbiota of infant fecal inocula (431). One important role of 2FL has been discovered in the 
inhibition of pathogen binding. Here, the beneficial effect of high 2FL levels in breast milk on 
Campylobacter jejuni infection of the infant is well documented (303). However, the isolated effect of 
fucosyllactose on the commensal intestinal microbiota composition had not been investigated so far 
in vivo. This led to the selection of fucosyllactose for our intervention study in mice. The 
supplementation with the two forms of fucosyllactose resulted in a change of the intestinal 
microbiota. This change was not seen in bifidobacteria, since no bifidobacteria were detected in the 
murine microbiota, but in the family of Barnesiella. Barnesiella belong to the most abundant species 
in the murine gut and their proportion increased with fucosyllactose supplementation. 
When testing the substrate utilization of selected Barnesiella strains, the two forms of fucosyllactose, 
2- and 3FL, showed very distinct capabilities in promoting growth of the two Barnesiella species. This 
different influence of 2- and 3FL on growth was also previously observed for two Bifibacterium 
longum strains in humans (293). These observations support the finding that every human milk 
oligosaccharide has a different potential to promote bacterial growth (218). Therefore, the individual 
differences in milk oligosaccharide profiles probably result in different infant microbiota. The 
changes in the microbiota composition observed in our mice study might influence the immune 
response and mediate the observed inflammation-reducing effect of 2FL in DSS-induced colitis. 
Functional studies of isolated milk oligosaccharide structures are always carried out with the ulterior 
motive to disclose benefits of these structures and make them available to patients and newborns 
that would profit from them. A possible application is the treatment of gastrointestinal diseases 
including chronic inflammation and bacterial infections causing diarrhea. In preterm newborns, the 
administration of milk oligosaccharides might lower the risk of developing NEC (436). Another aim is 
to provide the health advantages associated with breast-feeding to newborns that are fed infant 
formula. Milk oligosaccharides lower the amount of stimuli for the neonatal immune system. This 
anti-inflammatory effect of milk oligosaccharides can be looked at from two angles. On the one hand, 
it is a positive effect, since the breast-fed newborn is protected from a hyperactive immune system 
and hence, an exaggerated immune response. On the other hand, the immune system might be 
compromised as its actions are reduced. But the observation of less inflammatory diseases in human 
milk-fed children than in formula-fed ones supports the assumption that the overall anti-
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inflammatory effect of human milk oligosaccharides offers more advantages than disadvantages 
(275). 
One step to imitate the immune modulatory effect of human milk is the addition of galacto- and 
fructooligosaccharides to infant formula. These artificial alternatives may render the microbiota 
more bifidogenic. But human milk oligosaccharides have many other effects beyond promoting 
bifidobacteria. Lots of these effects are still unknown and are likely to be structure-specific such as in 
the inhibition of Campylobacter jejuni infection by α1,2-fucosylated oligosaccharides (235). Many 
functions rely on fucosylation or sialylation, like the reduced selectin-mediated leukocyte-adhesion 
or the protection from NEC (48). The oligosaccharides added to infant formula nowadays, whose 
structures of Gal and fructose oligomers do not occur naturally in human milk, cannot fulfill these 
functions, since they contain neither fucose nor Sia. 
A new element of the anti-inflammatory activities of human milk was discovered in the course of this 
work: the presence of anti-inflammatory and pro-resolving lipid mediators and their related hydroxy 
fatty acids. They were detected in human milk in amounts exceeding reported plasma values by up to 
100-fold. These high concentrations bear the potential to have a direct influence on the child’s 
inflammatory status. The lipid mediators from human milk might constantly lower the inflammation 
during the time of breast-feeding. Due to studies showing positive treatment effects with specific 
lipid mediators in diverse pathophysiological conditions, they are discussed as potential therapeutics 
(471-473). The tissue concentration of lipid mediators greatly depends on the levels of their 
precursors. Therefore, an increase of precursor concentrations already exerts positive effects. This 
was shown for resolvins and protectins in fat-1-transgenic mice (418). These fat-1-transgenic mice 
have higher stores of DHA and EPA and, resulting from this, higher levels of resolvins and protectins. 
Interestingly, these mice show reduced gastrointestinal inflammation. 
In non-transgenic animals and also in humans, the internal DHA and EPA stores depend on the 
dietary fatty acid pattern and represents an example how nutrition can influence the inflammatory 
activity. Therefore, the decision between human milk containing DHA and EPA and infant formula 
without these two fatty acids might have consequences for the immune response of the child. The 
dietary fatty acid intake determines the fatty acid composition of cell membrane phospholipids (474-
476). These membrane phospholipids deliver the fatty acid precursors for the biosynthesis of 
inflammatory mediators. Therefore, the fatty acid composition of the cell membrane influences the 
pattern of the eicosanoid synthesis. A Western-type diet leads to a cell membrane with an AA 
content of approximately 20% of the fatty acids (384, 477). In contrast, the concentration of DHA is 
around 2.5% and of EPA less than 1%. Thus, the supply of the omega-3 fatty acids DHA and EPA for 
the synthesis of anti-inflammatory and pro-resolving resolvins and protectins is much lower than the 
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supply of the omega-6 precursor AA for the production of pro-inflammatory leukotrienes and 
prostaglandins. But the composition can be altered by a higher intake of omega-3 fatty acids. The 
supplementation with fish oil, i.e. oil with high EPA and DHA concentrations, significantly increased 
the DHA and EPA concentration in plasma phospholipids (475). The altered ratio of omega-6 to 
omega-3 fatty acids might enhance a less inflammatory phenotype by increased production of 
resolvins and protectins, but also by influencing inflammatory gene expression. Mice supplemented 
with fish oil showed lower mRNA levels of tumor necrosis factor-α and IL-1β in several studies (478-
480). The different levels of the anti-inflammatory actions of omega-3 fatty acids support their 
importance in the daily nutritional intake. The content of omega-3 DHA and EPA is naturally high in 
human breast milk representing a natural anti-inflammation system for the newborn in addition to 
the present anti-inflammatory lipid mediators. Considering the diverse beneficial effects of DHA and 
EPA, their addition should be standard practice in the production of infant formula. 
Conclusion and future implications 
Human milk does not only provide the whole range of nutrients and bioactive components for the 
ideal development of the neonate, but also seems to adjust their concentrations to the needs of the 
neonate over time. This natural alignment cannot be fulfilled by infant formula. Even donor human 
milk does not provide the tailor-made composition of mother’s own milk. It is widely accepted that 
breast milk is the gold standard for the newborn’s nutrition. Still, out of diverse reasons, some 
mothers choose not to breastfeed or are unable to, and hence, rely on alternatives like donor human 
milk or infant formula. Donor human milk represents a valuable alternative to human milk and 
should be preferred over infant formula. The usual practice of pasteurization lowers the content of 
immunoglobulins, soluble CD14 and human milk B cells and T cells compared to “fresh” human milk. 
Also the activity of lactoferrin and lysozyme is decreased, but milk oligosaccharides are not affected 
in both their composition and their quantity (481, 482). Additionally, the fatty acid composition is 
only slightly altered by pasteurization: medium-chain unsaturated fatty acids increase and oleic acid 
decreases, but LCPUFA are not affected (483). Donor human milk is particularly needed for the initial 
provision of human milk to preterm infants, where the mother’s own milk is not sufficient in 
quantity. However, in case the mother produces adequate amounts of milk, the own milk should 
always be preferred to donor human milk or formula (484) because of the content of immune 
components such as immunoglobulins and the higher level of milk oligosaccharides and DHA. 
The solution for providing an alternative to human milk is formula. The general aim is to produce 
formula that more and more resembles human milk. The first step on this way has been made by 
adding the two essential fatty acids linoleic and α-linolenic acid as well as LCPUFAs like DHA and AA. 
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The regulations for infant formula composition define a maximum omega-3 LCPUFA content of 1% of 
the total amount of fatty acids (38). This upper limit does not impair proper DHA supply, considering 
that 0.33% DHA is sufficient to create a plasma DHA level in formula-fed infants similar to breast-fed 
infants (485). Also the demand for AA can well be covered with a defined upper limit of 1% of total 
fatty acids (38). Although the addition of LCPUFA to infant formula is only possible but not required 
by law, it should be self-evident. Many advantages are associated with the intake of LCPUFA apart 
from influencing the pattern of eicosanoid synthesis. Feeding an infant formula containing DHA and 
AA instead of a formula without those two fatty acids was shown to lower the blood pressure in 
children at the age of six years (486). It might also improve the infant’s cognitive development as 
shown by better problem solving at the age of ten months in children that had received the LCPUFA-
supplemented formula (487). Moreover, the addition of LCPUFAs improves the visual acuity of the 
infant in the first year of life (488, 489). 
The oligosaccharides added to infant formula are still far from original milk oligosaccharides. In order 
to improve infant formula in this regard, the specific functions of individual oligosaccharides need to 
be further identified and selected oligosaccharides need to be synthesized on a larger scale. 
Furthermore, the effects of milk oligosaccharide administration need to be tested. 
In this study, we showed the microbiota-changing and anti-inflammatory effect of 2FL administration 
in mice. It would be of interest how 2FL affects the microbiota in human newborns where 
bifidobacteria is one of the predominant bacterial species. As a similar supplementation study would 
not be possible in humans, one could take advantage of the fact that breast milk of non-secretors 
lacks 2FL. Newborns that receive milk of non-secretors would represent the ideal control group for 
investigations of effects of α1,2-fucosylated milk oligosaccharides on gut microbiota in humans. So 
far, the intestinal microbiota of breast-fed infants receiving non-secretor milk has not been 
described. Only the microbiota of adult individuals has been investigated in connection to the 
secretor status. In that study, the diversity of bifidobacteria in the adult gut had a higher diversity in 
secretors than in non-secretors (490). In contrast to non-secretors, the situation is different in non-
secretor milk-fed newborns which themselves express α1,2-fucosyltransferase, therefore bear α1,2-
linked fucose on mucosal glycan structures. They only lack the free α1,2-fucosylated oligosaccharides 
originating from breast milk. Without any intervention, a comparison of the gut microbiota from 
breast-fed infants of secretors and non-secretors would reveal if α1,2-linked-fucose from human 
milk, therefore mainly in the form of 2FL, increases the amount or diversity of bifidobacteria in 
breast-fed newborns. 
Nowadays, some companies are able to synthesize tri- and tetrasaccharides that also occur in human 
milk like fucosyl- and sialyllactose. This opens the possibility of infant formula supplementation after 
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thorough investigation of the specific effects of these isolated structures. But previous studies in 
humans with isolated structures did not disclose any effects (267, 268). The fact that isolated milk 
oligosaccharides might not be as effective as a mix of diverse structures represents a major challenge 
for milk oligosaccharide supplementation of infant formula. The extraction of milk oligosaccharides 
from human donor milk might be a possible way to obtain this complex natural mix. The milk 
oligosaccharides from cow’s milk are of limited suitability for supplementation. Apart from their 
lower abundance, they are less complex and show less variability than human milk oligosaccharides 
(46). The predominant type I structures in human milk have not been detected in cow’s milk. 
Moreover, bovine milk oligosaccharides hardly contain fucose, the main decorating monosaccharide 
in human milk. In contrast, they are mainly sialylated, not only with NeuAc like in human milk, but 
also with the structurally related N-glycolylneuraminic acid, which does not occur in humans (491). 
The acidic fraction of bovine milk oligosaccharides showed anti-microbial and brain growth 
promoting effects that could be of interest (reviewed in ref. (46)). But aside from the difficult large-
scale preparation, many structures typical for human milk cannot be provided by cow’s milk. 
Although fatty acids and maybe someday in the future also milk oligosaccharides can be added to 
infant formula, one factor for the perfect imitation of breast milk is still missing. Infant formula lacks 
protective components like lipid mediators and other immune factors that therefore remain one of 
the major reasons for the superiority of human milk over formula.  
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